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Abstract 
Lung cancer is the most common cancer killer worldwide. One of the major reasons for 
failing to cure this malignancy is the high rate of metastasis. Hence, understanding the 
mechanisms by which these cells metastasise is required to improve patients’ survival. 
Using the non-small cell lung cancer cell line A549 we optimised a 3D Invasion assay to 
enable a robotised high-throughput siRNA screen of large gene libraries. Despite thorough 
optimisation a pilot screen for the Phosphatome highlighted multiple issues with our set-up. 
Further optimisation work was conducted to improve the resolving power of the assay. 
However, as no clear explanation for the poor reproducibility could be uncovered, work 
began on a potential modulator of cell motility identified during a previous motility screen of 
the kinome. 
Microtubule affinity regulating kinases 4 (MARK4) is one of four members of the MARK 
family. A previously performed kinome siRNA screen for modulators of cell migration 
revealed that depletion of MARK4 reduced A549 cell migration. We validated this 
observation and additionally found that MARK4 silencing inhibited cell invasion through 3D 
collagen matrices. MARK4 depletion markedly changed cell structure, as exemplified by an 
increase tubulin network area. Follow-on experiments revealed an altered speed of 
microtubule polymerisation in MARK4-silenced cells. We observed that MARK4 
downregulation promoted resistance to the chemotherapeutic agents Paciltaxel and 
Cisplatin, an effect potentially linked to a reduced proliferation in MARK4-silenced cells. 
MARK4 overexpression in NSCLC cells increased cell motility but did not impact the cell area 
or resistance to chemotherapy. A targeted siRNA cell motility screen of a selection of 
proposed MARK4 interacting proteins enabled us to connect MARK4 with Protein 
Phosphatase 2A and GSK3.  
Although further investigation is required into the signalling pathways upstream and 
downstream of MARK4, this work identified novel functions for this kinase and highlighted 
potential mechanisms underlying its effects. 
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TK Tyrosine Kinase  
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1.1 Cancer 
Cancer is a disease in which abnormal cells undergo uncontrolled cell division and 
are able to spread throughout other tissues. It is the leading cause of death worldwide 
killing an estimated 7.6 million people in 2008, accounting for 13% of all deaths (WHO 
2011). This figure is expected to continue to rise and it is estimated that by 2030 13.1 
million deaths will be accounted to cancer each year (WHO 2011). There are certain 
hallmarks that distinguish cancerous from normal cells; uncontrolled proliferation, 
resistance to cell death, and changes to cell-cell and cell-microenvironment interactions 
(Hanahan & Weinberg 2000). 
Cancer can take many different forms, there are over 100 known different types of 
cancer. These can be divided into five broad categories. Firstly cancer beginning in the 
skin or tissues that line or cover internal organs is termed a carcinoma. Secondly, 
sarcoma, which originates from bone, cartilage, fat, muscle or other connective or 
supportive tissue. Thirdly, cancer starting in blood forming tissue is referred to as a 
leukaemia. The fourth category is lymphoma or myeloma cancers, covering those that 
begin in the immune system. And finally central nervous system (CNS) cancers are those 
which begin in the brain or spinal cord (WHO 2011).  
 
Figure 1.1 Incidence and deaths per year due to the leading cancer types worldwide as of 2008. 
Amongst these leading cancer types it is clear that the differential between incidence and death 
for some types is much greater (Breast & Prostate carcinomas) than for others (Lung & Liver 
cancer). Data obtained from World Health organisation GLOBOCAN 2008 (latest global statistics) 
(Ferlay et al. 2010) 
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1.1.1 Lung Cancer 
Lung cancer is the main cancer killer worldwide, with an estimated 1 in 5 cancer 
deaths attributed to lung cancer. It is the second most common cancer with 
approximately 40,000 people diagnosed each year in the UK, see Figure 1.1 (Cancer 
Research UK 2011c). The incidence of the disease is higher in men and in the 60-70 year-
old age group (Neal & Hoskin, 2002). Two main subtypes of lung cancer are commonly 
distinguished; small-cell lung cancer (SCLC) and the more common non small-cell lung 
cancer (NSCLC) that accounts for 75 to 85% of cases. NSCLCs are histologically classified 
into three subgroups; Squamous cell carcinoma (SCC), Adenocarcinoma and Large cell 
carcinoma (Spiro 2002). An additional form of lung cancer is Mesothelioma, this is often 
associated with exposure to asbestos (Macmillan 2010). 
 
 
Figure 1.2 Estimated deaths from Lung cancer worldwide.  
With the highest number of lung cancer deaths seen in the developed world, the difference in 
lung cancer deaths between the sexes is clear with up to 50% higher occurrence in men than 
women. Data obtained from World Health organisation GLOBOCAN 2008 (latest global statistics) 
(Ferlay et al. 2010). 
 
The survival rate for lung cancer is one of the lowest of any form of cancer. Only 
27-30% of patients remain alive one year after diagnosis with an overall 5-year survival 
rate of 7-9% (Cancer Research UK 2011c). Figure 1.2 demonstrates differences in lung 
cancer deaths between the two sexes and the high number of attributed deaths per year 
throughout the world (Ferlay et al. 2010). The development of drug resistance and the 
early dissemination of the disease are responsible for this poor survival rate (Woodhouse 
0 200 400 600
Western Pacific
Europe
Americas
South-East Asia
East
Mediterranean
Africa
Estimated Number (thousands) 
Women
Men
Both sexes
1.Introduction 
21 
 
et al. 1997; Zochbauer-Muller et al. 2002a). Indeed, it is estimated that around 80-90% of 
small-cell lung cancer patients have tumour cells disseminated beyond the thorax by time 
of diagnosis (Neal & Hoskin 2002). 
Early symptoms of lung cancer are vague and common to many other thoracic 
conditions (e.g. persistent coughing, breathlessness) making early diagnosis difficult 
(British Thoracic Society 2011). Treatment involves surgery, chemotherapy and 
radiotherapy with surgery offering the best chance of cure. However, only a small 
proportion of sufferers ever qualify for curative resection due to early dissemination of 
the tumours (Neal & Hoskin 2002; Spiro 2002). Hence the majority of the patients must 
rely on non-surgical and adjuvant therapies. Chemotherapy options differ dependent on 
the type of lung cancer, SCLC is often sensitive to chemotherapy and the majority of 
patients will be given combination therapy of cisplatin or carboplatin with etoposide. For 
NSCLC around 90% of patients will present with advanced disease and for these patients 
surgery is rarely curative. Chemotherapy is often only palliative and aimed at improving 
life expectancy by months and attempting to reduce symptoms by reducing tumour 
burden. Chemotherapy regimens again often use combinations of cisplatin or carboplatin 
with other drugs such as gemcitabine, pemetrexed, paclitaxel (Taxol) or vinorelbine (Spiro 
2002; Cancer Research UK 2011a). 
1.1.1.1 Origins of lung cancer  
The human respiratory system begins with the pulmonary airways at the 
nose/mouth and leads down to the pharynx and trachea. The airway divides into two 
main bronchi which enter the lungs where they continue to divide into smaller bronchi 
and bronchioles. The continued branching leads to terminal bronchioles at the end of 
which are the alveolar sacs. These contain clusters of alveoli, the site of gas exchange (See 
Figure 1.3).  
The pulmonary system is made up of a range of specialised cell types. The upper 
airway epithelium, the trachea, is a simple layer of basal, goblet (mucosal), Clara and 
ciliated cells. As the airway continues down the epithelium variant Clara cells and 
pulmonary neuroendocrine cells are also present, clustering to form neuroepithelial 
bodies (NEB) (Figure 1.3). The bronchioles are mainly covered with Clara and ciliated cells. 
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Specialised alveolar cells form the extremely thin (~0.5 micrometres) alveoli walls. Two 
subtypes of epithelial alveolar cells have been observed; alveolar type-I cells (type I 
pneuomocytes and alveolar type-II cells (type II pneuomocytes). The type-I cells are less 
numerous than the cubic type-II cells but cover a much larger surface area. The alveoli are 
surrounded by a network of small, single endothelial cell walled, capillaries to aide gas 
exchange into and out of the blood system (Breeze & Turk 1984; Sutherland & Berns 
2010). 
 
 
Figure 1.3. The human pulmonary system.  
The structure of the pulmonary airways and the different cell types making up the epithelium are 
pictured. Common locations for the development of lung cancer sub-types are indicated. The 
NSCLC Squamous cell carcinoma is found in the upper airways, SCLC in the midlevel bronchi and 
adenocarcinoma in the lower airway. Adapted from (Sutherland & Berns 2010). 
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 The origin of formation of lung cancer differs between subtypes; adenocarcinoma 
typically forms within the lower airway, the bronchioles or alveoli. SCC often forms in the 
upper airways and SCLC in the midlevel bronchi whereas adenocarcinomas typically form 
peripherally. The preference of certain subtypes to form in certain areas of the lung 
suggests they arise from cell types distinct to those regions, see figure 1.3.  
Small cell carcinoma is known to arise from the cells at the basal layer of the 
bronchial epithelium. It is morphologically characterised by small uniform cells with a 
number of neuronal characteristics such as neuronal cell adhesion molecules (NCAM) and 
neurosecretory granules (Neal & Hoskin 2002; Onganer et al. 2005). The presence of the 
neuroendocrine markers suggests that this form arises from the pulmonary 
neuroendocrine cells that make up the neuroepithelial bodies (Meuwissen et al. 2003; 
Wistuba et al. 2001). 
Evidence suggests that adenocarcinoma originates in the bronchioalveolar stem 
cells (BASCs) which express both the Clara cell marker CC10 and Surfactant Protein C 
(SPC), an alveolar type-II marker. The BASCs also express two stem cell markers, Sca-1 and 
CD34, known markers of hematopoietic and skin stem cells. To evaluate whether BASCs 
are the origins of adenocarcinoma Kim et al showed BASC number correlated with 
adenocarcinoma progression in Lox K-ras mice (Kim et al. 2005; Jackson et al. 2001; 
Sutherland & Berns 2010). 
SCC forms preferably in the upper trachea. The expression of keratin 5 and 14, 
markers of the progenitor cells of tracheal basal cells by SCC tumours suggests origins lie 
within this cell type which populates the upper trachea (Sutherland & Berns 2010; 
Giangreco et al. 2007). 
1.1.1.2 Molecular origins of lung cancer 
A number of genetic aberrations have been identified within lung cancer cells. The 
main subtypes are further broken down by genetic and molecular analysis and this often 
influences treatment options. Germ-line mutations in p53, retinoblastoma (RB) or the 
epidermal growth factor receptor (EGFR) gene increase risk of developing a number of 
cancers (Zochbauer-Muller et al. 2002b; Herbst et al. 2008). Table 1.1 details the common 
gene mutations and their frequency in different types of lung cancer. 
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Histological Subtype 
Non Small-Cell Lung Cancer 
Small-Cell Lung 
Cancer Squamous-Cell 
Carcinoma 
Adenocarcinoma 
 Precursor 
Genetic Change p53 mutation 
KRAS mutation, 
EGFR mutation  
Overexpression of  
c-Met 
  Cancer 
   KRAS mutation Very rare 10-30% Very rare 
BRAF mutation 3% 2% Very rare 
EGFR 
   
 
Kinase domain 
mutation Very rare 10-40% Very rare 
 
Amplification 30% 15% Very rare 
 
Variant III mutation 5% Very rare Very rare 
FGFR1 
       Amplification 20% Very rare ~50% 
HER2  
   
 
Kinase domain 
mutation Very rare 4% Very rare 
 
Amplification 2% 6% Unknown 
ALK Fusion Very rare 7% Unknown 
MET 
   
 
Mutation 12% 14% 13% 
 
Amplification 21% 20% Unknown 
TITF-1 amplification 15% 15% Very rare 
p53 mutation 60-70% 50-70% 75% 
LKB1 mutation 19% 34% Very rare 
PIK3CA 
   
 
Mutation 2% 2% Very rare 
 
Amplification 33% 6% 4% 
 
Table 1.1 Common genetic and epigenetic abnormalities within different subtypes of lung 
cancer. Percentage of cases for each mutation or amplification events is shown. Adapted from 
(Herbst et al. 2008) 
 
Mutations in, or amplification of, the tyrosine kinase receptor EGFR, are common 
in NSCLC, particularly in adenocarcinoma. The majority of mutations in the tyrosine kinase 
domain (TK) of the receptor lead to the hyperactivation of the receptor. This results in 
over activation of the many downstream pathways that are involved in cell proliferation 
and survival. A number of small-molecule inhibitors, tyrosine kinase inhibitors (TKI’s), 
have been developed to specifically target the receptor or its family members (HER2, 
HER3 and HER4). Two of these, erlotinib and gefitinib, were initially licensed for use for 
NSCLC patients who had failed to respond to typical therapy regimes. Both specifically 
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target the tyrosine kinase activity of the EGFR (Sharma et al. 2007).  More recent clinical 
trial results demonstrated that upfront use of these inhibitors was better than 
chemotherapy so they are now used as initial treatment in patients whose tumours 
contain activating mutations of EGFR. Although the initial response to TKIs is good, 
resistance is rapidly developed. In around 50-60% of cases this resistance has been shown 
to be due to a further mutation to the TK domain of EGFR, T790M mutation. Though it is 
important to note that this additional mutation has also been found in patients who have 
never received TKI treatment (da Cunha Santos et al. 2011; Zhang et al. 2010). c-Met is 
the hepatocyte growth factor (HGF) receptor which, upon ligand binding, activates 
downstream pathways such as the phosphatidylinositol 3-kinase (PI3K)/Akt and the signal 
transducers and activators of transcription (STAT) pathways. c-Met mutation or, more 
commonly, overexpression is also common in NSCLC and is suspected to be an additional 
marker for poor response to EGFR inhibitor treatment as the incidence of amplification of 
c-Met increases from 7%, in those that have not had TKI treatment, to 10-20% in those 
with acquired resistance to erlotinib or gefitinib (da Cunha Santos et al. 2011). It is 
proposed that amplification of c-Met drives HER3 dependent activation of the PI3K 
allowing the tumour to overcome its dependence on the EGF pathway (Engelman et al. 
2007). On-going investigations into therapeutics targeting the c-Met, PI3K and EGFR 
pathways along with other key molecules in oncogenic pathways suggest that the 
molecular signature of the tumour type, rather than the histopathological subtype, will be 
of increasing importance when making therapeutic decisions. 
1.1.1.3 Aetiology 
Smoking is a leading cause of lung cancer, responsible for approximately 86% of 
the burden. Tobacco contains over 3500 different chemicals of which at least 20 have 
been shown to be pulmonary carcinogens (Ruano-Ravina et al. 2003). The bronchial tree 
and alveoli of the lung are directly exposed to the hydrocarbons within the smoke, 
leading to damage over time. The risk of lung cancer attributed to smoking increases with 
time and intensity of smoking (Neal & Hoskin 2002; Ruano-Ravina et al. 2003). Of all lung 
cancers, 3% can also be attributed to inhalation of passive cigarette or cigar smoke 
(Cancer Research UK 2011c). Other causes of lung cancer have been identified. 
Occupational exposure to certain carcinogens is known to lead to high incidence of lung 
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cancer. Asbestos exposure in the construction industry has led to a high incidence of 
mesothelioma amongst this cohort. Radon gas, released from uranium present in all rocks 
and soils, is the second biggest cause of lung cancer. A high mortality rate of lung cancer 
was seen in miners in the 19th century as they were exposed to particularly high levels of 
radon gas (Neal & Hoskin 2002). Outside of chemical causes, previous lung disease such 
as tuberculosis or pneumonia, past cancer treatment or a family history of lung cancer 
can increase the risk of developing this disease. (Cancer Research UK 2011c) 
1.2 Metastasis 
Metastasis is the process by which cancer cells leave the primary tumour and 
colonize distant sites. Although metastatic lesions may only be visible at advanced stages 
of the disease, it is widely accepted that tumour cells disseminate early in the process of 
lung cancer (Tanaka et al. 1999) with common locations for secondary tumours including 
the liver, brain, adrenal glands and bone.  
There are a number of suggested models for how tumour cells acquire metastatic 
potential. The progression model suggests that successive mutations occur within a 
subpopulation of tumour cells providing these with the ability to metastasise. Despite a 
body of evidence supporting this model, it has met some criticism as cells in secondary 
sites sometimes lack increased metastatic potential as compared to those in the primary 
tumours. If the cells possessed a genetic disposition to metastasis then further 
dissemination would be expected to initiate from the secondary tumours. However, this 
has rarely been reported (Hunter et al. 2008; Geiger & Peeper 2009). A second model, the 
transient compartment model, suggests that all cells in the tumour have the ability to 
metastasize but only a small proportion detach and leave the primary lesion. This is 
determined by the cells positioning within the tumour mass, the surrounding 
microenvironment or epigenetic factors. Finally, a cell fusion model has been suggested 
to explain the acquisition of various characteristics required for metastasis. Fusion of 
epithelial tumour cells with more invasive cell types like fibroblasts or immune cells may 
provide the cells with these requirements, although there is currently no conclusive 
evidence for this model (Hunter et al. 2008; Geiger & Peeper 2009).  
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Although, the metastatic process is complex, five main steps are commonly 
accepted to be required (See Figure 1.4). These are:   
(1) Detachment from the primary tumour and local invasion of tumour cells;  
(2) Intravasation into nearby blood or lymph vasculature; 
(3) Survival in the circulation; 
(4) Arrest and extravasation at the distant site;  
(5) Proliferation to establish a secondary tumour. 
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Figure 1.4 The Metastatic Cascade.  
1) Tumour cells detach and invade through the local extracellular matrix away from the primary 
tumour. 2) Cells intravasate into a blood or lymph vessels and enter the stream. 3) Tumour cells 
resist anoikis by interaction with platelets, immune cells attempt to clear circulating tumour cells. 
4) At a distant site tumour cells arrest in the vessel and extravasate into surrounding tissue. 5) 
Cells proliferate to establish a secondary tumour. Adapted from (Bendas 2011) 
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The metastatic cascade is a highly selective process. Those cells which do have the 
potential to enter the metastatic cascade undergo multiple stages at which the lack of 
adhesion, the turbid pressures of being in the circulation or the action of immune cells 
may result in cell death. Tracking of fluorescently labelled cancer cells injected into mice 
have shown that fewer than 0.01% of cells that enter the circulation survive to form 
metastasis (Chiang & Massague 2008). 
At all stages of the metastatic cascade the loss of cell adhesion is extremely 
important. There are three types of cell-cell or cell-matrix adhesion; tight junction, gap 
junction and anchoring junction. Gap junctions are not considered to be adhesive 
structures but instead are crucial for facilitating the transfer of metabolites and electrical 
signalling between cells. They are therefore less important for cell motility though crucial 
for co-ordination of tumour behaviour. Tight junctions are essential for maintaining 
distinct tissue structures. The anchoring junctions connect the cytoskeletons of 
neighbouring cells or a cell to the extracellular matrix (ECM). They are formed by a 
number of key adherence molecule families such as cadherins, crucial for cell to cell 
anchoring junctions, integrins, required for anchoring to the ECM, immunoglobulins and 
other molecules such as CD44. The importance of cell-cell adhesion has been shown in 
several mouse models, for example the silencing of E-Cadherin within a prostate cancer 
mouse model leads to extensive invasive metastasis (Perl et al. 1998). If a tumour cell is to 
move away from the primary tumour mass these adhesions must be broken. Loss or 
deregulation of any of the key adhesion molecules can result in an increase in cell 
invasiveness and metastasis (Jiang & Mansel 2004; Thiery 2003). 
1.2.1 Detachment and invasion 
Detachment from the primary tumour mass requires the cells to undergo a 
number of dramatic changes to the cell structure and cell-cell junctions. Tumours are 
highly heterogeneous and not all cells within the tumour will possess the ability to 
undergo the metastatic cascade. In this first stage cells must lose their cell-cell junctions 
and invade through the basement membrane, a dividing structure between epithelial and 
stromal environments (Valastyan & Weinberg 2011). Tumour cells have been observed to 
invade through the surrounding tissue by two different methods; single-cell and multiple-
cell invasion (Friedl & Gilmour 2009). 
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1.2.1.1 Single-cell invasion 
In order for single cells to invade it is proposed that they adopt a mesenchymal 
phenotype. This process, epithelial-mesenchymal transition (EMT), is an important step in 
the development of the mesoderm during embryogenesis and has been observed to play 
a vital role in cancer progression. During EMT, epithelial cells lose the expression of key 
epithelial cell markers such as E-cadherin and increase expression of mesenchymal 
markers such as β-Catenin. This change in expression is orchestrated by a number of 
transcription factors, namely Slug, Snail, Twist and ZEB1/2 in response to stimulus from 
the microenvironment or genetic alterations (Valastyan & Weinberg 2011). Without the 
expression of key cell adherence molecules cell-cell and cell-matrix contacts are lost and 
cells become more motile (Fang, et al., 2011). E-cadherin is seen as the key marker for 
determining EMT. Loss of E-cadherin can be caused by a number of factors. The intrinsic 
genetic instability of cancer cells allows for mutations to be acquired to increase the 
metastatic potential (Chiang & Massague 2008). Mutations within the gene encoding E-
cadherin can lead to a decrease or loss of its expression. Signalling through a number of 
growth factor receptors such as EGFR, fibroblast growth factor (FGF) receptor (FGFR), 
hepatocyte growth factor (HGF) receptor (c-Met) and the activation of the tyrosine kinase 
SRC (v-src avian sarcoma viral oncogene homolog) can reduce E-cadherin and integrin 
expression giving a mesenchymal phenotype. The importance of integrin expression is 
discussed later in section 1.3.3. Signalling by growth factors is one of the ways in which 
the microenvironment of the tumour plays a key role in tumour invasion (Chiang & 
Massague 2008; Wang & Shawn 2010).   
It has been suggested that cell migration does not always require the acquisition 
of a mesenchymal phenotype and that amoeboid like cells may migrate faster than those 
with expression of mesenchymal traits. Amoeboid migration is used by a wide range of 
cell types and is defined by rapid protrusion and retraction of extensions termed 
pseudopods. Certain tumour cell lines have inherent amoeboid migration, such as the 
colon carcinoma cell line LS174T, others such as HT-1080 the fibrosarcoma line have been 
shown to adopt this migratory method after inhibition of proteases. This switch to 
amoeboid-type migration after matrix metalloproteinases (MMP) inhibition has 
suggested that this method is less dependent on the action of MMPs than mesenchymal 
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cell migration. However whether amoeboid migration is completely independent of MMP 
activity is still under scrutiny (Sanz-Moreno et al. 2011; Lämmermann & Sixt 2009; Sabeh 
et al. 2009).  
Histopathological analysis of secondary colonies or metastasis suggests the cells 
once again have an epithelial phenotype. This suggests that cells that do undergo EMT as 
part of the process of invasion convert back to an epithelial phenotype (MET – 
mesenchymal epithelial transition) during the colonization of a distant site (Kalluri & 
Weinberg 2010). 
1.2.1.2 Multiple-cell invasion 
Though single cell invasion is observed it is suspected that the majority of cancer 
cells invade via multiple-cell invasion. Cells invading collectively are thought not to 
undergo EMT, cell-cell contacts are conserved and the cells do not lose their polarity (Ilina 
& Friedl 2009). The leading edge of a collective migrating sheet is characterised by the 
presence of extremely motile cells, these act as the leading edge of a single cell. Migration 
occurs in a highly coordinated fashion by communication between cell-cell junctions in 
the cell mass (Khalil & Friedl 2010; Yilmaz et al. 2007). In order to move the cells 
synchronise their actin cytoskeleton to form a single contractile body. The cells at the 
leading edge of this mass provide traction via pseudopod activity, with those cells behind 
the leading edge being dragged passively along (Friedl & Wolf 2003).  
The ECM poses a massive challenge to collectively migrating cells, obstructing 
progression. Multiple-cell invasion therefore often results in dramatic remodelling of the 
ECM. An increase in expression of key MMPs allows for protease degradation of ECM 
components. For the cell, digestion of the ECM also results in a release of stored growth 
factors, increasing cell proliferation and directional migration (Ilina & Friedl 2009; 
Valastyan & Weinberg 2011; Yilmaz et al. 2007). 
1.2.1.3 Microenvironment  
The tumour microenvironment is extremely important in determining the fate of a 
tumour. The availability of oxygen and nutrients from a good blood supply, favourable 
interactions with immune cells and routes for cell invasion are all necessary for the 
tumour to continue to grow and metastasise. In order to adapt the microenvironment to 
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their needs, cancer cells often significantly remodel their environment, changing the ECM 
structure and initiating the formation of new blood vessels (angiogenesis). This 
remodelling is also crucial during the initial stages of the metastatic cascade. 
1.2.1.3.1 Matrix Metalloproteinases  
Matrix metalloproteinases (MMP) activity, as mentioned, is required by many 
forms of cell invasion to degrade and remodel the ECM. MMPs are zinc-dependent 
endopeptidases. There are 23 recognized MMPs, some are excreted, others membrane 
bound. They can be separated into groups based upon the nature of their substrates. 
Some are very selective in their targets like collagenases (MMP-1, -8 and -13) and 
gelatinases (MMP-2 and -9), while others degrade a broad spectrum of ECM components 
such as stromelysins (MMP-3, -10, and -11) and matrilysins (MMP-7) (Woodhouse et al. 
1997; Radisky & Radisky 2010). MMPs have a general structure of three domains; a 
catalytic domain, a hemopexin-like C-terminal domain and a pro-peptide region. 
Expressed in an inactive form they are activated by the disruption of the inhibitory 
binding between a cysteine residue of the pro-peptide domain and the zinc ion of the 
catalytic domain. This activation is carried out by convertases which proteolytically 
remove the pro-peptide domain. This is the key stage for regulation of MMP activity and 
can be controlled by other active MMP’s (Kessenbrock et al. 2010). Certain MMPs have 
been observed to play central roles in aiding the progression of metastasis. MMP-7 is 
expressed by osteoclasts at the interface between bone and tumour. Its expression 
triggers osteolysis via activation of RANKL (Receptor activator for Nuclear Factor κB 
Ligand), and allows the tumour cells to embed into the bone structure and form 
metastatic sites (Lynch et al. 2005). Adhesion molecules at cell-cell junctions are cleaved 
by MMP-1, -3 and -7, facilitating the initial release of cells from the tumour mass. MMPs 
can also induce the cleavage of other proteases, such as the cleavage of protease 
activated receptor-1 (PAR-1) by MMP-1 which has been implicated in the increased 
migration and invasion of breast cancer cells (Radisky & Radisky 2010; Boire et al. 2005). 
1.2.1.3.2 Stromal cell interaction 
It is well established that tumours are infiltrated and surrounded by stromal cells 
of varying types. The tumour uses the responses of fibroblasts and many types of bone 
marrow derived cells (BMDCs) including macrophages, mast cells and mesenchymal stem 
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cells to promote its progression (Joyce & Pollard 2009). The recruitment and proliferation 
of tumour associated macrophages occurs at the tumour site in response to 
inflammation. These macrophages release key growth factors such as EGF, FGF and PDGF 
(platelet-derived growth factor), along with secreting their own MMPs. The increase in 
growth factor secretion promotes the tumour cells proliferation and invasion. Whilst 
MMP activity will remodel the surrounding ECM creating tracks for MMP independent 
tumour cell invasion, the presence of macrophages activates myofibroblasts which 
secrete SDF-1 (Stromal-cell derived factor) and HGF. SDF-1 release recruits endothelial 
progenitor cells to the tumour site, again aiding cell proliferation, whereas HGF will 
further stimulate tumour cell invasion by signalling through c-Met (Sahai 2005; Chiang & 
Massague 2008; Joyce 2005).  
1.2.1.3.3 Angiogenesis 
Angiogenesis is the vital process of forming of new blood vessels and is strictly 
controlled during development and wound healing. It is also a key process for tumour 
biology, beyond a certain size, ~1-2 mm3, tumour cells suffer from a lack of oxygen, 
hypoxia, and other nutrients. Tumour cells release a range of growth factors to stimulate 
the development of new vessels, predominantly vascular endothelial growth factor A 
(VEGFA), FGFs and EGF. The hypoxic conditions within a tumour lead to accumulation of 
hypoxia-inducible factors (HIF1A, HIF2A). HIF targets many angiogenesis related genes 
such as VEGF as well as promoting migration by regulating c-Met expression (Yilmaz et al. 
2007; Geiger & Peeper 2009). Imaging of the vessels produced by tumour angiogenesis 
has shown that the vasculature is abnormal. The vessels are often poorly organised and 
leaky due to poor interactions between the cells of the endothelial walls (McDonald & 
Choyke 2003). 
In addition to promoting the formation of new blood vessels, it has been observed 
that lymphangiogenesis, proliferation of new lymphatic vessels, is also stimulated by 
tumours releasing VEGFC and VEGFD (Bogenrieder & Herlyn 2003). This observation was 
surprising as the lymphatic system does not supply oxygen or nutrients to the tumour and 
therefore offers little advantage.  It may be than lymphangiogenesis is simply a side effect 
of the release of pro angiogenesis factors by the tumour (Cao 2005) 
1.Introduction 
34 
 
1.2.2 Intravasation 
Tumour cells enter the blood or lymphatic system by a process termed 
intravasation. This can be a result of cells actively invading away from the primary tumour 
towards established vessels. Invasion is directed by chemokine gradients from the 
vessels. The presence of TGFβ (transforming growth factor β) enhances mammary 
carcinoma’s intravasation by increasing penetration of the vessel walls (Valastyan & 
Weinberg 2011). As described, tumours often induce the formation of new blood vessels, 
by neo-angiogenesis to obtain the nutrients and oxygen supply they require. New vessels 
often have weak interactions between the endothelial cells which make up the vessel 
walls, this leaky and disorganised structure provides a much easier route into the 
circulation (Goel et al. 2011; Valastyan & Weinberg 2011). Tumour cells are not only 
attracted to blood vessels by chemokine gradients, TMAs have been shown to guide 
tumour cells to sites of intravasation (Wyckoff et al. 2007; Joyce & Pollard 2009). Entering 
blood or lymph vessels through the vessel walls requires further molecular changes by the 
cancer cell. Entry into blood vessels is accompanied by cytoskeletal deformation and 
electron microscopy has shown that tumour cells produce membrane protrusions into 
gaps in the endothelial wall in order to enter lymph vessels (Mehlen & Puisieux 2006). 
From a clinical perspective tumours with an extensive blood supply, independent of the 
condition of this supply, are not indicative of good prognosis due to the ease by which the 
tumour can disseminate throughout the patient (Mankoff & Dunnwald 2009). Indeed 
quantification of the number of circulating tumour cells is proposed as a potential 
prognostic marker. 
1.2.3 Survival in circulation 
Once cells enter the circulation they can be rapidly spread throughout the body. 
This is a highly selective environment for the tumour cell. The pressure exerted on the cell 
by blood flow, the lack of cell-cell adhesion and the interaction with host immune cells 
can result in cell death (Joyce & Pollard 2009). Cell death that occurs when adherent cells 
lose contact with the extracellular matrix and neighbouring cells is termed anoikis. This 
mechanism of cell death is designed to regulate tissue organisation and restrict growth of 
cells which may reattach at inappropriate sites (Frisch & Francis 1994). The ability of 
metastasizing cancer cells to resist this form of cell death is crucial to their survival in 
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circulation (Mehlen & Puisieux 2006). Hence, this is a critical bottleneck in the cancer 
dissemination. Cancer cells however do have a number of adaptions which allow them to 
increase their chances of survival. EMT, described above, reduces the expression of key 
adherence molecules leaving the cell less reliant on cell-cell or cell-matrix adherence. 
Immune cells such as natural killer (NK) cells are a particular risk for cancer cells in 
circulation. Expression of tissue factor, a receptor for coagulation factors VIIa and X, 
results in the formation of platelet aggregates around the cancer cell protecting it from 
lysis by NK cells. The formation of these platelet aggregates around the tumour cells also 
serves to protect the cells from the shearing forces of circulation and may aid the 
eventual arrest of the cell (Joyce & Pollard 2009). It is suspected that tumour cells do not 
persist in the circulation for longer than a few hours due to their larger diameter than the 
majority of naturally circulating cells and the large platelet aggregates they form. They are 
therefore likely to arrest in small capillaries very quickly (Valastyan & Weinberg 2011). 
1.2.4 Cell arrest and Extravasation 
It was noted even in the fifth century BC by the Egyptians that the destination of 
metastasis is not random (Nguyen & Massagué 2007). Breast cancer commonly 
metastasises to the lung, liver, bones or brain, Lung cancer metastasis preferentially form 
in the bone, liver and brain whereas metastatic prostate cancer forms almost exclusively 
in the bone. Questions have been raised over whether the site of metastasis is 
determined by passive of predefined homing of the tumour cell. Two main theories have 
been put forward to explain this preference for certain primary cancer types to 
metastasize to certain organs or tissues.  
Mechanistic Theory was proposed by James Ewing in 1928. This proposes that the 
destination of the metastasis is determined by the layout of the circulation and the 
haemodynamics relative to the primary tumour (Ewing 1928). The commonly supplied 
evidence for this is that colorectal cancers often metastases to the liver via the portal vein 
which drains directly from the bowel to the liver. However this theory is much disputed, 
for example breast carcinoma often metastasizes to the liver however rarely to the spleen 
to which it has a very similar circulation (Gupta & Massagué 2006).  
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The second proposed theory was developed by Paget in 1889. His “Seed and Soil” 
theory described his interpretation of how tumour cells, when entering the circulation, 
are like plant seeds, being spread in all directions. He likened the specificity of metastatic 
sites to seeds only propagating in suitable soil conditions. A more modern analysis of this 
would be that the cancer cell must acquire certain characteristics in order to be able to 
populate the target site, and that these are determined by the target organ rather than 
the parental tumour (Joyce & Pollard 2009). This theory has been demonstrated using 
mouse models; injecting parental cells and selected metastatic variants and observing the 
location of eventual colonisation within the mouse (Hart & Fidler 1980). Transcriptome 
profiling of parental and metastatic tumours has confirmed tissue tropism is genetically 
determined. This is further demonstrated in breast cancer where ER+ tumours 
metastasise to the bone whereas ER- tumours aggressively spread to the visceral organs 
(Nguyen & Massagué 2007; Joyce & Pollard 2009; Fidler 2003)  
Although it is clear that blood vessel architecture is not the only determinant, it is 
a crucial factor in the arrest and extravasation process (Mehlen & Puisieux 2006). After 
exiting from vessels into the tissue, cells will die if the microenvironment is not 
favourable. At this stage many adhesion molecules are involved in establishing contact 
with the extracellular matrix and surrounding cells. One such molecule, CD44, is 
expressed by tumour cells allowing them to interact with the ECM. Disruption of this 
interaction can result in the tumour cell undergoing apoptosis (Mehlen & Puisieux 2006; 
Zetter 1993). The need to reattach to a matrix and form new cell to cell contacts may 
explain why cells undergo MET, and are found with epithelial rather than mesenchymal 
characteristics at metastatic sites. 
1.2.5 Proliferation 
Once in a suitable microenvironment, secondary tumours are thought to develop 
by clonal growth. Survival of cancer cells during the initial proliferation has been shown to 
be a consequence of the cells ability to interact and participate in molecular cross talk 
with the microenvironment surrounding it. Growth factor receptor and ligand interaction 
between the cancer cell and stromal cells such as macrophages and fibroblasts are crucial 
for induction of angiogenesis and up-regulation of pro-survival pathways within the cell 
(Mendoza & Khanna 2009). Disseminated cells often do not proliferate straight away and 
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single cells can remain dormant in tissues for a number of years before recuperating their 
proliferative potential (Geiger & Peeper, 2009). Lack of angiogenesis may limit growth 
and encourage dormancy; however in some cases tumour cells have been observed 
quiescent where angiogenesis does not seem to be the rate limit step. It may be that 
disseminated tumour cells are not able to re-enter the normal cell cycle, this could 
explain why chemotherapy agents fail to eradicate dormant metastatic cells (Gupta & 
Massagué 2006). Expression of key adherence molecules, such as integrins, is seen to be 
required to initiate the proliferative process. This is shown by inhibition of metastasis in 
tumours with suppressed urokinase plasminogen activator which blocks aνβ1 integrin 
expression. A disseminated cell must also be able to adhere to components of the ECM, 
Laminin for example (Joyce & Pollard 2009; Aguirre-Ghiso 2007). 
1.3 Cell Motility 
Cell motility is crucial in developmental processes such as gastrulation and later 
for wound healing and the inflammatory response where migration of cells such as 
fibroblasts and leukocytes is required. Several diseases are characterised in part by 
uncontrolled cell motility which drives their progression of symptoms; these include 
cancer, osteoporosis and chronic inflammation (Ridley et al. 2003). In many cancer types 
the occurrence of metastasis is one of the key causes of death. Developing therapeutics 
to target the tumour cells ability to migrate and invade away from the primary tumour 
could help to reduce the occurrence of metastasis and therefore improve cancer, 
specifically lung cancer, survival rates.  
As with invasion, cells move either as single cells (with amoeboid or mesenchymal 
form) or as a collective sheet (Friedl & Wolf 2010). The form of migration used is 
dependent on cell type but also largely on the microenvironment. While cell migration is 
a highly integrated process with many components working simultaneously, a series of 
steps are commonly accepted to be involved, (Figure 1.5). Cells migrating as single 
entities display a number of macroscopic changes. The cell must first acquire polarity, 
with a clear distinction between the cell’s front and rear. Polarization results in increased 
membrane activity at the leading edge of the cell, seen as extension of lamellipodia and 
filopodia. This is accompanied by the sensing of chemo-attractants by proteins on the 
surface of the pseudopodia to coordinate protrusions (Woodhouse et al. 1997). 
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Lamellipodia are broad, sheet-like structures while filopodia are thinner more needle-like 
projections. These extensions are actin-rich and can extend in any direction. The leading 
edge of the cell is also characterised by increased formation of attachments or adhesions. 
These attachments act as hinges with the cell moving across and over the adhesions 
(Ridley et al. 2003). The appropriate regulation of these adhesion complexes in time and 
space is crucial to successful migration. A number of cytoskeletal proteins are 
phosphorylated upon adhesion or filopodia extension. These proteins include focal 
adhesion kinase (FAK), paxillin and tensin. Inhibition of these phosphorylation events 
reduces the ability of cells to migrate, highlighting the importance of these post-
translational modifications (Lauffenburger & Horwitz 1996). Once new adhesions are 
formed the cell contracts, moving forward on the new adhesions and detaching old tail 
attachments. The tail is retracted and the cell moves forward, Figure 1.5. 
 
 
Figure 1.5. Polarization of a cell.  
In order to migrate a cell must first polarise, often as a result of stimulation by a chemoattractant 
gradient towards which the cell will moves. The leading edge is defined by protrusion of the cell 
membrane in the direction of travel. Significant changes to both the actin and microtubule 
cytoskeleton allow for protrusions to be formed. New focal adhesions are formed at this leading 
edge. The cell body is then pulled forward using force generated by actomyosin contraction 
through the new focal adhesions. The tail is retracted and old focal adhesions are lost as the cell 
moves forward. Adapted from (Badano et al. 2005; Ridley et al. 2003) 
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1.3.1 The Actin cytoskeleton 
The globular ATP-binding protein Actin is the key component of the three 
dimensional actin cytoskeleton. This cytoskeleton is vital for cell structure and a range of 
cellular processes. Actin is found either as monomers (G-actin/Globular-actin) or as 
polarised filaments (F-actin/Filamentous-actin) that are made up of double helical 
polymers of G-actin subunits (Welch & Mullins 2002; Pollard 2007).  The reorganisation 
and growth of the polarized filaments of the actin cytoskeleton is crucial for cell motility. 
Each filament has a “barbed” plus (+) end and a slower growing pointed minus (-) end. 
The barbed ends of the filaments are commonly placed towards the cell membrane 
(Pollard & Borisy 2003). It is these filaments that form the lamellipodia and filopodia 
protrusions in a migrating cell. Lamellipodia contain a highly branched F-actin network 
whereas the longer finger-like filopodia contain long parallel bundles of F-actin (Ridley et 
al. 2003). In the formation of these protrusions and in the movement of the cell body 
there are three main mechanisms which drive F-actin growth and reorganisation; 
Polymerisation of the plus end of the filaments to form protrusions, depolymerisation of 
the F-actin minus end and finally the coupling of F-actin to myosin II allowing for 
actomyosin contraction which moves the cell body. The polymerisation and 
depolymerisation of this network is orchestrated by Formins, Profilin and the actin 
related protein 2 and 3 (Arp2/3) complex (Ridley et al. 2003; Pollard & Borisy 2003).  
1.3.1.1 The role of Actin related protein 2 and 3 complex (Arp2/3) in 
filament polymerization 
Arp2/3 complex is composed of seven subunits; Arp2 and Arp3 and five other 
subunits which stabilize them. The stabilizing units are ARPC1, ARPC2, ARPC3 ARPC4 and 
ARPC5. This complex is highly conserved amongst fungi, plants, amoebae and metazoans, 
as is actin (Pollard 2007). This complex is biologically inactive without the engagement of 
nucleation promoting factor (NPF) proteins. Nucleation is the initiation of actin 
polymerization using free G-actin monomers. Once activated it then initiates the 
formation of daughter filaments from existing filaments at a 70° angle, giving a branched 
structure (Welch & Mullins 2002; Goley & Welch 2006). Key NPFs that activate Arp2/3 
include ActA (the first established activator of Arp2/3), WASP (Wiskott-Aldrich syndrome 
protein), Myosin I, Scar/WAVE proteins (Suppressor of cAR/WASP family verprolin 
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homologous proteins), CARM1L (amoeba capping protein, Arp2/3 myosin I linker), 
metazoan cortacin, yeast Adp1p and Pan1p (Welch & Mullins 2002; Pollard & Borisy 
2003). Though all very structurally different, all Arp2/3 activating proteins share a CA 
region made up of a stretch of basic (C, connector region) and acidic (A, acidic region) 
amino acids and an adjacent F or G- actin binding site (Welch & Mullins 2002). This CA 
region has been shown by crystallography to bind at least four of the Arp2/3 subunits 
though the orientation of binding appears to be dependent on the NPF in question 
(Pollard 2007).  
Two mechanisms have been proposed to explain how Arp2/3 complex initiates the 
growth of a branched filament. The first, the “dendritic nucleation” model, was published 
by Pollard et al in 2000. This suggested that the active Arp2/3 complex bound to its 
activating NPF beginning the formation of the daughter filament by binding to the side of 
the existing ‘mother’ filament (Pollard et al. 2000). In the same year an alternative 
mechanism was put forward termed the “barbed end branching” model. Pantaloni et al 
suggested the Arp2/3 NPF complex binds to the barbed end of the filament and therefore 
induces branching at this point. This model therefore suggests that the active Arp2/3 
complex becomes part of the filament rather than just binding to its side (Pantaloni et al. 
2000). Evidence from fluorescent microscopy and labelling of the proteins involved 
favours the dendritic nucleation model (Welch & Mullins 2002). 
1.3.1.2 Formation of un-branched actin filaments 
Formins also play a role in actin polymerization, namely the production of un-
branched F-actin that forms the actin bundles in filopodia. Formins are large proteins that 
contain two conserved domains; formin homology-1 (FH1) and formin homology -2 (FH2) 
(Welch & Mullins 2002). Formins allow for the growth of un-branched filaments by 
binding to the barbed growing end of the filament. Here it nucleates filament assembly by 
stabilizing the interaction between the filament and actin monomers, dimers and 
trimmers. It is thought to remain attached to the growing end of the filament, referred to 
as progressive capping, thus preventing capping proteins from binding and allowing for 
continued growth of the filament (Goode & Eck 2007). Models have predicted this is done 
by each half of the FH2 homodimer interacting with only one actin subunit, and then 
stepping along as new subunits are joined (Kovar 2006). 
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1.3.1.3 Regulation of actin polymerization by Profilin and Thymosin-β4  
In order to maintain a steady rate of actin polymerization and for the cell to 
respond rapidly to non-steady state polymerization (e.g. migration) certain proteins bind 
free actin monomers and/or cap growth of filaments. Profilin is 12-15 kDa protein with a 
high binding affinity for G-actin at a 1:1 ratio (Pantaloni & Carlier 1993). By binding to the 
barbed end of actin monomers profilin allows the elongation of the barbed end of 
filaments but prevents polymerization at the pointed ends. It has also been shown to bind 
to multiple actin nucleation proteins, formins, VASP and N-WASP, again to promote 
filament growth. Thymosin-β4 acts in the opposing fashion to Profilin. By binding actin 
monomers it prevents the association between monomers and growing filaments at both 
the minus and plus end, safeguarding a reserve of G-actin. Profilin and Thymosin-β4 
compete to bind to actin monomers, and with their opposing roles they ensure that there 
is a reservoir of actin ready to be incorporated into filaments and a reserve store (Pollard 
& Borisy 2003; Pollard et al. 2000). 
1.3.1.4 Actomyocin contraction 
After the formation of protrusions and new focal adhesion complexes at the 
leading edge of the cell, the cell body must be moved forward. This is powered by the 
contractile forces produced by actomyosin contraction (Friedl & Wolf 2003). Myosin II 
interacts with F-actin, which is bound to focal adhesion complexes, generating contractile 
forces similar to those seen in muscle contraction. Myosin light chain (MLC) 
phosphorylation regulates Myosin II activity. Phosphorylation by MLC Kinase (MLCK) 
activates MLC whereas by dephosporylation by MLC phosphatase is inhibitory. The 
activity of these two regulators is controlled in response to the need for actomyosin 
contraction (Ridley et al. 2003). The activity of the small GTPases, Rho, Rac and Cdc42 are 
crucial to this process. Rho activates myosin II via Rho Kinase (ROCK) which 
phosphorylates MLCK, resulting in its activation, and MLC phosphatase, giving the 
opposite effect (Paluch et al. 2006; Ridley et al. 2003). 
1.3.2 RhoGTPases  
The activity of the small Rho GTPases is mentioned in several sections of this 
thesis. The roles of this family extend throughout a wide range of cellular processes 
including the regulation of cell motility, proliferation and survival. Deregulation of this 
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family, by mutation or altered activity, is known to be involved in tumour progression and 
metastasis (Alan & Lundquist 2013). The small GTPases are monomeric guanine 
nucleotide binding proteins of between 21 and 30 kDas. They belong to the Ras 
superfamily, with the most commonly described members being; Rac1, Cdc42 and RhoA 
(Yang 2002). The proteins in this family cycle between a GTP bound active state and a 
GDP bound inactive conformation. When in an active confirmation GTPases are able to 
bind with downstream effector proteins, interactions that are blocked in the GDP bound 
state (Alan & Lundquist 2013). The activity of these Rho GTPases is modulated by the 
activity of Rho guanine nucleotide exchange factors (RhoGEFs, GEFs), Rho GTPase-
activating proteins (RhoGAPs) and Rho guanine nucleotide-dissociation inhibitors (GDIs). 
RhoGEFs were initially identified as oncoproteins; they increase the activity of Rho 
GTPases by stimulating the formation of Rho-GTP. GEFs share a 200 amino acid catalytic 
Dbl homology (DH) domain and a 100 amino acid pleckstrin homology (PH) domain. These 
consensus domains are often flanked by a wide range of protein-protein/protein-lipid 
interaction domains which determine the regulators of the RhoGEFs along with their 
localization in the cell (Cook et al. 2013). By stimulating the conversion between GTP and 
GDP, RhoGAPs negatively regulate Rho GTPase activity. GDIs also negatively impact Rho 
GTPases, either by inhibiting GDP nucleotide dissociation and therefore maintaining the 
inactive state or by sequestering Rho GTPases from the membrane of the cell where they 
would be activated (Alan & Lundquist 2013; Cook et al. 2013). 
Rho GTPases have numerous roles throughout the process of cell motility. Actin 
polymerization is regulated by Arp2/3 and NPF’s (see section 1.3.1.1). The activity of NPFs 
is closely regulated by Rac and Cdc42. GTP bound Cdc42 or Rac1 along with 
phosphatidylinositol 4,5-bis-phosphate (PIP2) bind to the G protein-binding domains 
(GBD) of NPFs such as N-WASP removing the auto-inhibitory intramolecular interaction to 
activate these NPFs (Welch & Mullins 2002; Pollard 2007). Rac is also implicated in the 
activation of the NPF WAVE/Scar however the mechanism of this is, as yet, 
undetermined. Rho GTPases are also involved in the depolymerisation of F-actin. Rac 
stimulates p21-activated kinase (PAK) to activate LIM Kinase (LIMK) which in turn 
phosphorylates ADF/cofilin resulting in its inactivation. As the key complex in 
depolymerisation of actin filaments its inactivation prolongs the lifetime of the filaments 
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(Pollard & Borisy 2003). For un-branched actin filament growth both Rac and Cdc42 are 
again involved, this time by regulating the activity of formins. 
As described above in section 1.3.1.4 Rho GTPase activity results in the activation 
of its downstream kinase ROCK. ROCK inactivates MLC phosphatase and activates MLCK 
by phosphorylation. This increases the activity of MLCK’s downstream target MLC and 
therefore myosin II, increasing contractility of the cell and tension on focal adhesions 
(Sanz-Moreno et al. 2008; Ridley et al. 2003). The majority of the effects which Rho 
GTPases have on cellular processes are controlled by the balance of activity and location 
between the different Rho GTPase members. For instance, Rac is often found at the 
leading edge of cells where it mediates the formation of protrusions via its role in actin 
polymerization. However this activity is balanced by Rho/ROCK signalling at the rear of 
the cell. The balance of activity between the two can determine the mode of migration; 
amoeboid if there is little Rac activity, or mesenchymal when Rac-GTP levels are high 
(Friedl & Wolf 2010).  
1.3.3 Focal adhesions  
The formation and detachment of adhesions is key for the formation of traction to 
move the cell forward. As a cell migrates it forms new adhesions to the ECM, known as 
focal complexes or focal adhesions at the leading edge of the cell. These adhesions 
stabilise the lamellipodia protrusions in migrating cells (Ridley et al. 2003). The strength 
or size of adhesions formed is dependent on the cell type and therefore the form of 
migration used. Amoeboid migration forms much weaker focal adhesions and is less 
dependent on them for movement (Sahai 2005). Larger focal adhesions can inhibit 
migration as they are too strong for the cell to rapidly disassemble. Focal adhesion 
strength is also altered by the microenvironment, the matrix to which the cell adheres or 
the extracellular stimulus that has initiated novel adhesion formation must be considered 
(Fraley et al. 2010). These adhesions are integrin dependent (Sahai 2005; Ridley et al. 
2003). Integrins are trans-membrane glycoproteins formed of 18α and 18β subunits that 
assemble into 24 different integrin heterodimers with a large ligand binding domain and a 
shorter cytoplasmic tail (Bogenrieder & Herlyn 2003; Ridley et al. 2003). The cytoplasmic 
tail of the receptor is bound to the cytoskeleton. The binding of a ligand to the 
extracellular ligand binding domain results in a confirmation change in the cytoplasmic 
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domain and the clustering of integrin receptors to that location on the cell surface. This 
initiates the formation of focal complexes and the recruitment of cytoskeletal adaptor 
proteins (Ridley et al. 2003; Ilina & Friedl 2009). Over 50 different proteins have been 
identified within focal adhesions, the most characterised of these are Focal adhesion 
kinase (FAK), p130Cas, Src, talin, vinculin, paxillin, zyxin and PAK (Ilina & Friedl 2009; 
Fraley et al. 2010). Paxillin and talin are integrin binding proteins which recruit the 
adapter protein FAK and the structural protein vinculin to the focal adhesions. With a β-
integrin binding site and multiple binding sites for adhesion proteins such as actin and 
vinculin, talin is crucial in the initial stage of focal adhesion assembly to recruit other 
adhesion components (Nagano et al. 2012). Zyxin is a stress fibre binding protein that 
increases the strength of the adhesion by tethering the cytoskeleton to it. FAK is a 125 
kDa protein that was identified in 1992 by Hanks et al (Hanks et al. 1992) as a substrate of 
the known oncogene Src (Mitra et al. 2005). As well as being required for the maturation 
of focal adhesions FAK plays a role in their disassembly. FAK contains a N-terminal FERM 
(protein 4.1, ezrin, radixin, and moesin homology) domain, a kinase domain and a C-
terminal focal adhesion-targeting (FAT) domain (Nagano et al. 2012). FAK is 
autophosphorylated at Tyr397, a prerequisite for interaction with Src. The formation of a 
FAK-Src complex in focal complexes results in a structural change in Src. Src then 
phosphorylates FAK at additional tyrosine sites, this mediates the interaction with a range 
of other members of the adhesion complex all of which aide the development of the 
adhesion (Ezratty et al. 2005; Nagano et al. 2012). 
1.3.4 The microtubule network 
The actin cytoskeleton is not the only filamentous network within the cell. The 
microtubule (MT) network is composed of highly dynamic tubulin filaments and is 
required for establishing cell polarity, cell migration, vesicle trafficking and cell division. 
The MT network is found in all eukaryotic cells (Wiese & Zheng 2006). Microtubules (MTs) 
are polarised cylindrical structures assembled from polymerized tubulin heterodimers. 
Each heterodimer is composed of an α-subunit and a β-subunit joined head to tail, see 
Figure 1.6. This positioning leaves the units exposed and able to interact with the next 
dimer along forming a chain of α-β-α-β (Tang et al. 2013).  
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The structures of the heterodimers contribute to the microtubules’ polarised 
form. Each filament has a plus end from which it grows rapidly; it is terminated by a β-
subunit. The minus end is slower growing and completed by an α-subunit. This end is 
often anchored to the microtubule organising centre (MTOC) (Howard & Hyman 2003). 
The MT network is made up of a lattice consisting of ten to fifteen MT filaments bundled 
to form a hollow, rigid cylinder. It is a highly dynamic network with MTs constantly 
undergoing cycles of polymerisation and depolymerisation (Wiese & Zheng 2006). The 
fast growing plus end switches between growth and rapid shrinkage. This conversion to 
shrinkage is termed catastrophe and the change back to a growth phase called rescue, 
this behaviour is described as ‘dynamic instability’ (Mitchison & Kirschner 1984; Howard 
& Hyman 2003) (Figure 1.6).  
 
   
Figure 1.6. Microtubule structure and development.  
Microtubules constantly cycle through phases of growth and shrinkage. A shift in phase from 
polymerisation to depolymerisation is described as catastrophe, the return to growth phase is 
termed rescue. Tubulin dimers made up of α- and β-subunits are added in a GTP-bound state. 
Delayed hydrolysis of GTP to GDP helps to stabilise the microtubule until the next subunit can be 
added. Non-hydrolysed GTP-tubulin dimers do remain within the growing filament. These act as 
stop-points to prevent total depolymerisation of the filament during catastrophe and offer a point 
of return to rescue phase. Adapted from (de Forges et al. 2012). 
 
The incorporation of new tubulin dimers is dependent on GTP hydrolysis. Tubulin 
polymerises in the presence of non-hydrolysable GTP by incorporating GTP bound dimers 
at the plus end (Howard & Hyman 2003). The highly stable GTP dimers allow for 
polymerisation to be stable, the GTP bound dimer creating a GTP-tubulin cap preventing 
depolymerisation. This hold on depolymerisation allows for the recruitment of additional 
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dimers to the MT. GTP hydrolysis occurs eventually and either allows for further 
additional dimers to polymerise to the filament or for shrinkage to begin as the GTP-
tubulin cap is lost (de Forges et al. 2012). It is the composition of the tubulin dimers that 
allows for this GTP cycle to control MT growth stability. The plus end β-subunit contains a 
binding pocket for GTP but not the necessary residues for hydrolysis. These residues are 
however present on the α-subunit and therefore only available as the next dimer docks 
for polymerization (Howard & Hyman 2003). Non hydrolysed tubulin dimers are found 
within the MT filament using antibodies specifically designed to recognize GTP-tubulin. It 
is proposed that as depolymerisation reaches these more stable dimers there is a delay in 
catastrophe allowing for a return to a rescue phase (de Forges et al. 2012). 
The microtubule organising centre (MTOC) was a term first used by Pickett-Heaps 
in 1969 (Pickett-Heaps 1969). This describes the structure from which MTs originate and 
is key during cell division as two MTOCs form the poles to which chromosomes are 
separated (Lüders & Stearns 2007). It is perinucelar in location and composed of nine 
triplets of MT surrounded by proteins key for MT nucleation. One of the key components 
of the MTOC, and indispensible for nucleation, is γ-tubulin (de Forges et al. 2012). γ-
tubulin is the third member of the tubulin family and along with two accessory proteins 
Spc97 and Spc 98 forms the 300 kDa γ-tubulin small complex (γ-TuSC). The γ-TuSC 
associates with additional MTOC proteins to form open γ-tubulin ring complexes (γ-TuRC) 
from which MT nucleation arises (O’Toole et al. 2012; Lüders & Stearns 2007).  
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Figure 1.7. The two models of microtubule nucleation. 
The γ-TuRC is composed of γ-tubulin (dark blue) and additional accessory proteins such as Spc97 
and Spc98 (green ovals) docked on to MTOC capping proteins. There are two proposed models for 
microtubule nucleation from the γ-TuRC. The template model proposes tubulin dimers (grey) are 
docked onto the γ-tubulin monomers which stabilises the minus end of the growing filament. The 
alternative protofilament model suggests that tubulin heterodimers dock laterally onto γ-tubulin 
chains. Adapted from (Wiese & Zheng 2006; Zheng et al. 1995; Erickson & Stoffler 1996) 
 
There are two proposed theories to explain how MT nucleation occurs from the γ-
TuRC, Figure 1.7. The ‘template model’ (also referred to as the ‘seed nucleation’ model) 
suggests that γ-tubulin subunits serve as a template for the assembly of tubulin α/β 
dimers (Zheng et al. 1995). As the initial dimers polymerise the γ-tubulin stabilises them 
by capping the minus end. A second model, describes nucleation occurring by the 
addition of tubulin heterodimers laterally to the γ-tubulin (Erickson & Stoffler 1996), 
rather than longitudinally as described in the first model. In this model it is proposed that 
it makes no difference whether the α- or β- subunit is at the minus end. Crystal structures 
of human γ-tubulin support the proposed template model as does the positioning of the 
GTP-binding pocket of γ-tubulin in the γ-TuRC (Wiese & Zheng 2006).  
1.3.4.1 Regulation of microtubule dynamics 
For the microtubule network to perform its wide range of functions its highly 
dynamic nature must be regulated. This regulation is performed by a collection of 
proteins that fall under the umbrella of ‘microtubule associated proteins’. Within this 
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host of proteins are true MAPs (microtubule-associated proteins, those that bind directly 
to the microtubules), motor proteins (myosin VII, Dynien and kinesin), and glycolytic 
enzymes and kinases (Tang et al. 2013). These can also be grouped by function or binding 
site; destabilizing factors, severing proteins, stabilizing factors and plus-end tracking and 
minus-end capping proteins (de Forges et al. 2012).  
The most studied stabilizing proteins are the MAPs TAU, MAP2 and MAP4. TAU 
and MAP2 are highly expressed in neurons; TAU in the axons and MAP2 in dendrites. 
MAP4 is ubiquitously expressed (Susanne Illenberger et al. 1996; Tang et al. 2013). Very 
similar in structure they contain an N-terminal projection domain and a C-terminal 
microtubule binding region. This C-terminal MT binding domain contains three to four 
repeats of a highly conserved amino acid sequence (Hirokawa 1994; Susanne Illenberger 
et al. 1996). TAU is highly studied as it is the main component of the neurofibrillar 
plaques found in the brains of Alzheimer’s sufferers. In these aggregates TAU is highly 
phosphorylated at Ser-Pro or Thr-Pro motifs and specifically at Ser262 (Mandelkow & 
Mandelkow 1995). It has been shown that it is the phosphorylation of TAU and the other 
MAPs which triggers their detachment from MTs. When bound to MTs, MAP2/4 and TAU 
promote the formation of stable bundles of MTs. Upon phosphorylation at any site, MT 
binding appears to be weakened. It is thought, however, that detachment is a result of 
specific phosphorylation within the repeated motifs of the MT binding domain (Figure 
1.8). Phosphorylation of Ser262 within the first Lys-Xaa-Gly-Ser (KXGS) motif of the MT 
binding region of TAU abolishes MT binding (Drewes et al. 1998). Cells undergoing 
processes that require dramatic microtubule restructuring such as cell migration or 
division are noted to have higher levels of Phospho-Ser262 TAU.  
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Figure 1.8 Microtubule regulation by MAPs and associated kinases.  
Microtubule associated proteins (MAPs) are bound to the microtubules. MAPs are 
phosphorylated on serine residues within the KXGS motif repeats that are crucial for microtubule 
binding. This phosphorylation disrupts binding and leads to removal of the MAPs from the 
filament, decreasing the stability of the filament. This phosphorylation by key microtubule 
regulating kinases is crucial to maintain the state of dynamic instability within the microtubule 
network. Detachment of the MAP TAU leads to formation of TAU aggregates which are implicated 
in the development of Alzheimer’s. Adapted from (de Forges et al. 2012) 
 
Other microtubule binding proteins have different roles to the MAPs discussed 
above. Katanin, spastin and fidgetin are known as severing proteins; they regulate the 
length and number of MTs (de Forges et al. 2012). Their action results in release of MTs 
from nucleation sites, and seeding of new MT growth as well as triggering catastrophe 
(Sharp & Ross 2012). Strathmin is a destabilising MAP that sequestered free tubulin 
dimers and increases GTP hydrolysis and therefore encourages dynamic instability (de 
Forges et al. 2012).  
One very important family of microtubule regulating proteins is the end binding 
proteins. These are split into two classes; MCAKs (mitotic centromere-associated kinesins) 
and plus-end-binding proteins (+TIPs). MCAKs bind the plus end of MTs, specifically to the 
bend in filaments that is formed by the conformation of GDP bound tubulin dimers. Once 
bound to this curvature further bending is induced thereby weakening the association 
between the α and the β-subunit below. This triggers catastrophe in the filament (Howard 
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& Hyman 2003). Plus end binding proteins, as the name suggests, bind to the growing end 
of the microtubule filaments. They play a major role in the regulation on MT dynamics 
and MT interactions with the actin cytoskeleton, chromosomes and cell cortex (de Forges 
et al. 2012). This collection of proteins includes cytoplasmic linker proteins (CLIPs), CLIP-
associating proteins (CLASPs), p150Glued (cytoplasmic dynein/dynactin complex) and End 
binding proteins 1 – 3 (Mimori-Kiyosue 2003). End binding proteins 1 – 3 (EB1-3) are 
widely studied and play a key role in coordinating the binding and actions of other +TIPs 
(Leterrier et al. 2011). Their location and function is observed using GFP-tagged 
constructs which has allowed visualisation of the plus end growth and catastrophe of the 
MTs. EB1-3 autonomously tracks plus ends, binding ether to the sides of the 
protofilament or to the GTP cap. In these positions they aide nucleation of MTs and the 
rapid incorporation of tubulin dimers, resulting in more stable polymerization of the MT 
(Etienne-Manneville 2010).   
End binding proteins 1 – 3 also assist the binding of other non-autonomous +TIPs 
to the microtubule. An EEY/F motif in the C-terminal of the EB proteins allows CLIP 
proteins to bind whereas others such as MCAK and CLASPs bind through serine rich 
regions to the hydrophobic cavity of EB1-3 (de Forges et al. 2012). CLIP170 was the first 
+TIP to be identified (Pierre et al. 1992). Forming a complex with p150Glued (a relative of 
CLIP-170) and the MT-binding subunit of dynactin CLIP-170 co-localises to the 
microtubule plus end, recruited by EB1. There the complex is involved in MT rescue and 
stabilisation (Mimori-Kiyosue 2003; de Forges et al. 2012). Its interaction with p150Glued is 
crucial for the recruitment of dynactin to MT tips and therefore for ensuring dynein 
mediated vesicle transport along the MTs (Lansbergen et al. 2004). 
The activity of the majority of +TIPs is regulated by phosphorylation. There are a 
number of kinases which are responsible for this regulation. Glycogen synthase kinase3β 
(GSK3β) is involved in a wide range of cellular processes including MT regulation.  It is 
responsible, in this setting, for the inhibition of CLASPs by phosphorylation. CLASP activity 
is required for recruitment of tubulin dimers to growing microtubules. Phosphorylation by 
GSK3β or the mitotic kinase Aurora B decreases CLASPs affinity for binding to EB1 and 
therefore its activity at the MT plus ends (de Forges et al. 2012). GSK3β controls MCAK 
activity in the same way. CLIP170 is phosphorylated by protein kinase A (PKA) and AMP 
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kinase, inhibiting its MT binding. FKBP-Rapamycin-Associated protein (FRAP) enhances 
CLIP’s affinity for MT by phosphorylation at an alternative site (de Forges et al. 2012; 
Akhmanova & Steinmetz 2008). CLIP activity is not only regulated by phosphorylation, it is 
auto-inhibited by a conformational change in its structure. In an open, extended 
confirmation, it is able to interact with its binding partners and the MT via the exposed 
binding sites. However in a close state, the N-terminal and C-terminal are folded back on 
themselves, this restricts access to its binding domains. This change in confirmation could 
be triggered by phosphorylation but this is yet to be confirmed (Lansbergen et al. 2004). 
The above examples clearly demonstrate that the presence of these microtubule 
associated kinases and control of their activity is crucial for regulation of MAPs and 
therefore for maintaining microtubule dynamics. 
1.4 Microtubule Affinity Regulating Kinase Family 
Microtubules, as has been described above, rely on a wide range of proteins to 
regulate their instability. The activity of these microtubule associated proteins is 
regulated by phosphorylation, implicating many kinases and phosphatases in their 
control. One key family involved in this is the microtubule affinity-regulating kinase 
(MARK) family (Figure 1.9). The first members of this family were discovered in 1995 by 
Drewes et al during studies of the Ser262 site of the MAP TAU (Drewes et al. 1998). This 
phosphorylation site was found to be within a repeated motif at the microtubule binding 
region known as the KXGS motif. This motif is also found within other MAPs. Using a 
range of in vitro studies Drewes et al found that this site could be phosphorylated by 
brain extract but not by a number of known kinases. By purifying the Ser262 
phosphorylating activity in the brain extract they identified a novel protein of 110 kDa, 
MARK1, that would phosphorylate Tau at this site (G Drewes et al. 1995). This initial 
finding led, over a number of years, to the identification of four MARK family members, 
MARK1-4. The MARK family members are referred to by a range of names due to their 
homologs in other species; MARK1 – PAR-1c, MARK2 – EMK/PAR-1b, MARK3 – PAR-1a/C-
TAK, MARK4 – MARKL1/PAR-1d (Bright et al. 2009). The PAR-1 nomenclature leads to 
some confusion in many publications with MARK1 and 2 both commonly referred to as 
PAR-1 with no specification of which MARK is under discussion. 
 
1.Introduction 
52 
 
 
 
Figure 1.9. Functional domains structure of the MARK family.  
Domains include the N-terminal header, the kinase catalytic domain (Kinase domain), the 
common docking (CD) domain, the UBA domain, spacer region and the tail domain. Adapted from 
(Tang et al. 2013; Timm, Marx, et al. 2008).  
 
MARKs 1-4 are found on chromosomes 1, 11, 14 and 19 respectively (Timm, Marx, 
et al. 2008). MARKs are members of the AMP-activated protein kinase (AMPK) family, 
more specifically to the subfamily of AMPKs, the calcium/calmodiulin-dependent protein 
kinases (CaMKs) (Tang et al. 2013). All members of the MARK family have a similar 
domain structure, an amino-terminal header, a kinase catalytic domain, a common 
docking domain (CD), a ubiquitin-associated (UBA) domain, a spacer and a C-terminal tail 
domain (Figure 1.9).  
The MARK family members shall be described individually below, it should be 
noted that there is a large degree of overlap in their functions and regulation. 
1.4.1 Regulation of MARK activity 
MARK family members are regulated by a number of different methods including 
phosphorylation, ubiquitination and interaction with inhibitory proteins (Drewes 2012). 
Like many kinases MARKs are commonly activated by phosphorylation within the kinase 
domain. MARK2 purified from rat brain is phosphorylated at Thr 208 and at least partially 
at Ser212, sites which both lie within the activation loop of the kinase domain (Gerard 
Drewes et al. 1997). Active forms of the other MARK family members were also found 
phosphorylated at this conserved threonine residue (Thr 215 in MARK1, Thr 208 in 
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MARK2, Thr 211 in MARK3, and in MARK4, Thr 214 (Bright et al. 2009)) and mutational 
analysis has shown this site is crucial for kinase activity (Timm, Marx, et al. 2008). This site 
is primarily phosphorylated by the master kinase LKB1 (STK11). LKB1 is a serine/threonine 
kinase that has been shown to phosphorylate the majority of AMPK subfamily members 
(Bright et al. 2009). Mutations in this kinase have been shown to cause Peutz-Jeghers 
syndrome which predisposes sufferers to developing vascular overgrowths as well as 
benign and malignant tumours. In a complex with STRAD (STE20-related kinase adapter 
protein) and CAB39 (MO25, calcium binding protein 39), LKB1 phosphorylated MARKs 
within at the conserved threonine site in the kinase domain (Lizcano et al. 2004). MARKK 
(MARK kinase) also phosphorylates this site, though STRAD and MO25 are not required 
for MARK activation by MARKK (Tang et al. 2013). 
As mentioned, purified MARK2 is also phosphorylated at serine 212. This is the 
second key phosphorylation site located within a Ser-Pro motif in the kinase domain of 
the MARKs. However result of phosphorylation at this site is as yet not confirmed. GSK-3β 
is shown to phosphorylate MARK2 at this serine residue and two conflicting reports 
suggest that this results in inhibition and targeting for degradation of this kinase or 
further activation (Timm, Balusamy, et al. 2008; Kosuga et al. 2005). Known inactivating 
phosphorylation’s include that by aPKC (atypical protein kinase C) at serine 595 in the C-
terminal spacer domain of MARK2 which also induces 14-3-3 protein binding (Drewes 
2012; Bright et al. 2009).  
All four members of the MARK family contain a rare ubiquitin binding domain 
(UBA) adjacent to the catalytic domain. Mutation of this domain has been observed to 
disrupt LKB1 activation. Jaleel et al proposed this was due to a conformational change in 
the orientation of the UBA domain which would assist phosphorylation by LKB1, this 
change would not occur if the UBA mutated (Jaleel et al. 2006). Jaleel et al also suggests 
that no ubiquitin or polyubiquitin-like molecules interact with the UBA domain. However 
MARK4 has been shown to be polyubiquitinated in vivo and to interact with USP9X a 
deubiquitination enzyme (Al-Hakim et al. 2008). In addition a TAP-Tag of MARK4 
suggested USP7 an additional ubiquitin-dependent protease binds MARK4 (Brajenovic et 
al. 2004). This work would suggest that MARK4 is ubquitinated and that other MARK 
family members may also be. The effect on MARK activity is yet to be confirmed.  
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1.4.2 MARK1  
MARK1 (PAR1c, p110mark) was the first MARK family member to be identified in 
1995. Studies on this kinase have focused mainly on its potential role in Alzheimer’s 
development though it has also been implicated recently in autism (Maussion et al. 2008). 
Due to its implication in Alzheimer’s development, studies of MARK1 have many focused 
on its involvement in neurone development; namely polarisation of neurones. Loss of 
MARK1 from neurones has been observed to result in deregulation of neurone growth 
and loss of neuronal polarity, both markers for Alzheimer’s disease. Originally identified 
for its key role in phosphorylating Tau at Ser262 to trigger its detachment from the 
microtubule filament (G Drewes et al. 1995). MARK1 has also been shown to 
phosphorylate MAP2 and MAP4 on their microtubule binding domains within the KXGS 
motifs. As with TAU, this also triggers their detachment from the MT maintaining the 
dynamics of the MT network (Susanne Illenberger et al. 1996). Both MARK1 and MARK2 
have been shown to be required for polarisation of kidney and liver epithelial cells (Cohen 
et al. 2004; Böhm et al. 1997). As discussed, MARKs are activated by phosphorylation, see 
section 1.4.1. MARK1 is phosphorylated at Thr215 and the adjacent Ser219 by a number 
of kinases including MARK Kinase (MARKK) a member of the Ste20 kinase family. This 
kinase has also been shown to activate the other MARK family members on their relevant 
serine and threonine sites (Timm et al. 2003).  
1.4.3 MARK2 
MARK2 is the most commonly studied of the MARK family. The majority of 
publications regarding MARK activation and regulation have used MARK2 as a model 
example of the MARK family (Kosuga et al. 2005; Timm, Balusamy, et al. 2008). The 
availability of the crystal structure of a number of its key domains, the UBA and catalytic 
domain, may encouraged this work (Panneerselvam et al. 2006). Due to MARK2’s role in 
phosphorylating TAU protein, a key protein in Alzheimer's development, work on MARK2 
has focused on its role in neurones to help further understand the implications of its 
expression for Alzheimer's disease. Modulating levels of MARK2 in developing neurones 
has significant consequences for their development. In hippocampal neurones MARK2 
depletion was found to promote axon outgrowth. The opposite was seen when MARK2 
was overexpressed, axon formation was inhibited and neurones were not polarised. This 
1.Introduction 
55 
 
kinase’s role in cell polarity is proposed to be regulated by aPKC which activates MARK2 
by phosphorylation (Chen et al. 2006; Bright et al. 2009). Calcium-dependent neuron 
development also requires MARK2 activity. Calcium/calmodulin-dependent protein kinase 
type 1 (CaMK I) has been shown to phosphorylate MARK2 at three novel sites (Ser 91-93), 
mutation of these sites results in loss of MARK2 activity and reduced neuron outgrowth 
(Bright et al. 2009; Uboha et al. 2007).  A third example of the role of MARK2 in neuron 
development is its interaction with Phosphatase and tensin homolog (PTEN)-induced 
kinase 1 (PINK1). Matenia et al demonstrated in 2012 that MARK2 binds to and 
phosphorylates the cleaved form of PINK1 (ΔN-PINK1) at Thr313. This activates ΔN-PINK1 
effecting mitochondria transport along neurones (Matenia et al. 2012). It is clear from the 
number of published roles for MARK2 in neurone development that MARK2 is a crucial 
regulator of this process. 
In addition to its roles in neurone outgrowth MARK2 has also been implicated in 
the immune system and metabolism. Work with MARK2 null mice has shown a ~20% 
reduced body mass compared to the wild-type control group. Further investigation 
concluded that this is due to a decrease in adipose tissue. MARK2 null mice are resistant 
to weight gain even on a high fat diet as the loss of MARK2 results in an increased 
metabolic rate and altered glucose tolerance (Hurov & Piwnica-worms 2007). The same 
group has also shown altered immune cell function in mice depleted of MARK2. Hurov et 
al demonstrated, using MARK2 null CD4+T cells, that MARK2 loss results in an increased 
presentation of the memory marker CD44 (phagocytic glycoprotein-1) and changes in 
interferon gamma (IFM-γ) and Interleukin-4 (IL-4) production. They also observed the 
development of a number of immunological disorders in 7- to 12-month old MARK2 -/- 
mice. It was concluded that MARK2 was required for correct function of T and B cells, 
though their production was unaffected by MARK2 loss (Hurov et al. 2001).  
With regards to cell motility, MARK2 has been implicated as a downstream target 
of Rac1. Depletion of MARK2 was identified, in an RNAi screen, to suppress microtubule 
dynamics in osteosarcoma cells expressing constitutively active Rac1. Rac1 activity 
stimulates the formation of long lived microtubule protrusions in lamellipodia at the 
leading edge of a motile cell. In the absence of MARK2 this does not occur, instead only 
short lived microtubules form (Nishimura et al. 2012). This would suggest unstable 
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incorporation of tubulin dimers in the absence of MARK2, which leads to a rapid switch 
back to catastrophe rather than sustained growth of the MT. It was shown that due to 
this loss of the downstream effect of Rac1 activity migration of these cells was impaired 
(Nishimura et al. 2012). This would suggest that MARK2 is a major regulator downstream 
of Rac1 induced cell motility. 
It has been clearly demonstrated that MARK2 has a greater role than simply 
phosphorylating MAPs to maintain the dynamics of microtubules. The additional roles of 
MARK2 described here could implicate MARK2 expression in the development and 
progression of a number of diseases outside of Alzheimer's including immune disorders 
and cancer progression.  
1.4.4 MARK3 
The focus of the reported work on MARK3 (C-TAK1) has been in cell cycle control. 
Peng et al demonstrated that MARK3 phosphorylated Cdc25 phosphatase. Cdc25 controls 
the entry of a cell into mitosis. The inactivating phosphorylation of Cdc25 at Ser 216 is 
only present during interphase, and is required for the interaction between Cdc25 and 14-
3-3 protein (Peng et al. 1998). For cells to enter mitosis, Cdc25 must be dephosphorylated 
by Cdc25 phosphatase allowing it to activate the Cdc2/cyclin B complex that is required 
for mitotic entry. MARK3 has been shown to phosphorylate and therefore inactivate the 
phosphatase responsible for this process (Bright et al. 2009). In Vitro kinase assays 
suggested that MARK3 directly phosphorylated Cdc25 at Ser216. This suggests that 
MARK3 is not only responsible for maintaining the phosphorylation at this site but also its 
formation (Peng et al. 1998). MARK3 activity has been shown to be regulated by a key cell 
cycle serine/threonine kinase, Pim-1. These two kinases directly interact leading to 
phosphorylation of MARK3 by Pim-1. This phosphorylation was seen to be inhibitory and 
therefore regulated MARK3’s activity in the progression into mitosis by the mechanism 
described above (Bachmann et al. 2004; Bright et al. 2009). 
MARK3 is not the only MARK member that interacts with 14-3-3 proteins directly 
or those bound to them. 14-3-3 proteins are related to the MARK family. They interact 
with phosphorylated serine or threonine residues of a large number of proteins and are 
implicated in a wide range of cellular processes. The interaction between MARKs and 14-
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3-3 proteins is often phosphorylation dependent. For MARK3, binding to 14-3-3 has been 
found to be independent of phosphorylation at the previously identified sites, T211 and 
T564/S619, phosphorylated by LBK1 and PKC respectively. Instead 15 novel 
phosphorylation sites were identified and only with mutation of all these sites, and the 
previously reported two, (17A-MARK3), was 14-3-3 protein binding disrupted (Göransson 
et al. 2006). In addition to binding to 14-3-3 proteins itself, MARK3 also phosphorylates 
other proteins to promote their binding to 14-3-3 proteins. This is demonstrated by the 
kinase suppressor Raf-1. Raf-1 is an effector protein downstream of Ras GTPases and is 
involved in many key cellular pathways via its interactions with MEK and MAPK. MARK3 
binds to the N-terminus of Raf-1 where it phosphorylates it at Ser392. Phosphorylation at 
this site is crucial for Raf-1’s binding to 14-3-3 proteins. Disruption of this binding leads to 
altered cellular localisation and an increase in downstream signalling of Ras-MAPK 
pathway suggesting MARK3 as a key regulator of Raf-1 activity (Müller et al. 2001; Bright 
et al. 2009).  
1.4.5 MARK4 
The fourth member of the MARK family is the most recently identified, reported 
first by Kato et al in 2001 (Kato et al. 2001). Initially termed MARKL1 (microtubule affinity-
regulating kinase-like 1), it was identified in a cDNA microarray as being down regulated 
in response to a decrease in TCF/LEF1 (transcription complex, T-cell factor/lymphoid 
enhancer-binding factor) activity in hepatocellular carcinoma cells. TCF/LEF1 is a 
transcription complex that interacts with β-catenin, a key protein in the development of 
hepato-carcinoma. In 8 of 9 cases of hepatocellular carcinoma tested by Kato et al, 
MARK4 expression was higher than in the noncancerous control liver cells. This first 
publication of MARK4 already pointed towards a role for this kinase in cancer 
development (Kato et al. 2001). MARK4 expression is also increased in gliomas and 
glioblastoma cell lines (Beghini et al. 2003). Chromosome 19, where MARK4 is found 
(19q13.3), has been frequently observed to be altered in glioblastomas. However 
Magnani et al suggest that MARK4’s increased expression in glioma is not due to 
amplification of the encoding gene (Magnani et al. 2011). 
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Figure 1.10. Transcripts and Protein structures of MARK4S and MARK4L.  
MARK4 is found as two splice isoforms, a short and long form (A), taken from (Beghini et al. 2003). 
Alternative splicing results in loss of exon 16 from MARK4L and repositioning of the stop codon 
resulting in a longer transcript. MARK4L contains a Kinase associated domain (KA1) that is found 
in other MARK family members but not in MARK4S (B). Adapted from (Beghini et al. 2003; Timm, 
Marx, et al. 2008). 
  
MARK4 is found as two isoforms; a short form (MARK4S), and a long form 
(MARK4L). The two isoforms are formed by alternative splicing of exon 16 which results in 
a frame shift and alters the position of the stop codon (Magnani et al. 2011), Figure 
1.10A. MARK4S contains 18 exons encoding a 688 amino acid peptide (75.3kDa). MARKL 
lacks exon 16 but due to the re-positioning of the stop codon, encodes a longer peptide of 
752 amino acids (82.5kDa). There is no alteration to the catalytic domain present but 
MARK4L contains a kinase-associated 1 domain (found in all MARK family members) 
which is absent in MARK4S (Naz et al. 2013), Figure 1.10B. The full sequence homology 
with the three other members of the MARK family is 55%. The catalytic domain is more 
highly conserved, 90%, as is the UBA domain. The spacer region of MARK4 is least 
conserved with the homology shown to be <30% (Trinczek et al. 2004a). The crystal 
structure of MARK4 is as yet unavailable, though structure prediction models and 
comparison to the crystal structures of MARK1, MARK2 and MARK3 have allowed 
prediction of its structure, Figure 1.11 (Naz et al. 2013).  
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Figure 1.11. Predicted MARK4 structure. 
Generated using I-TASSER homology modelling software and presented using PyMOL. The three 
key domains can be seen; Kinase domain (Red), UBA domain (Blue), and the kinase associated 
domain (Pink). Taken from (Naz et al. 2013). 
 
MARK4 mRNA is ubiquitously expressed, though found in higher levels in the brain 
and testes (Trinczek et al. 2004a). Within cells, exogenous MARK4 exhibits strong 
colocalisation with microtubules and the MTOC. Exogenous expression of other MARK 
family members shows they do not display the same localisation and instead are found 
throughout the cytoplasm (Naz et al. 2013). Endogenous MARK4 has been shown, by 
immunofluorescence, to localise to the centrosomes, midbody and nucleus (Magnani et 
al. 2009; Naz et al. 2013). 
The homology between MARK4 and the other MARK family members is high, as 
are the mechanisms of regulation and interacting partners. MARK4 is activated by 
phosphorylation at Thr 214 by LKB1 and MARKK. GSK3β phosphorylates another site 
within the activation loop of MARK4, at Ser 218. This phosphorylation is suspected to 
inhibit MARK4’s activity, preventing interactions between Ser 218 and other amino acids 
in the activation loop. Atypical protein kinase (aPKC) inactivates MARK4 by 
phosphorylating a serine (homologous to Ser 595 within MARK2) affecting 14-3-3 protein 
binding and as a result cellular localisation (Drewes 2012). MARK4 is the only MARK on 
which polyubiquitination has been detected. It has been shown to interact with USP9X, a 
1.Introduction 
60 
 
deubiquitinating enzyme. It is proposed that polyubiquitination of the UBA domain may 
prevent access of LKB1 to the activation loop preventing phosphorylation induced 
activation (Al-Hakim et al. 2008; Naz et al. 2013).  
A recent review by Naz et al gave a detailed review of MARK4, including the 
suggested interacting partners (Naz et al. 2013). A tandem affinity purification (TAP) 
approach was used by Brajenovic et al in 2003 to identify binding partners of 6 Par family 
members; MARK4, Par-3, LKB1 (Par-4), 14-3-3η (Par-5), Par-6C, PKCλ (aPKC) (Brajenovic et 
al. 2004). Though many of the identified interacting proteins lack functional annotation, 
there were a number found which gave further indication of MARK4 function and 
regulation. Interaction with USP9x and USP7 provided initial evidence of MARK4’s 
involvement with ubiquitinating enzymes, which is discussed above (Al-Hakim et al. 2008; 
Brajenovic et al. 2004). MARK1 and 2 have been previously shown to interact with 14-3-3 
proteins, this TAP-MARK4 confirmed that MARK4 also binds to 14-3-3 proteins and 
further investigation has shown 14-3-3η is the key binding partner of this MARK 
(Brajenovic et al. 2004).  
A number of the MARK4 interacting proteins uncovered by Brajenovic et al are 
known to be involved with cytoskeleton regulation. Amongst these ARHGEF2 (GEF-H1) is 
a microtubule-associated exchange factor for Rac and Rho GTPases, suggesting a role for 
MARK4 in GTPase regulation. The phosphatase Phosphatase 2A (PP2A) has been shown to 
dephosphorylate TAU and other MAPs controlling their MT binding affinity (Sontag et al. 
2012). The TAP-MARK4 suggests PP2A binds to MARK4, suggesting its involvement within 
TAU regulation or regulation of MARK4’s activity. This phosphatase was also shown to 
antagonise MARKs activity, dephosphorylating MARK phosphorylated Par-3 to affect its 
cellular localisation in Drosophila (Matenia & Mandelkow 2009). These binding partners 
and MARK4’s interaction with three forms of tubulin (α-, β-, γ-tubulin), myosin and actin 
suggest a clear role for MARK4 in control of the cytoskeleton (Naz et al. 2013; Trinczek et 
al. 2004a). The work contained in this thesis identifies MARK4 as a regulator of cell 
motility and cell division, through its involvement with the cytoskeleton, within lung 
cancer cells.  
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1.5 Studying Cell Motility 
The limiting initial stage of the metastatic cascade is the cell invasion away from 
the primary tumour mass. Cell motility is also important during extravasation from vessels 
to form the secondary tumour. Attempts to reduce metastasis, a common explanation of 
cancer deaths, have focused on modulating the motility of cancer cells with the aim of 
preventing disease spread. Additionally work on cell motility can uncover insights into 
development and wound healing.  
So far, most endeavours to study cell migration employed 2-dimensional assays 
such as the commonly used scratch wound assay (Simpson et al. 2008). This assay uses 
cells grown to confluency which are then scratched to remove cells from a defined area. 
This field of view is then imaged for 6 to 72 hours to observe cell migration into the 
cleared area. The rate of disappearance of this scratched area is then calculated. Although 
2D assays have their merits; low technical requirements and rapid analysis, they do not 
replicate in vivo conditions. However, the use of 3-dimensional matrices enables us to 
study cell migration within an environment closer to the in vivo ECM. Nevertheless, 
efforts to screen for genes regulating cell migration and invasiveness in this assay format 
have been limited (Lara et al. 2011).  
Several assay types have been developed to study cell invasion. One of the most 
common methods is the Boyden Chamber technique that involves seeding cells on top of 
a gel composed of ECM components such as collagen or matrigel. This gel is placed on top 
of a filter with a pore size that enables invading cells to pass across towards a 
chemoattractant. Invading cells digest through the gel, traverse the filter and their 
numbers determined to quantify the degree of invasion. However not all cells that digest 
the collagen  will reach or cross the filter meaning that the counted cells represent only a 
small proportion of the invading cells. Another method consists of seeding cells as a single 
cell suspension or as spheroids within an ECM gel. The migration of these cells is then 
monitored under microscopy either by time-lapse or end-point imaging. However, it can 
be difficult to define the point of origin of the tracked cells to enable precise 
quantification of invasion. A third method involves seeding cells onto a thin layer of ECM 
components such as collagen and fibronectin. The cells are then allowed to invade down 
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through the gel and the extent of invasion is quantified by tracking the cells from the 
defined start point (Brekhman & Neufeld 2009; Sanz-Moreno et al. 2011). 
Within this thesis we have employed another 3D invasion assay that has been 
previously used within our laboratory. Here, tumour cells are transfected in a 96-well 
plate format and a collagen matrix is overlaid. The cells are then allowed to invade 
upward through the matrix towards a gradient of chemoattractant molecules. This 
method was optimised as part of this thesis in preparation for an RNAi screen using this 
assay to identify novel regulators of cell motility. 
1.6 RNA Interference and Druggable Genome Screens 
In 1998 Fire et al successfully demonstrated how the injection of RNA interference  
(RNAi) preparations resulted in the powerful silencing of the target gene expression (Fire 
et al. 1998). Interference RNA was initially identified in plants and fungi (Ecker & Davis 
1986; Romano & Macino 1992), and later found to be a highly conserved mechanism for 
controlling expression of both endogenous and exogenous mRNAs. Injection of RNAi into 
cells resulted in a decrease in target expression. Fire et al compared the potency of 
different RNAi structures to decrease the expression of unc-22 gene expression. They 
confirmed, in C.elegans, that double stranded RNA (dsRNA) was required to potently 
silence gene expression. Single stranded sense or antisense mRNA only gave a marginal 
effect (Fire et al. 1998). Although RNAi was observed in mouse oocytes and embryos 
introduction of dsRNAs into mammalian cells, rather than worms, flies or plants, did not 
result in specific gene silencing. Instead introduction of dsRNAs triggered a strong 
interferon response within the cells which resulted in unspecific mRNA degradation 
(Moffat & Sabatini 2006; Elbashir et al. 2001). To avoid this interferon response and to 
achieve gene silencing in mammalian cells shorter RNAi molecules of 21- and 22-
nucelotides must be used (Elbashir et al. 2001). Depending on their structure and target 
these are termed short interfering RNAs (siRNAs), short hairpin RNAs (shRNAs) or 
microRNAs (miRNAs). These short interfering RNAs are now chemically synthesised and 
commercially available to allow for the specific silencing of any gene in the majority of cell 
types.  
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Transfection of siRNAs into cells allows for the transient silencing of the 
expression of target proteins. The mechanisms by which RNAi results in gene silencing is 
as follows. Long dsRNA precursor sequences are generated in the cell by RNA viruses, or 
endogenous transcripts. These dsRNAs are processed by a RNaseIII endonuclease, Dicer, 
to yield short siRNA duplexes, figure 1.12. MiRNAs are generated as endogenous primary-
miRNAs that are processed by second RNaseIII, Drosha. Drosha removes a hairpin region 
from pri-miRNA in the nucleus after which they are exported to the cytoplasm as 
precursor-miRNA’s (pre-miRNA). Pre-miRNAs are then cleaved by Dicer to give a final 
miRNA duplex (Jinek & Doudna 2009). Once processed siRNAs and miRNAs are 
incorporated into RISC (RNA induced silencing complex). One strand of the RNAi acts as a 
template for RISC to bind to the complementary mRNA sequence. This results in the 
cleavage of the mRNA and its rapid degradation (Moffat & Sabatini 2006; Echeverri & 
Perrimon 2006), Figure 1.12. 
Chemically synthesised siRNAs can be introduced into cells by a variety of 
methods including lipid-based transfection, which is the method used in this thesis. 
Cationic lipids that form complexes with DNA/siRNA are used to generate positively 
charged particles. These interact with the negatively charged cell membrane, leading to 
fusion and endocytosis. Another way to introduce nucleic acid molecules into cells uses 
electroporation, where high-voltage electric shocks are applied to temporarily 
permeabilise the cell membrane and allow DNA/RNA to be internalised. Encoded RNAi 
sequences can also be virally packaged and the target cells infected. While vector-based 
RNAi can lead to long-term down-regulation if mammalian drug selection is applied, 
siRNA-mediated knockdown is only transient due to inherent un-stability of these 
molecules and their dilution as a consequence of cell division. Optimal protein 
knockdown is normally seen between 48-72 hours post transfection, although this may 
vary depending on the target. 
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Figure 1.12. Processing of RNA interference.  
mRNA is produced by transcription of the genomic sequence by RNA polymerases and exported 
to the cytoplasm. Endogenous RNA interference provides a complementary sequence in the 
cytoplasm which binds to the mRNA forming dsRNA. The dsRNA is cleaved by DICER to form short-
interfering RNA (siRNA) duplexes of ~21 base pairs. Synthetic siRNA duplexes can be introduced 
into the cell by transfection. The siRNA duplex is then loaded into the RISC and its catalytic 
subunit Argonaute 2 (AGO2). The passenger strand (red) is then cleaved and released, the guide 
strand (blue) is then used by RISC to recognise and cleave further complementary mRNA 
molecules. The RISC complex is then recycled. Adapted from (Jinek & Doudna 2009). 
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siRNA libraries, containing collections of siRNA sequences against targets of 
interest, have been compiled to enable high-throughput screening of proteins involved in 
particular phenotypes. These libraries allow for systematic loss of function screens to 
identify novel roles for previously identified or poorly characterised proteins. It should 
however be noted that siRNA screening is not 100% reliable. siRNA’s themselves give only 
transient knockdown of target, the length of which cannot be assumed without 
knowledge of protein half-life. Often an excessive concentration of siRNA is used to 
attempt to ensure complete silencing of the target. However this can lead to off-target 
effects with other mRNAs degraded as a result of unspecific binding or toxicity to the cell. 
For certain cell types siRNA is not an ideal method for silencing gene expression as the 
cells are hard to transfect, rendering siRNA screening unsuitable (Moffat & Sabatini 2006). 
The characteristics of, or issues with, siRNAs must be considered when designing an siRNA 
screen. The false positive and the false negative rate must be given thought. The 
aforementioned off target effects can contribute to the false positive rate. Analysis of 
screening data can lead to inclusion or exclusion of potential hits, often multiple analysis 
methods can be applied and compared to produce a strong final list (Willingham et al. 
2004). No siRNA screen will be without error, but with comprehensive optimisation prior 
to screening, inclusion of good controls, repeat or secondary screens and thorough 
validation true hits can be identified (Echeverri & Perrimon 2006). 
  In this project we intended to use a large library covering the druggable genome. 
This library contains around 9000 siRNA targeting genes which are either known 
therapeutic targets or are perceived as potentially druggable. In order to confirm the 
assays suitability for such a large-scale screen, a pilot screen of a small gene family, 
phosphatases, was carried out. This systematic approach allowed us to identify the 
suitability of our assay for large scale siRNA screening.  
1.6.1 Kinome Screen 
A previous siRNA screen was carried out within our laboratory. This screen aimed 
to identify novel 2D cell migration regulators using an siRNA library targeting the kinome. 
A random 2D migration assay was used; the NSCLC cell line A549 were transfected then 
imaged over 18 hours to observe migration. After automated tracking siRNAs were 
ranked according to their impact on cell migration compared to the non-targeting siRNA 
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control. This screen identified RSK1 and RSK4 as increasing and decreasing cell motility 
respectively, and these two hits were further characterised within our group (Lara et al. 
2011). Within this thesis a third hit from this screen is characterised, MARK4. Upon siRNA 
silencing of MARK4 a significant decrease in cell motility was observed. We have 
attempted to further investigate MARK4’s role in cell motility and have begun to uncover 
some of the mechanisms behind its function.  
1.7 Chemoresistance 
Chemotherapy is a major avenue of treatment for multiple cancers. However, for 
all commonly used chemotherapy drugs, chemoresistance can occur and is one of the 
main causes of cancer deaths. Tumours can be intrinsically resistant or acquire resistance 
after previous therapy treatment or as the disease advances. Studies into the 
mechanisms of chemoresistance have uncovered a number of explanations for both 
intrinsic and acquired chemoresistance. Efforts have also been made to modify existing 
drugs or develop novel methods of drug delivery or composition to overcome 
chemoresistance. However due to the adaptability and high mutation rate of tumour cells 
it seems unlikely that chemoresistance will ever be completely overcome. 
1.7.1 Mechanisms of chemoresistance 
The major mechanisms used by tumour cells to avoid chemotherapy induced cell 
death will be briefly described.  
For many chemotherapeutics the method of uptake to the cell is not known. 
However it is observed that in resistant cells the intracellular drug concentration is 
decreased, suggesting altered drug influx or perhaps increased efflux of the drug from the 
cells (Gatti & Zunino 2005). One example of this is the overexpression of the 170 kDa 
transmembrane protein P-170 (P-gp) by multiple cancer types including; neuroblastoma, 
colon carcinoma, renal cell carcinoma and non-Hodgkin’s lymphomas. P-170 is encoded 
by the MDR1 gene (multidrug resistance gene) and is a key protein for exporting 
chemotherapeutics out of the cell. Overexpression of P-170 increases efflux of a drug 
from the cell, reducing the intracellular concentration to below that required to give a 
response, therefore making the cell resistant (Giaccone & Pinedo 1996). This form of 
resistance often results in multidrug resistance as the import or export proteins affected 
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are often responsible for the transport of multiple agents. The overexpression of other 
multidrug resistance proteins, MRP1, MRP2 and MRP3 export drugs as conjugates with 
free glutathione. MRP2 is implicated in cisplatin resistance, MRP1 and MRP2 in resistance 
to vincristine, vinblastine and doxorubicin amongst others (Gatti & Zunino 2005). 
Agents such as Irinotecan, a DNA topoisomerase I inhibitor, require metabolic 
activation within the cytosol. Preventing this conversion to an active form by, for 
example, the loss of rate limiting conversion enzymes can render treatment with these 
drugs useless. In the case of Irinotecan, reduced levels of the enzyme carboxyestherase, 
which catalyses its conversion to an active metabolite (SN-38), have been detected in 
resistant cancer cell lines (Giaccone & Pinedo 1996). A similar change is seen in colorectal 
cancer cells. The rate limiting enzyme for activating the chemotherapy agent 5-
fluorouracil (5-FU); dihydropyrimidine dehygrogenase (DPD), is altered to reduce its 
activity, leading to the development of 5-FU resistance (Gatti & Zunino 2005). 
The chemotherapeutic 5-FU is a good example for a third method of resistance; 
altered expression or structure of drug target. 5-FU catalysed into an active form, FdUMP, 
is a potent inhibitor of TS (thymidylate synthase, a crucial enzyme for DNA synthesis and 
repair). Studies of patient tumour samples using immunohistochemistry and reverse 
transcriptase-PCR have shown that expression levels of TS correlate with 5-FU response. 
Patients with high TS expression show a reduced response (Longley & Johnston 2005; 
Longley et al. 2003). This overexpression of the target makes complete inhibition 
impossible. This is one of the observed methods of cancer cells altering the drug target to 
induce resistance. Other mechanisms include changes in the amino acid composition of 
the target to reduce the affinity of the target for the drug, increased levels of normal 
substrate to out-compete the drug for the target enzyme, and decreases in required co-
substrates can prevent the formation of required complexes. These different methods all 
alter the availability of the target for the drug and confer resistance (Giaccone & Pinedo 
1996).  
The end result of the majority of chemotherapy agents is to induce apoptosis. 
Apoptosis is one form of programmed cell death which is triggered in damaged or 
redundant cells. Cells undergoing apoptosis become rounded and retract from 
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neighbouring cells. Condensation of the nucleus and cytoplasm is observed and apoptotic 
bodies are formed and then degraded by phagocytes (Kerr et al. 1972). The mechanism 
and regulation of apoptosis is widely studied. The ability to modulate either route of cell 
death allows for the development of targeted therapeutics and identification of methods 
to overcome drug resistance. The activation of caspases 3 and 7 are crucial for the 
apoptotic cascade and the cleavage activity of these proteases is often used to quantify 
apoptosis in an in vitro setting (Taylor et al. 2008). Caspase activity and therefore 
apoptosis is tightly regulated by the Bcl-2 family; BAX, BAK and BAD promote apoptosis 
whereas Bcl-XL, Mcl-1 and Bcl-2 are anti-apoptotic (Reed 1998; Longley & Johnston 2005). 
Unsurprisingly the expressions of the Bcl-2 family members are often altered in tumours. 
In some cancers high levels of the anti-apoptotic factor Bcl-2 correlates with poor 
chemotherapy response. Whereas in others it is the pro-apoptotic Bcl-2 family members 
that show altered expression in more resistant tumours (Longley & Johnston 2005; 
Campos et al. 1993; Bonetti et al. 1998; Krajewski et al. 1995). Alteration of the Bcl-family 
expression is a clear example of another mechanism for drug resistance; resistance to 
apoptosis. 
Pro-survival signalling is another method by which cancer cells avoid 
chemotherapy induced apoptosis. Changes in Bcl-2 expression are described as pro-
survival signalling, as the expression of this anti-apoptotic protein alters a cells 
susceptibility to enter apoptosis. Another well studied change to promote pro-survival 
signalling is mutations in the protein tyrosine kinase; epidermal growth factor receptor 
(EGFR). As previously mentioned in section 1.1.1.2, EGFR is frequently mutated in lung 
cancer. Signalling through this receptor activates downstream pro-survival pathways such 
as the PI3K/Akt pathway and STAT pathway. In lung cancer EGFR is found with an 
activating mutation (L858R), which leads to constant signalling activating these pro-
survival pathways. This receptor is also frequently overexpressed in other carcinomas 
(Zhang et al. 2010; Longley & Johnston 2005; da Cunha Santos et al. 2011). 
Two chemotherapy agents were used in this thesis; cisplatin and taxol. The 
mechanisms by which these two drugs result in cell death are briefly described below. 
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1.7.2 Mechanism of action of Cisplatin 
Cisplatin was first discovered in 1965 by Dr Rosenberg as an inhibitor of bacterial 
cell division (Rosenberg et al. 1965). He hypothesised at this point that rapidly dividing 
cancer cells would perhaps be susceptible to this agent (Basu & Krishnamurthy 2010). 
First approved for patient use in 1978 to treat testicular and bladder cancer, cisplatin has 
become a commonly used chemotherapy agent (Galluzzi et al. 2012). Cisplatin is used to 
target a range of solid tumours including those developed in the lungs, breast, head and 
neck. Cisplatin, cis-diammine-dichloro-platinum, is a neutral inorganic drug that via a 
number of pathways results in DNA damage. This damage leads to either repair of DNA 
and therefore cell survival or activation of apoptosis resulting in cell death (Siddik 2003). 
Given intravenously, Cisplatin induces a wide range of side effects including kidney 
toxicity and peripheral nerve damage (Galluzzi et al. 2012). In an effort to avoid some of 
the more serious side effects of cisplatin, several cisplatin derivatives have been licensed 
for use. These include carboplatin and oxaliplatin (Galluzzi et al. 2012). 
Cisplatin is activated in the cytoplasm by interaction of its cis-chloro groups with 
water molecules. Activated cisplatin has a high affinity for DNA, binding preferentially to 
nucleophilic N7-sites on purine bases (Siddik 2003). Binding of cisplatin to DNA results in 
formation of protein-DNA complexes and DNA-DNA inter- and intra-strand adducts 
(covalent bonds between DNA strands and cisplatin molecules) (Eastman 1987). This 
crosslinking causes distortion and damage to the DNA resulting in recruitment of DNA 
repair complexes to restore correct DNA structure and prevent abnormal cell cycle 
progression. Damage that is beyond repair triggers apoptosis. The apoptotic cascade is 
triggered via activation of ATR (Ataxia telangiectasia mutated (ATM) and RAD3-ralated 
protein), a sensor of DNA damage and CHEK1 (checkpoint kinase 1). CHEK1 
phosphorylates tumour suppression protein TP53 which triggers downstream 
mitochondrial permeabilisation and increased death receptor signalling resulting in cell 
death (Galluzzi et al. 2012).  
1.7.3 Mechanism of action of Taxol 
Purified in 1967 from the bark of the Pacific Yew tree by Wani et al, Paclitaxel 
(Taxol) is another commonly used chemotherapeutic (Wani et al. 1971). Taxol is a 
microtubule disrupting agent, binding to the β-subunit of the tubulin dimer at the plus 
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end of a growing microtubule. Taxol binding hyper-stabilizes the microtubule and allows 
for further incorporation of tubulin dimers without GTP hydrolysis therefore preventing 
catastrophe of the filament (Orr et al. 2003). Unlike other microtubule agents such as 
vinblastine, Taxol does not inhibit microtubule assembly, instead it stabilises and 
promotes tubulin polymerization (Kumar 1981). This inhibits the dynamic behaviour of 
the microtubules (discussed earlier in 1.3.4), resulting in abnormal mitosis and triggering 
cell death (Xiao et al. 2006).  
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1.8 The Thesis 
The aims of this thesis are: 
 Optimise a 3D invasion assay for high-throughput siRNA screening 
 Carry out a siRNA screen to identify novel modulators of NSCLC cell motility 
 Characterise the role of the kinase MARK4 in cell motility 
 Elucidate the mechanisms of action of a MARK4 in NSCLC progression 
 Investigate the potential clinical implications of MARK4 expression  
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2.1 Materials 
2.1.1 Equipment and Software  
Item Manufacturer 
7900 HT Fast-Real-Time PCR system  Applied Biosystems, UK 
Axio Observer Inverted Widefield Microscope with VivaTome 
Spinning Disc 
Zeiss, Germany 
CyBi®-Well  CyBio, Germany 
Eppendorf centrifuge 5810  Eppendorf, Germany 
EVOS® FL Cell Imaging System  Life Technologies, UK 
FACSCanto A flow cytometer  BD Biosciences, UK 
FIJI ImageJ NIH, USA 
FlowJo version 7.6.5 Tree Star Inc, USA 
Fusion SOLO Chemiluminescence Imager PEQLAB, UK 
iBlot® Dry Blotting System  Invitrogen, UK 
ImageXpress High content Screening Microscope Molecular Devices, USA 
KONICA SRX-101A film processor  Konica Minolta 
LSM-780 inverted microscope Zeiss, Germany 
MetaXpress 2.0 Molecular Devices, USA 
Mini-PROTEAN® 3 cell and Mini Trans-Blot module Bio-Rad Laboratories Ldt, UK 
Multidrop® Combi robot  Thermo Fisher Scientific, UK 
NanoDrop 1000 Spectrophotometer  Thermo Fisher Scientific, UK 
NuAire Laboratory CO2 Incubators NuAire, USA 
Opera® High Content Screening System  PerkinElmer, USA 
PHERAstar luminescence microplate reader BMG Labtech, Germany 
qbasePLUS 2.1 software  Biogazelle, Belgium 
Sorvall® Legend RT centrifuge  Thermo Fisher Scientific, UK 
Sunrise™ microplate absorbance reader  Tecan Trading AG, Switzerland 
Veriti® Thermal Cycler  Applied Biosystems, USA 
Wolfram Mathematica 8 Wolfram, USA 
Zen Software Zeiss, Germany 
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2.1.2 Reagents and chemicals 
Reagent Source 
4’, 6-diamidino-2-phenylindole (DAPI)  Invitrogen, UK 
Acetic acid (glacial) Thermo Fisher Scientific, UK 
AllStars Negative Control siRNA QIAGEN, UK 
Ammonium persulfate (APS)  Sigma-Aldrich, Germany 
Ampicillin  Sigma-Aldrich, Germany 
Attractene Transfection Reagent QIAGEN, UK 
Bio-Rad protein assay reagent  Bio-Rad Laboratories Ltd, UK 
Bovine serum albumine (BSA)  Sigma-Aldrich, Germany 
Bromophenol blue sodium salt  Sigma-Aldrich, Germany 
Caspase-Glo® 3/7 Assay  Promega Corp., USA 
Cisplatin [cis-Diammineplatinum(II)dichloride] Sigma-Aldrich, Germany 
Click-iT® EdU cell proliferation assay kit Life Technologies, UK 
Collagen (Type I, Rat Tail) 100 mg BD Biosciences, Belgium 
Crystal violet Sigma-Aldrich, Germany 
Dimethyl sulfoxide (DMSO)  Sigma-Aldrich, Germany 
Dithiothreitol (DTT)  Fluka Chemicals, Switzerland 
Dulbecco’s Modified Eagle’s Medium (DMEM) Sigma-Aldrich, Germany 
Dulbecco’s Modified Eagle’s Medium (DMEM) 
Powder Sigma-Aldrich, Germany 
Enhanced chemiluminescence system (ECL) reagent Thermo Fisher Scientific, UK 
Epidermal Growth Factor human Sigma-Aldrich, Germany 
Ethanol  Sigma-Aldrich, Germany 
Ethylenediamine tetra acetic acid (EDTA)  Thermo Fisher Scientific, UK 
Fast SYBR® Green PCR Master Mix Applied Biosystems, USA 
Fibroblast growth factor 10 (FGF10)  Abcam Plc, UK 
Fibroblast growth factor 2 (FGF2)  Calbiochem, Germany 
Fibronectin  BD Biosciences, Belgium 
Foetal Calf Serum (FCS)  First Link Ltd., UK 
FUJIFILM High contrast X-ray film (blue sensitive)  
FUJIFILM, Photon Imaging Systems 
Ltd, UK 
Glycerol Thermo Fisher Scientific, UK 
Glycine (electrophoresis grade)  Sigma-Aldrich, Germany 
High Capacity cDNA Reverse Transcription Kit Applied Biosystems, USA 
HiPerFect Transfection Reagent QIAGEN, UK 
Human Hepatocyte Growth Factor (Recombinant) Millipore, UK 
Hydrochloric acid 37%  Thermo Fisher Scientific, UK 
INTERFERrin®  Polyplus Transfection®, USA 
Isopropyl alcohol  Thermo Fisher Scientific, UK 
Lamin  BD Biosciences, Belgium 
L-Glutamine GIBCO  Invitrogen, UK 
Lipofectamine™ RNAiMAX Invitrogen, UK 
Methanol  Thermo Fisher Scientific, UK 
Mg2+ Lysis/Wash Buffer  Millipore, UK 
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Nitrocellulose iBlot® membranes Invitrogen, UK 
Nocodazole  Sigma-Aldrich, Germany 
Oligofectamine™ 2000 reagent Invitrogen, UK 
One Shot® TOP10 Chemically Competent E.coli  Invitrogen, UK 
Paciltaxel Sigma-Aldrich, Germany 
PageRuler™ Prestained Protein Ladder  Fermentas, UK 
Paraformaldehyde (PFA)  Sigma-Aldrich, Germany 
Phalloidin (Alexa Fluor® 488-conjugated) Invitrogen, UK 
Phosphate buffered saline (PBS) OXOID, UK  
Platelet Derived Growth Factor (Recombinant) Millipore, UK 
Poly-L-lysine Sigma-Aldrich, Germany 
Polyvinylidene difluoride (PVDF) iBlot® membranes Invitrogen, UK 
Porcine collagen  Nittagelatin, China 
ProLong® Gold antifade mounting reagent Invitrogen, UK 
Protease inhibitor mix  Hoffmann-La Roche, Switzerland 
ProtoGel® Acrylamide 30%  National Diagnostics, UK 
PureLink® HiPure Plasmid Filter Maxiprep Kit Invitrogen, UK 
Rho Assay reagent (Rhotekin RBD, GST tagged, 
Agarose) Millipore, UK 
RNeasy® kit  QIAGEN, UK 
RPMI 1640 Sigma-Aldrich, Germany 
Silencer Select Human Phosphatome Library AMBION, USA 
Skim milk powder  AppliChem GmbH, Germany 
Sodium azide  Sigma-Aldrich, Germany 
Sodium chloride  Thermo Fisher Scientific, UK 
Sodium Dodecyl Sulfate (SDS) Thermo Fisher Scientific, UK 
Sodium fluoride Sigma-Aldrich, Germany 
Sodium orthovanadate Sigma-Aldrich, Germany 
Sodium selenite Sigma-Aldrich, Germany 
SYTOX® Green  Invitrogen, UK 
TEMED (N,N,N’,N’-tetramethylethylene diamine) Sigma-Aldrich, Germany 
Transferrin Sigma-Aldrich, Germany 
Tris-(hydroxymethyl) aminomethane  VWR International, Belgium 
Trypsin Sigma-Aldrich, Germany 
Tween 20 Sigma-Aldrich, Germany 
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2.1.3 Antibodies 
Antibody Catalog # Source Application Provider 
Protein size 
(kDa) 
GAPDH ab9484 Mouse - HRP  WB Abcam 37 
GEF-H1 (55B6) #4076 Rabbit WB Cell Signalling 120 
GFP (7.1 & 13.1) 
#11814460001 
Mouse WB, IP Roche 25 
GSK3 alpha (SDGSK3a1) 
ab24864 
Mouse - HRP  WB Abcam 51 
GSK3 α/β (4G-1E) #05-412 Mouse WB Millipore 51(α)/46(β) 
GSK-3α (D80E6) #4337 Rabbit WB Cell Signalling 51 
GSK-3β (27C10) #9315 Rabbit WB Cell Signalling 46 
HA (HA-7) #H9658 Mouse WB, IP Sigma-Aldrich - 
HSP90 Mouse WB NeoMarkers  90 
Lamin B (C-20) SC-6216 Goat WB Santa Cruz 45/67 
MARK2 (EPR8553) ab133724 Rabbit WB Abcam 88 
MARK4 (N-term) 
SAB1300394 
Rabbit IHC Sigma-Aldrich 79 
Phospho-GEF-H1 (Ser885) 
ab94348 
Rabbit WB Abcam 112 
Phospho-GSK-3α (Ser21) 
(36E9) #9316 
Rabbit WB Cell Signalling 51 
Phospho-GSK-3α/β 
(Ser21/9) (37F11) #9327 
Rabbit WB Cell Signalling 51(α)/46(β) 
Phospho-GSK-3β (Ser9) 
(D85E12) #5558 
Rabbit WB Cell Signalling 46 
Phospho-PP2A alpha (Y307) 
(E155) ab32104 
Rabbit WB Abcam 35 
Phospho-Tau (Ser262) #44-
750G 
Rabbit WB Invitrogen 70 
PP2A α/β (Y119) ab32141 Rabbit WB/IP Abcam 36 
PPP2CB ab72343 Rabbit WB Abcam 36 
Tau (D-8) sc-166060 Mouse WB, IP Santa Cruz 46-80 
Tau (H-159) sc-5587 Rabbit WB, IP Santa Cruz 46-80 
YFP (F-20) sc-33261  Rabbit WB, IP Santa Cruz 27 
Table 2.1. Details of antibodies used in this thesis. 
2.2 Methods 
2.2.1 Cell lines and culture 
A549 and PC3 are part of the NCI60 library and were a kind gift from Julian 
Downward (Cancer Research UK/London Research Institute, London, UK). H1299 were 
purchased from the ATCC. CCL-211 and HUVEC cell lines were previously used in our lab. 
All cell lines used are listed and detailed below (Table 2.2). 
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Cell Line Type Culture 
Subcultivation 
(twice a week) 
Medium 
A549 NSCLC, adenocarcinoma Adherent 1:10 DMEM 
H1299 NSCLC, metastatic lymph node Adherent 1:10 DMEM 
PC-3 Prostate Adherent 1:10 DMEM 
CCL-211 Fibroblast Adherent 1:10 RPMI 1640 
HUVEC 
Human Umbilical Vein 
Endothelial Cells Adherent 1:5 
Medium 
199 
Table 2.2. List of cell lines used. Details of cell line origin and culture conditions. 
A549, H1299 and PC-3 were maintained in Dulbecco’s Modified Eagle’s medium 
(DMEM) supplemented with 10% FCS, 2 mM L-glutamine, 50 U/ml penicillin and 50 µg/ml 
streptomycin. They were kept at 10% CO2 at 37°C in a humidified atmosphere. CCL-211 
were cultured in RPMI 1640 medium supplemented with 10% FCS, 2 mM L-glutamine, 50 
U/ml penicillin and 50 µg/ml streptomycin at 37°C  in the presence of 5% CO2.  HUVEC 
were grown in fibronectin coated flasks at 5% CO2 and 37°C. Medium 199 (SIGMA-
ALDRICH) was used, supplemented with 20% FCS, 3mM L-glutamine, 50 U/ml penicillin, 
50 µg/ml streptomycin and 300 μg/ml Endothelial cell growth factor (ECGF) (Sigma-
Aldrich) dissolved in a Heparin solution (1000 IU/ml) (Leo Laboratories). All cell lines were 
maintained at a sub-confluent density, typically passaged twice a week. This was achieved 
by initially washing the cells with 0.02% EDTA before incubation in 2.5 mg/ml trypsin in 
0.02% EDTA, 0.09% NaCl at 37°C until cells are detached from the culture plate. After 
inhibition of trypsin using culture media, cells were passaged into new culture flasks at a 
suitable ratio. All cells were regularly tested for mycoplasma contamination. 
2.2.2 RNA interference 
Dependent on the assay format cells were plated into 6-well plates (1.5x105), 96-
well plates (1x103 – 7x103) or 10 cm dishes (1x106) 24 hours (h) prior to transfection with 
30 nM siRNA (Dharmacon) using Lipofectamine™ RNAiMAX transfection reagent 
(Invitrogen) diluted in OptiMEM reduced serum medium (Invitrogen). Briefly, for a 6-well 
plate, 0.25 μl siRNA was added to 250 μl OptiMEM. 2.5 μl of Lipofectamine™ RNAiMAX 
was added to 250μl OptiMEM and incubated for 5-10 minutes (min). The OptiMEM 
containing the siRNA and that containing the transfection reagent were combines, mixed 
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and incubated for a further 10-15 min at room temperature. Once complex formation had 
been allowed to occur the complexes were added drop-wise to the well, giving a final 
volume of 2.5 ml. When testing additional reagents, namely Oligofectamine™ 2000 
reagent (Invitrogen), HiPerFect (QIAGEN) and INTERFERrin® (Polyplus Transfection™), 
transfections were performed according to the manufacturer’s instructions. As a control 
for all siRNA transfections, AllStars Negative Control siRNA (QIAGEN, Netherlands) was 
used. siRNA’s used in this thesis are detailed in Table 2.3.  
Supplier Target Gene 
Dharmacon 
siGENOME siRNA ID 
Sequence 
Dharmacon ARHGEF2 
D-009883-01 GGACAAGCCUUCAGUGGUA 
D-009883-02 CAACAUUGCUGGACAUUUC 
D-009883-03 GAAUUAAGAUGGAGUUGCA 
D-009883-05 GUGCGGAGCAGAUGUGUAA 
Dharmacon CAB39 
D-015407-01 GAACCAGGCCAAACUCAUA 
D-015407-02 CGAGAAGACCUAUUUAGUU 
D-015407-03 AGACAAAUUGGUACGAGAA 
D-015407-04 CGGAGGAUGAGCAGUUUAA 
Dharmacon CLIP1 
D-005294-01 GGGAUGACCUAAACAAUUA 
D-005294-02 GAAGGUAUCUUUCAGCAAA 
D-005294-03 GGACAGGACUAUUGACUGA 
D-005294-04 GAAGGUAAAUCGGAAAUGA 
Dharmacon GSK3A 
D-003009-05 GGACAAAGGUGUUCAAAUC 
D-003009-06 GAACCCAGCUGCCUAACAA 
D-003009-07 GCGCACAGCUUCUUUGAUG 
D-003009-08 GCUCUAGCCUGCUGGAGUA 
Dharmacon GSK3B 
D-003010-05 GAAGAAAGAUGAGGUCUAU 
D-003010-06 GGACCCAAAUGUCAAACUA 
D-003010-08 GAUGAGGUCUAUCUUAAUC 
D-003010-09 GAAGUCAGCUAUACAGACA 
Dharmacon LIMK1 
J-007730-09 GGAGACCGGAUCUUGGAAA 
J-007730-08 GCCCAGAUGUGAAGAAUUC 
J-007730-07 GAAGCGAGUUGCCCGUGUG 
J-007730-06 GAGCAUGACCCUCACGAUA 
Dharmacon MAP2 
D-007299-02 CAACAGACAACAUCAAAUA 
D-007299-03 GAAGAAGGUCGCCAUCAUA 
D-007299-04 GACCUCAGCUGACAGAGAA 
D-007299-17 AGAAAGGAACUGAUCGUUU 
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Dharmacon MAPT (TAU) 
D-012488-01 GCAAAUAGUCUACAAACCA 
D-012488-02 UAGGCAACAUCCAUCAUAA 
D-012488-03 GGACACGUCUCCACGGCAU 
D-012488-04 AAGCUGACCUUCCGCGAGA 
Dharmacon MAP4 
D-011724-09 GGAGUAGAAGGGAGCGAUA 
D-011724-10 GGAGAGAUAAAGCGGGACU 
D-011724-11 GAUGAUGUUGUGGGAGAAA 
D-011724-12 GAGUCAAAGAAGAAACCGU 
Dharmacon MARK1 
D-004259-01 GGACAUCUAUUGCCUUUAA 
D-004259-02 GACCACAGAUCGAUACGUA 
D-004259-03 GGAAAUUACCGUUUACAAA 
D-004259-07 UGAAGGUGGUGAAUCGUUA 
Dharmacon MARK2 
D-004260-02 GCGGAGAGGUAUUUGAUUA 
D-004260-03 GGAACAAGCUGGACACCUU 
D-004260-04 GAAACUAUUCCGCGAAGUA 
D-004260-05 GCUCAGACCUCACGUGGUG 
Dharmacon MARK3 
D-003517-02 GAAAUACGAUGAAAUCACA 
D-003517-03 GGAAUGACACGACGAAAUA 
D-003517-04 GAAGUUACCUCUCGUACCA 
D-003517-10 GGAAUGCAAGUAAUCCUAA 
Dharmacon MARK4 
D-005345-06 GCUGUACUCUCGAGCAAAU 
D-005345-05 GGAUCAACAUCGGCUAUGA 
D-005345-02 GGAAGUACCGGGUCCCUUU 
D-005345-01 GAUCGAAGCUGGACACGUU 
Dharmacon PPP2CB 
D-003599-03 GUAAGCAGCUGAACGAGAA 
D-003599-04 CACGAAAGCCGACAAAUUA 
D-003599-06 AAAGGUGCGUUAUCCAGAA 
D-003599-19 UAGCAUUAAAGGUGCGUUA 
Dharmacon PPP2R1A 
D-010259-05 UAGACGAACUCCGCAAUGA 
D-010259-06 AGGCGGAACUUCGACAGUA 
D-010259-20 UCAAGGAGCUGGUGUCCGA 
D-010259-21 UCAUAGACGAACUCCGCAA 
Dharmacon PRKCI 
D-004656-02 UGAAGAACAYGCCAGAUUU 
D-004656-03 UUACAUUGCUCCUGAAAUU 
D-004656-05 GGAUUACGGCCAGGAGAUA 
D-004656-06 CAAAUUCGCAUACCACGUU 
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Dharmacon ROCK1 
J-003536-09 GCCAAUGACUUACUUAGGA 
J-003536-08 CCAGGAAGGUAUAUGCUAU 
J-003536-07 UAGCAAUCGUAGAUACUUA 
J-003536-06 CUACAAGUGUUGCUAGUUU 
Dharmacon RPS6KA1 (RSK1) 
 D-003025-06  GAGAAUGGGCUCCUCAUGA 
 D-003025-07  CAAGCGGGAUCCUUCAGAA 
 D-003025-08  CCACCGGCCUGAUGGAAGA 
 D-003025-12  GCUAUACCGUCGUGAGAUC 
Dharmacon RPS6KA2 (RSK3) 
D-004663-02 GAUCGAAGAUGGAGAGAGA 
D-004663-04 UCAAGGAUGUCUAUGAUGA 
D-004663-05 GCAAGCGAUGUGUGCAUAA 
D-004663-18 CGAAUGAAAUGCUCCGUAU 
Dharmacon RPS6KA6 (RSK4) 
D-004670-01 GCAAAUGUAUUACCAAUUG 
D-004670-02 GGACAACAUCCCAACAUUA 
D-004670-03 GGUGGAAACUGGGACAAUA 
D-004670-04 GUAGAUAUGUUUACCUUGU 
Dharmacon STK11 
D-005035-01 UGAAAGGGAUGCUUGAGUA 
D-005035-03 GAGAAGCGUUUCCCAGUGU 
D-005035-05 GCUCUUACGGCAAGGUGAA 
D-005035-06 GCAUGACUGUGGUGCCGUA 
Dharmacon STRADA 
D-005343-02 CCUAGAAGCUUGUUCCAAU 
D-005343-02 UGAAUGAGCUGGCGAUUGC 
D-005343-02 UGGCAUACGGUUCUGCAAA 
D-005343-02 GGAUUAACCUAGAAGCUUG 
Dharmacon TP53 
D-003329-05 GAGGUUGGCUCUGACUGUA 
D-003329-07 GCACAGAGGAAGAGAAUCU 
D-003329-08 GAAGAAACCACUGGAUGGA 
D-003329-26 GCUUCGAGAUGUUCCGAGA 
Dharmacon USP21 
D-006071-01 GUACAAAGAUUCCCUCGAA 
D-006071-02 GAACCUGAGUUAAGUGAUG 
D-006071-03 GAGCUGUCUUCCAGAAAUA 
D-006071-04 GAGCAGCACUCGACCUCUU 
Dharmacon YWHAH 
D-010626-01 GCAAUGAUUUCCAGUAUGA 
D-010626-02 GAAUGAACCUCUCUCCAAU 
D-010626-03 UGGAGAAAGUUAAAGCUUA 
D-010626-04 GAGCAAGCCUGCCUCUUAG 
 
Table 2.3. Details of siRNAs used in this thesis.  
siRNAs were purchased from Dharmacon, Thermo Fisher Scientific, UK. 
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For the phosphatome screen a siRNA library targeting the phosphatome was 
obtained from AMBION, Silencer Select Human Phosphatome Library. The control siRNA’s 
for this screen were also purchased from AMBION. These are detailed in table 2.4. 
Supplier Target Gene AMBION siRNA ID Sequence 
AMBION LIMK 1 
s8190 GCAUGAGCCCAGAUGUGAAtt 
s8189 CCUCACGUGUGGGACCUUUtt 
s8188 GCAUGACCCUCACGAUACAtt 
AMBION RPS6KA1 (RSK1) 
s12273 CACUGAUUCUGAAGGCGAAtt 
s12275 CAUUGACUGGAAUAAGCUAtt 
s12274 ACGGCUACGUGGUAAAGGAtt 
AMBION ROCK 1 
s12097 GGUUAGAACAAGAGGUAAAtt 
s12099 GCUUGUAGGUGAUACACCUtt 
s12098 CCUUCAAGCUCGAAUUACAtt 
AMBION RPS6KA6 (RSK4) 
s12273 CACUGAUUCUGAAGGCGAAtt 
s12275 CAUUGACUGGAAUAAGCUAtt 
s12274 ACGGCUACGUGGUAAAGGAtt 
AMBION SRC 
s13412 CCAUUUACAUCGUCACGGAtt 
s13413 GCACAGGACAGACAGGCUAtt 
s13414 GCCUCUCAGUGUCUGACUUtt 
AMBION EGFR 
s564 CCAUAAAUGCUACGAAUAUtt 
s565 GAUCUUUCCUUCUUAAAGAtt 
s563 GAAUAGGUAUUGGUGAAUUtt 
AMBION MET (HGFR) 
s8700 GCACUAGCAAAGUCCGAGAtt 
s8701 CACCUUAUCCUGACGUAAAtt 
s8702 GCUACUUAUGUGAACGUAAtt 
AMBION PDGFR-A 
s10234 CUCUAGGAAUGACGGAUUAtt 
s10235 GGCCUUACUUUAUUGGAUUtt 
s10236 CAUCAGAGCUGGAUCUAGAtt 
AMBION Non Targeting 1# AM4635 - 
AMBION Non Targeting 2# AM4637 - 
AMBION PLK1 
S449 CAACCAAAGUCGAAUAUGAtt 
s448 CCAUUAACGAGCUGCUUAAtt 
s450 GCAAUUACAUGAGCGAGCAtt 
AMBION KIF11 
s7902 CCAUCAACACUGGUAAGAAtt 
s7903 GACUGAUCUUCUAAGUUCAtt 
s7904 CCACGUACCCUUCAUCAAAtt 
Table 2.4. Details of siRNAs used as controls in the phosphatome screen.  
siRNA’s were purchased from AMBION, USA. 
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2.2.3 Bacterial transformation and Plasmid preparation 
Amplification of plasmids was done by transforming the plasmid of interest into 
chemically competent bacteria using the heat shock method. One Shot® TOP10 
Chemically Competent E.coli cells (Invitrogen) were used, 2.5 μl of plasmid was mixed 
with 25 μl competent bacterial and incubated on ice for 30 min. The bacteria were then 
heat shocked to aid uptake of the plasmid by being placed at 42°C for 30 sec before being 
put back on ice. To allow the bacteria to recover from transformation, transformed 
bacteria were mixed with 250 μl of warmed Super Optimal broth Catabolite (SOC) 
repression media for 1 h at 37°C. The bacteria cell suspension was then added to 250 ml 
Luria-Bertani (LB) broth containing 100 μg/ml Ampicillin and grown overnight at 37°C 
shaking. Plasmid was extracted from bacteria cultures using the PureLink® HiPure Plasmid 
Filter Maxiprep Kit (Invitrogen) following the manufacturer’s instructions.  
2.2.4 Plasmid transfection  
Cells were transfected with plasmids using the DNA transfection reagent 
Attractene (QIAGEN). Transfections were carried out using the manufactures protocol as 
a guideline. For certain dish sizes different DNA amounts were added. For 15 cm dishes 10 
μg was used, for 6well plates 1.2 μg and for 10 cm dishes 3μg. Briefly, for 15 cm dishes, 37 
μl Attractene reagent was added to 1 ml OptiMEM with 10 μg of plasmid. Once mixed this 
was incubated for 10 min at room temperature to allow for complex formation before 
complexes were added drop-wise to the plate. Overexpression was then measured at 24 
or 48 h. Plasmids used in this thesis are detailed in Table 2.5. As a control for plasmid 
expression the corresponding empty vector was always used. 
Plasmid name Insert Tag/ Position Backbone Origin 
HA-MARK4 MARK4L HA  N-Terminal pCDNA3 Trinczek et al JBC 2004 
GFP-MARK4 MARK4L GFP  N-Terminal pCDNA3 Trinczek et al JBC 2004 
Flag-MARK4 MARK4L Flag  C-Terminal pRK5F 
Wu et al, Cell Death 
Differ, 2011 
EB3-GFP 
End binding protein 
3 (EB3) 
GFP  N-Terminal peGFPC1 
Erik Sahai, CRUK, LRI, 
London, UK 
Table 2.5. Plasmids used in this thesis. 
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2.2.5 Cell proliferation and viability assay 
A549 or H1299 were plated, 3x103 per well, in clear 96 well plates and incubated 
for 24 h at 37°C, 10% CO2 before transfection. If required, 24 h following transfection, 
cells were treated with increasing concentrations of Cisplatin (Sigma-Aldrich) or Paciltaxel 
(Sigma-Aldrich). After 48 h the cells were washed twice with Phosphate buffered saline 
(PBS) before being fixed in 4% (w/v) paraformaldehyde (PFA) and stained using 0.08% 
crystal violet solution for 30 min. Plates were washed with water and air dried. In order to 
obtain quantitative data, the crystal violet-precipitates were solubilised in 10% (v/v) 
Acetic acid for 30 min at room temperature with gentle shaking. The intensity of the 
staining was measured using Sunrise (TECAN) absorbance microplate reader at 595 nm. 
Mean and standard error of the mean (SEM) of independent experiments were 
calculated. The response of drug treatment was seen by normalising the mean of the 
treated values to the DMSO control. Each condition was present in triplicate and each 
experiment repeated at least three times. 
2.2.6 Caspase 3/7 assay 
To determine the activation of caspase 3 and caspase 7 following treatment with 
Cisplatin or Paciltaxel, or induction of anoikis, the Caspase-Glo® 3/7 Assay kit (Promega) 
was used. Briefly, 100 μl of Caspase-Glo 3/7 reagent was added to the 100 μl of media 
already present in each well. This resulted in cell lysis and caspase-mediated cleavage of 
the luminogenic caspase 3/7 substrate. The resulting luminescence signal produced is 
proportional to the amount of active capsase 3/7 in the sample. The sample was 
protected from light and incubated for 1 h at room temperature. After incubation the 
luminescence was measured using the PHERAstar luminescence microplate reader (BMG 
LABTECH). Mean and standard error of the mean (SEM) of independent experiments were 
calculated. The caspase 3/7 induction in response of drug treatment was seen by 
normalising the mean of the treated values to the untreated DMSO control. Each 
condition was present in triplicate and each experiment repeated at least three times. 
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2.2.7 Anoikis Assay  
To observe any changes in NSCLC’s ability to survive in suspension 5x103 A549 
were plated in standard adhesion clear 96well well plates. 24 h after plating the cells 
were transfected with ether non-targeting control siRNA or siRNA against MARK4 as 
described above. 48 h after knockdown, cells were trypsinised. Once detached from the 
plate cells were suspended in 120 μl DMEM complete before 50 μl of each well was 
placed in a low adhesion 96 well plate (Plate A) and the other 50 μl into a standard clear 
96well plate (Plate B), the final volume in all wells of plates A and B was then made up to 
100 μl. The remaining 20 μl of cell suspension was discarded. The plates were then 
incubated at 37°C overnight in 10% CO2. 18 h after transfer into low adhesion plates, the 
cells in low adhesion (Plate A) were transferred into a standard adhesion plate (Plate C) 
and allowed to adhere for 8 h before both plates (Plates A & C) were fixed with 4% (w/v) 
PFA for 30 min. Once fixed the cells in the plates were stained using 0.08% crystal violet 
solution for 30 min. Plates were then washed with water and air dried prior to imaging.  
In order to obtain quantitative data, the crystal violet staining was dissolved in 
10% (v/v) Acetic acid for 30 min at room temperature with gentle shaking. The intensity 
of the staining was measured using Sunrise (TECAN) absorbance microplate reader at 595 
nm. Mean and standard error of the mean (SEM) of independent experiments were 
calculated. Survival in suspension was measured by taking a ratio between staining 
intensity in Plate C compared to Plate A. The effect of MARK4 depletion was seen by 
normalising the mean of the treated values to the non-targeting siRNA control wells. Each 
condition was present in triplicate and each experiment repeated at least three times. 
2.2.8 Preparation of cell protein extracts 
Protein was extracted from adherent cells using a HEPES lysis buffer (20 mM 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid HEPES-NaOH (pH 7.4), 150 mM NaCl, 2 
mM EDTA, and 10% (v/v) glycerol). Freshly supplemented with 1x protease inhibitor 
cocktail (Roche), 0.05% (v/v) Triton X-100, and 1 mM Sodium Orthovanadate (Na3VO4) (a 
tyrosine phosphatase inhibitor), 10mM β- Glycerophosphate and 10 mM Sodium Fluoride 
(NaF) (serine/threonine phosphatase inhibitors). Cells were washed twice with ice-cold 
PBS before 100 μl HEPES lysis buffer was added. Cells were then scraped from the plates 
using a cell scraper and the lysate transferred into eppendorfs. The samples were 
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vortexed every 10 min for 30 min to ensure full lysis of the cells and the release of cellular 
content. The samples were clarified by centrifugation at 4°C for 10 min at 12,500x g. The 
supernatant was then removed and placed at -20°C for short-term storage.  
 Cells were also lysed directly in Laemmli lysis buffer. For this 1x Laemmli lysis 
buffer (62.5 mM Tris-HCl, pH 6.8, 2% (w/v) SDS, 10% (v/v) glycerol, 10% (v/v) β-
mercaptoethanol, 0.0105% (w/v) bromophenol blue) was applied directly to washed 
adherent cells. Cells were scraped, transferred into eppendorfs and vortexed every 10 
min for 30 min before being stored at -20°C for storage. 
2.2.9 SDS PAGE and Western blotting 
The protein concentration of HEPES lysates was established by spectrophotometry 
using the Bio-Rad protein assay based on the method by Bradford (Bradford 1976) and 
the manufacturer’s instructions. Equal protein amounts were then aliquoted and 1/4th 
volume of 4x Laemmli buffer was added to denature the proteins. The protein 
concentration of samples directly lysed in 1x Laemmli buffer was not determined. Equal 
volumes of these samples were used in the assumption of similar protein concentrations 
in all samples. All samples were boiled at 100°C for 5 min prior to loading on a gel. In 
order to quantify protein size PageRuler™ Plus Prestained Protein Ladder (Fermentas) was 
resolved alongside the protein samples. The mini-PROTEAN II gel electrophoresis system 
(Bio-Rad) was used. Gels were prepared with a 5% acrylamide stacking gel (5% (v/v) 
acrylamide, 0.125 M Tris, pH 6.8, 0.1% (w/v) SDS, 0.075% (v/v) ammonium persulphate 
(APS) and 0.083% (v/v) TEMED) and a 10% acrylamide resolving gel (10% (v/v) acrylamide, 
0.375 M Tris pH 8.8, 0.1% (w/v) SDS, 0.06% (v/v) APS, 0.07% (v/v) TEMED). When high 
resolution on lower molecular weight proteins was required a 12% acrylamide resolving 
gel was used (10% (v/v) acrylamide, 0.375 M Tris pH 8.8, 0.1% (w/v) SDS, 0.06% (v/v) APS, 
0.07% (v/v) TEMED). Electrophoresis was performed using a 1x SDS-PAGE running buffer 
(2.5 mM Tris, 0.2 M Glycine and 0.1% (w/v) SDS) at 100 mV until the dye had reached the 
bottom of the gel. 
The gels were electrophoretically transferred onto nitrocellulose or PVDF 
membranes (Invitrogen) using the Invitrogen iBlot® Dry Blotting System (Invitrogen). Once 
transferred the membranes were blocked for 1-2 h at room temperature in Tris-buffered 
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saline/Tween (TBST) (0.01 M Tris, pH7.4, 75 mM NaCl, 1.25 mM EDTA, pH 8.0, 0.1% (v/v) 
Tween 20) containing ether  5% (w/v) fat-free milk or 5% bovine serum albumin (BSA). 
Membranes were then incubated over-night at 4°C with the relevant antibody diluted in 
5%(w/v) BSA/TBST, containing 0.04% sodium azide, or if specified by the manufacturer, 
5% (w/v) fat-free milk/TBST. Membranes were then washed three times in TBST to 
remove excess antibody. The appropriate HRP-conjugated secondary antibody was then 
applied diluted in 5% (w/v) fat-free milk/TBST and incubated at room temperature for 1-2 
hr. The membranes were then washed again as described above before the bound 
secondary antibody was detected using enhanced chemiluminescence (ECL) solution, 
according to the manufacturer’s instructions (Thermo-fisher Scientific). Luminescence 
was then detected ether by exposing the membranes to X-Ray film (FUJIFILM) then 
developing the film using a Konica SRX-101A film processor or by imaging the 
chemiluminescence using Fusion Solo Chemiluminescence Imager (PEQLAB).   
PVDF membranes were stripped, if required, using a stripping buffer (2 M Glycine, 
pH 2.5, 0.1% (w/v) SDS). When probing for phosphorylated proteins and their total forms, 
the phosphorylated form was always probed for first, then the membrane stripped before 
probing for the total protein. HSP90, GAPDH or Lamin were used as loading controls 
2.2.10 Active Rho pull-down assay 
A GST-tagged fusion protein that corresponds to the Rhotekin Rho Binding Domain 
bound to glutathione-agarose beads (Millipore) was used to perform a pull-down assay 
for Rho GTPase in its active form. When Rho is in an active confirmation the Rhotekin is 
able to bind. Active Rho can then be pulled down using the agarose beads to which 
Rhotekin is bound. The activity assay was carried out as specified by the manufacturer. 
Briefly, H1299 were plated in 15 cm dishes to achieve 70% confluency 24 h after plating. 
Cells were then transfected with ether siRNA to deplete cells of MARK4 or plasmid to 
overexpressing MARK4 as per the manufacturer’s instructions. 48 h after transfection 
cells were lysed using 1x Mg2+ Lysis/Wash Buffer (MLB) (125 mM HEPES, pH 7.5, 750 mM 
NaCl, 5% Igepal CA-630, 50 mM MgCl2, 5 mM EDTA, 10% Glycerol) (Millipore) containing 
25 mM NaF, 1 mM Sodium Orthovanadate and 1 x Protease inhibitors (Roche). Plates 
were first washed with ice-cold PBS before 1 ml of MLB was added to the rinsed plates. 
Cells were detached by scrapping and lysates transferred into tubes on ice. Lysates were 
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clarified, after 15 min on ice, by centrifuging for 6 min at 13,000 x g, 4°C. The supernatant 
was transferred to a clean tube and stored on ice. The pull down was performed on 500μl 
of the cell extract. To this 40 μl of the Rhotekin GST-agarose slurry was added before the 
lysate mix was incubated for 45 min at 4°C with gentle agitation. After this time the 
agarose beads were pelleted by centrifugation for 10 sec, 14,000 x g, 4°C and the 
supernatant removed and discarded. The beads were washed three times by addition of 
500 μl MLB, gently agitation, pelleting of the beads once more and removal of MLB. Once 
washed the agarose beads were re-suspended in 25 μl of 2x Laemmli buffer and boiled 
for 5 min. 10% of the input lysate for each condition, 50 μl, was mixed with 1/4th volume 
of 4x Laemmli buffer and also boiled for 5 min. SDS-PAGE was performed on the input 
lysate and the pull down to analyse the quantities of active Rho relative to total Rho 
present between conditions. This experiment was carried out a minimum of three times. 
2.2.11 Co-Immunoprecipitation 
H1299, A549 or HEK293 were plated in 15 cm dishes and transfected with plasmid, 
HA-MARK4 or GFP-MARK4, when cells reached 60-70% confluency. After 48 h cells were 
harvested in 1 ml 1x MLB (see above) supplemented with 25 mM NaF, 1 mM Sodium 
Orthovanadate and 1 x Protease inhibitors (Roche). Cells were scraped and the lysate 
collected into a tube. Lysates were clarified by centrifugation for 6 min at 13,000 g, 4°C. 
Protein concentration was quantified using the Bio-Rad protein assay. At least 500 ug of 
protein extract was then subject to immunoprecipitation overnight at 4°C using the 
following concentrations of the required antibody; 2-5 μg anti- PP2A α/β (Y119) (Abcam, 
ab32141), anti-Tau (H-159) (Santa Cruz, sc-5587), anti-HA (HA-7) (Sigma-Aldrich, #H9658). 
Anti-YFP (F-20) (Santa Cruz, sc-33261) was used as the IgG control. Magnetic Protein G 
beads (Sigma-Aldrich) were blocked overnight in 3% BSA, 1x MLB. After overnight 
incubation of lysate with antibody, 30 μl of bead slurry was added and the lysates subject 
to a further incubation of 1.5 h at 4°C. Immune complexes were then washed four times 
using 500 μl of ice-cold MLB using a magnet to separate the beads from solution. Once 
washed the immune complexes were re-suspended in 2 x Laemmli buffer and boiled for 5 
min. They were then subjected to SDS-PAGE/Western blotting as described above. 
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2.2.12 Quantitative Real-time PCR (qPCR) 
2.2.12.1 RNA extraction 
RNA was extracted from cells in 6well plates using the RNeasy® Mini kit (QIAGEN) 
following the manufacturer’s protocol. Briefly, cells were lysed in 350 μl RLT buffer and 
scraped from the plastic surface for collection then put through a QIAshredder spin 
column (QIAGEN) to ensure complete cell lysis and homogenization. The supernatant was 
then mixed with equal volumes of 70% (v/v) ethanol before being loaded into the RNeasy 
column and centrifuged at 13,000 g for 15 sec. RNA bound to the column was then 
washed with the supplied wash buffers; RW1 (700 μl) once and RPE (500 μl) twice. The 
column was dried by centrifugation for 1 min before the RNA was eluted with RNAase-
free water. 
The RNA concentration was measured using a NanoDrop 1000 Spectrophotometer 
(Thermo Fisher Scientific). RNA was transcribed into cDNA using the High Capacity cDNA 
Reverse Transcription Kit (Applied Biosystems) according to the manufacturer’s 
instructions. Briefly, a 20 μl reaction containing 1x RT Buffer, 1x dNTP mixture, 1x RT 
Random primers, 1 μl MultiScribe™ Reverse Transcriptase (50 U/μl) and 1 μg of RNA was 
made up. Reverse transcription was then carried out using the Veriti® Thermal Cycler 
(Applied Biosystems) with first an initiation step of 10 min at 25°C before 120 min at 37°C 
to reverse transcribe the RNA. A final step at 85°C for 5 min deactivated the reverse 
transcriptase. cDNA samples were then stored short term at 4°C or long term at -20°C 
until relative gene expression levels were measured by qPCR. 
2.2.12.2 Quantitative Real-time PCR (qPCR) 
To quantify changes in gene expression levels, RNA reverse transcribed into cDNA 
was analysed using Quantitative Real-time PCR (qPCR). This was done using the Fast 
SYBR® Green PCR Master Mix (Applied Biosystems) and the Applied Biosystems 7900HT 
Real-time PCR System. Reverse transcription generated 1 μg of cDNA (a 1:1 ratio of 
conversion is assumed), this was diluted to 20 ng/ul then a 1:10 working dilution was 
made using nuclease-free water. A volume of 5 μl of the working dilution was used as the 
template in a 20 μl reaction of 10 μl 2x Fast SYBR® Green PCR Master Mix, 0.6 μl of both 
forward and reverse qPCR primers (5 μM stock) and 3.8 μl nuclease-free water. The 
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thermal cycler conditions were carried out as described in the manufacturer’s instructions 
for the appropriate thermal cycler. Briefly, an initial 20 sec activation stage at 95°C was 
followed by 40 cycles of a 1 sec 95°C denaturation step and 20 sec at 60°C to allow for 
annealing and extension. Every reaction was present in triplicate. Housekeeping genes 
hypoxanthine phosphoribosyl-transferase (HPRT) and glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) were used as reference genes to normalise the expression of 
target genes. Analysis of relative gene expression was carried out using the qbasePLUS 
2.1 software (Biogazelle) using the 2(-Delta Delta C(T)) method (Livak & Schmittgen 2001). 
Sequences of all primers used are listed in Table 2.6. Primers were purchased from Sigma-
Aldrich. 
Target Gene Forward primer sequence Reverse primer sequence 
CLIP170 AGAAGACGCTGCTGGACACAGA TGGCATCTTCCGCTGTTTGAGC 
E-CADHERIN TGGAGGAATTCTTGCTTTGC CACTGTTTTGCCTTCATCCA 
GAPDH AGCCACATCGCTCAGACAC GCCCAATACGACCAAATCC  
GEF-H1 CCGAGACAAACGCTTCCAGCAA GGTACTTGGTGATGCGCTGAGT 
GSK3α ACCTACCCTCACTAACTCTTCCTG GTAGAAGGTCCTCATACCCCAAAC 
GSK3β CCGACTAACACCACTGGAAGCT AGGATGGTAGCCAGAGGTGGAT 
HPRT TGACACTGGCAAAACAATGCA GGTCCTTTTCACCAGCAAGCT 
MARK1 TGCTCACCTGAAGGTCCAGAGA CTTTCCACACTGTTAGCCTGAGG 
MARK2 CTGATCTGACCAATAGCAGCGC TTAGAGGTGGGAATGGCAGGAC 
MARK3 CAGTCTCCTCACCACAAAGTGC TGCTGGTCTGACTCCTTTTCGG 
MARK4 GTCAACAGACTGTGAGAGCATCC GCTCTGTGTATGGCTTCAACTCC 
N-CADHERIN CCTCCAGAGTTTACTGCCATGAC GTAGGATCTCCGCCACTGATTC 
p21 TGAGCCGCGACTGTGATG GTCTCGGTGACAAAGTCGAAGTT 
p53 TAACAGTTCCTGCATGGGCGGC AGGACAGGCACAAACACGCACC 
PP2CB CCATGCCAATGGTCTCACACTG CAGCCTGGTTCCCACAACGATA 
SNAIL TGCCCTCAAGATGCACATCCGA GGGACAGGAGAAGGGCTTCTC 
TAU CCAGTCCAAGTGTGGCTCAAAG GCCTAATGAGCCACACTTGGAG 
TCF-1 GACATCAGCCAGAAGCAAG CACCAGAACCTAGCATCAAG 
VIMENTIN AGGCAAAGCAGGAGTCCACTGA ATCTGGCGTTCCAGGGACTCAT 
YWHAH ACGACATGGCCTCCGCTATGAA GCTAATGACCCTCCAGGAAGATC 
β-ACTIN ACCGAGCGCGGCTACAG CTTAATGTCACGCACGATTTCC 
β-CATENIN AAAATGGCAGTGCGTTTAG TTTGAAGGCAGTCTGTCGTA 
Table 2.6. Details of qPCR primers used in this thesis 
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2.2.13 Immunohistochemistry 
Lung cancer tissue microarray’s (TMA’s) LC817 and LC951 were obtained from US 
Biomax Inc (US). LC1002, LC814 and BC041114 were purchased from Insight 
Biotechnology Limited (UK). LC1002 contained 52 cases of lung adenocarcinoma (grade II-
III) tissue with self-matched adjacent normal tissue and 4 non-cancer normal lung tissue 
samples. The lung carcinoma tissue microarray, LC817, contained 16 cases of squamous 
cell carcinoma, 16 adenocarcinoma cores, 1 bronchioloalveolar carcinoma case and 6 
small cell carcinoma cases all with matched lymph node metastasis samples. LC951 tissue 
array contained cores from 30 lung carcinoma cases, 8 of which had matched metastatic 
carcinoma samples, 2 unmatched metastatic carcinoma and 8 normal tissue samples. 
LC951 also supplied follow up data of the patients sampled. LC814 contained 40 cases of 
matched lung cancer and metastatic lymph node cores. BC041114 array consisted of 90 
cases of lung carcinoma and 10 normal tissue samples. 
The TMA’s were kindly stained by Dr Francesco A. Mauri (Histopathology, Imperial 
College London, Hammersmith Hospital, London, UK). The primary antibody against 
MARK4 used was Anti-MARK4 N-Term (Sigma-Aldrich, SAB1300394) at a 1:50 dilution. A 
semi quantitative scoring of the histochemical staining was used (Immunohistochemical 
score, HIS) (REF from RL). The intensity of the staining was given a score of 0, negative, to 
3, strongly positive. The percentage coverage of the staining was assessed and scored 
between 0 and 100%. Scores were multiplied together to give a range of possible scores 
between 0 and 300. The cores were all scored bind of all clinical data. The TMA data for 
each array was analysed separately then appropriately grouped to assess any changes in 
MARK4 protein levels in tissue within different stage, grade’s, classification of tumours. 
2.2.14 Cell cycle analysis by FACS 
The Click-iT® EdU cell proliferation assay kit (Life Technologies) was used to assess 
changes in cell cycle profile. Following the desired treatment, before harvesting the cells, 
5-ethynyl-2’-deoxyuridine (EdU) was added to the culture medium (10 μM) for 1 h, at 
37°C 10% CO2, to allow for incorporation into the DNA during active DNA synthesis. Cells 
were then trypsinised, corpses were collected from the culture media and used to 
neutralise trypsin activity. Cells were pelleted and washed with 1% (w/v) BSA in PBS, 
pelleted again and the supernatant removed. 100 μl of Click-iT® fixative was added to the 
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loosened pellet and incubated at room temperature, protected from the light, for 15 min. 
The cells were again washed with 1% BSA PBS before again being pelleted and the 
supernatant removed. To permeabilise the cells 100 μl of 1X Click-iT® saponin-based 
permeabilisation and wash reagent was added and incubated with the cells for a further 
15 min. As per the manufacturer’s instructions, 1X Click-iT® reaction cocktail was 
prepared (For 1ml; 100 μl 1X Click-iT® EdU buffer additive, 875 μl PBS, 20 μl CuSO4, 5 μl 
Alexa Fluor® 488 azide). 500 μl of Click-iT® reaction cocktail was added to the cells and 
mixed before being incubated at room temperature for 30 min in the dark. Cells pellets 
were then washed with 1X Click-iT® saponin-based permeabilisation and wash reagent 
once before the pellet is re-suspended in 500 μl 1X Click-iT® saponin-based 
permeabilisation and wash reagent. The stained cells were analysed using the FACSDiva 
software v6.12 on a FACSCanto A flow cytometer. Data was analysed using FlowJo v7.6.5 
(Tree Star Inc). 
2.2.15 Cell migration assay 
NSCLC cells, 1x103 cells per well, were plated in black, flat and clear bottomed 96 
well plates (BD Biosciences). After 24 h the cells were transfected and incubated for 24 h 
with 10 % CO2 at 37 °C. 24 h after transfection, time-lapse imaging was performed for 18 
h (1 image/10 min) using a motorized-staged environment-controlled ImageXpress high 
content screening microscope powered by MetaXpress 2.0 (Molecular Devices). Two sites 
were acquired per well, each condition was present in triplicate. To quantify the degree of 
migration cells were tracked using MetaXpress Track Points application. Tracks were 
analysed using a previously published Mathematica (Wolfram Research) notebook (Katso 
et al. 2006). 
2.2.16 3D Invasion assay 
A549 or H1299 were plated, 7x103 cells/well, in flat-bottomed black walled 96 well 
plates (BD Biosciences) and incubated at 10% CO2 37°C. Cells were then transfected 24 h 
after plating, as described above, using Lipofectamine RNAiMAX (Invitrogen). 24 h after 
transfection, with cells at 70-90% confluency, the media was removed and an 
extracellular matrix of rat tail collagen (3 mg/ml) (BD Biosciences) was overlaid on the 
cells. The collagen was allowed to polymerize at 37°C 10% CO2 for 1 h after which 50 µl of 
DMEM containing 1% FCS, 0.5 μg/ml Epidermal Growth Factor (EGF) (Sigma-Aldrich) was 
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added to each well. Plates were then incubated at 37°C, 10% CO2 for 48 h to allow cell 
invasion to occur. The plates were then fixed using 100 µl a 4% (w/v) PFA solution 
containing 1.25 μM SYTOX® Green (Invitrogen). SYTOX® Green was used to stain the 
nuclei of the cells throughout the collagen matrix. To observe the effect of overexpressing 
proteins of interest, cells were plated in 15 cm dishes and transfected as described above. 
24 h after transfection these cells were re-plated into the 96 well plates and incubated for 
a further 24 h at 37°C, 10% CO2 before the collagen layer was placed above. The assay 
was then continued as described above. 
In order to image the degree of invasion in each well image stacks were acquired 
using an Axio Observer Inverted Widefield Microscope with VivaTome Spinning Disc 
system. Stacks of 500 μm were taken at six adjacent sites in the centre of each well with a 
distance of 10 μm between image planes. Images were then analysed using FIJI ImageJ 
using the plugin 3D object counter and a batch processing macro script kindly written by 
Stephen Rothery (Facility for Imaging by Light Microscopy (FILM), Imperial College 
London, London, UK). From this the Z distance of cells detected was determined, the data 
was normalised and the 75th and 90th percentile Z distances were averaged between wells 
of the same condition. All conditions were present in triplicate and at least three 
independent repeat experiments were always conducted. 
2.2.16.1 ECM composition 
The collagen extracellular matrix used was made as follows; Rat tail collagen (BD 
Biosciences) 3 mg/ml supplemented with 0.01% (v/v) Foetal Calf Serum (FCS) and 20% 
(v/v) 5x DMEM. In some experiments, Fibronectin 1 µg/ml or Lamin 1 µg/ml (BD 
Biosciences) or both were added to the matrix. During optimisation experiments, an 
alternative source of collagen was also tested, Porcine collagen (Nittagelatin), used at 3 
mg/ml supplemented with 0.01% (v/v) FCS and 20% (v/v) 5x DMEM. 
2.2.17 3D Invasion assay screen 
A549 were reverse transfected, as described below, and plated at 7x103 cells/well 
in flat-bottomed black 96-well plates (BD Bioscience) and incubated for 48 h at 10% CO2 
37°C. The media was removed and the extracellular matrix of rat tail collagen (3 mg/ml) 
was overlaid on the cells. The collagen was allowed to polymerize at 37°C 10% CO2 for 1 h 
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after which 25 µl of DMEM containing 1% FCS, EGF (0.5 µg/ml), HGF (0.5 µg/ml) and 
PDGF-1 (0.5 µg/ml) was added. 48 h later, the plates were fixed using 70 µl a 4% (w/v) 
PFA solution. The cells were then stained using SYTOX® Green (Invitrogen) at 1.25 µM in 
PBS. All reagents apart from the siRNA were added to the plates using a Multi-drop robot 
(Thermo Scientific). 
Image stacks were then acquired by spinning-disk confocal imaging using an Opera 
high-content microscope (PerkinElmer).  Stacks of 360 μm were acquired at four separate 
sites per well with a distance of 10 μm between focal planes. The images were processed 
using a Matlab code and analysed using a Mathematica notebook (Wolfram Research) 
programmed by Dr Daniel Zicha (Light Microscopy Department, CRUK, London, UK). 
2.2.17.1 Screen Transfection Protocol 
Briefly, 3.6 µl siRNA from the daughter library plates (at 1 µM) were spotted into 
the assay plates (Appendix Figure 10.2 B), where all wells were pre-filled with 35 µl 
OptiMEM, using a CyBi-well  robot (CyBio) to give a final siRNA concentration of 30 nM.  
10 µl of transfection reagent mix (OptiMEM (Invitrogen) containing 0.75% HiPerFect 
transfection reagent (QIAGEN) was then added to each well using a Multi-drop robot. The 
plates were incubated at room temperature for 20 min to allow for complex formation 
between the siRNA and the transfection reagent prior to cells being seeded into each well 
as described above.  
2.2.18  Cytoskeletal staining  
Cells in flat-bottomed black 96-well plates (BD Bioscience) were washed twice 
with ice-cold PBS then fixed with 100 μl 4% (w/v) PFA for 15 min. Plates were then 
washed again with PBS before cells were permeabilised with 100 μl of 0.1% (v/v) Triton X-
100 in PBS for 5 min, and washed 3 times more with PBS. To block unspecific antibody 
interaction 100 μl of 3% (w/v) BSA in TBS-T was then added to the plates and incubated at 
room temperature for at least 1 h. To stain the cytoskeleton ether Alexa Fluor® 488-
conjugated Phalloidin (Invitrogen) (1:1000), to stain Actin, or Cy3 conjugated anti-Beta 
Tubulin antibody (1:1000), to stain the microtubules, were used at the indicated 
concentrations. Nuclear DNA was stained using 4’, 6-diamidino-2-phenylindole (DAPI) 
(Invitrogen) (1:200, 1 μg/ml). Plates were images using an ImageXpress High content 
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Screening Microscope (Molecular Devices) and the MetaXpress software (Molecular 
Devices). Area covered by actin or tubulin was quantified using the Multi Wavelength cell 
scoring analysis module within the MetaXpress software. Mean and standard error of the 
mean (SEM) of independent repeat experiments were calculated. The average stained 
area for each condition was normalised to the control value.  
2.2.19  Microtubule comet imaging and analysis 
To analyse the speed of microtubule growth a plasmid encoding GFP tagged End 
Binding Protein 3 (EB3) was used. This protein binds to the growing end of the 
microtubules (MT) and by imaging the movement of the GFP comets produced as the 
microtubule grows we were able to quantify the speed of growth. The plasmid was 
transfected into 70% confluent A549 cells in 10 cm dishes 24 h before the cells were re-
plated into 8-well chamber slides (PAA laboratories). To observe the effect on MARK4 
depletion on microtubule growth speed, at the point of re-plating, cells were reverse 
transfected with siRNA against the MARK4 or a non-targeting control siRNA. The HA-
MARK4 plasmid or the empty vector control was co-transfected with the EB3-GFP plasmid 
to see if overexpressing MARK4 gave the opposite effect on microtubule growth. Once re-
plated cells were incubated for 48 h at 37°C 10% CO2. The movement of the EB3-GFP 
comets was imaged using a Zeiss LSM-780 inverted microscope (Zeiss) using the Zen Black 
software (Zeiss). 8-well chamber slides were imaged at 37°C, 10% CO2 using a 40x 
magnification, individual cells were imaged, one image per sec for a total of 2 min with a 
1.3 μm section.  
A total of 12 cells per condition were imaged in each independent repeat 
experiment. Comets were tracked using FIJI ImageJ (NIH, USA) and the plugin wrMTrck 
(J.Pedersen).  The number of frames each comet was tracked in and the distance covered 
was used to calculate the speed of movement. An average speed was calculated per 
condition and averaged between repeat experiments and normalised to the control.  
2.2.20  Microtubule polymerisation and depolymerisation assays 
2.2.20.1 Microtubule polymerisation assay – Nocodazole washout 
To observe the polymerisation, growth, of the microtubule network the drug 
Nocodazole was used. Coverslips were acid washed and coated with Poly-L-lysine (Sigma-
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Aldrich) to aid the adherence and culture of cells upon them. 5x104 A549 were plated 
onto coated coverslips in 24 well plates and incubated at 37°C 10% CO2 24 h before they 
were transfected using Lipofectamine RNAiMAX (Invitrogen) as described above. After a 
further incubation of 24 h at 37°C 10% CO2 cells were treated with 10 μM Nocodazole for 
16 h (overnight). A washout experiment was then performed by removing the media 
containing the nocodazole, washing the cells once with PBS and then adding normal 
media. This was done for the following time periods, 2, 5, 10, 20 and 30 min starting with 
the longest time point. Cells were then fixed using 4% (w/v) PFA in PBS for 15 min. Once 
fixed the cells were washed with PBS and permeabilised using 0.1% (v/v) Triton X-100 for 
5 min before being washed again with PBS. The cells were blocked using 3% (w/v) BSA in 
PBS Tween 20 (PBST) at room temperature for at least 1 h. In order to stain the 
microtubule network present the cells were incubated with a Cy3 conjugated anti-Beta 
Tubulin antibody (1:1000) and DAPI (1:200, 1 μg/ml) diluted in 3% (w/v) BSA PBST at 4°C 
overnight. The stained coverslips were washed three times with PBST to remove any 
unspecific staining. The coverslips were then mounted onto imaging slides using ProLong® 
Gold antifade mounting reagent (Invitrogen) and imaged using the EVOS® FL Cell Imaging 
System (Life Technologies™) upright fluorescent microscope. The produced images were 
then processed in FIJI ImageJ (NIH), thresholding the area covered by tubulin and 
quantifying the average area amongst cells imaged per condition. 
2.2.20.2 Free and Polymerised tubulin 
The quantities of free, soluble, and polymerized forms of tubulin within the cells 
were analysed using previously described protocols (Joshi & Cleveland 1989). Briefly, 
cells, in a 10 cm dish, were washed gently with a microtubule stabilizing buffer (0.1 M 
MES, pH 6.75, 1 mM MgSO4, 2 mM EGTA, 0.1 mM EDTA, 4 M Glycerol). The free tubulin 
fraction was then extracted by incubating the cells in 500 μl of microtubule stabilizing 
buffer containing 0.1% Triton X-100 at 37°C for 5 min. The free tubulin extract was then 
removed and clarified by centrifugation for 2 min at 16,000xg, the supernatant was then 
stored on ice. The polymerised tubulin fraction was collected by dissolving the remaining 
cytoskeletal fraction in the dish in 500 μl of 25 mM Tris, pH 6.8, 0.5% (w/v) SDS. This 
extract was combined with the pellet from the soluble tubulin fraction. The concentration 
of both fractions was quantified using the Bio-Rad protein assay and equal protein 
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quantities, mixed with ¼th volume of 4x Laemmli buffer, were analysed by SDS-PAGE 
western blot using an anti-β-tubulin. 
2.2.21  Statistical Analysis 
In all cases data was normalised to the relevant control value. Error is displayed in 
all results as +/- the standard error of the mean (SEM). GraphPad Prism 6 (GraphPad 
Software, USA) was used to perform statistical analysis on all data. When only two 
conditions were used a Students T-Test was performed (two sample equal variance, two 
tailed distribution). A significant change was determined with a p value less than 0.05. 
When suitable, when the differences between more than two conditions were to be 
considered, statistical significance was determined using a ANOVA, Bonferroni’s multiple 
comparison test. In all data the degree of significance was denoted as follows; *, P<0.05; 
**, P<0.01; ***, P<0.001, ****, P<0.0001. 
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3.1 Introduction  
Preventing or reducing the occurrence of metastasis would greatly improve 
survival rates for a number of cancers. In this thesis we focus upon lung cancer. This is 
one of the most common forms of cancer worldwide and has one of the lowest five-year 
survival rates of only 7-9%. There are two main causes for lung cancer death; the 
appearance of distant metastasis and resistance to therapy (Cancer Research UK 2011b; 
Woodhouse et al. 1997; Zochbauer-Muller et al. 2002b). If novel regulators of lung cancer 
metastasis could be identified there is the potential to develop new therapeutics which 
would dramatically improve survival. In an attempt to further understand the 
mechanisms behind metastasis in lung cancer we wished to identify key proteins involved 
in lung cancer cell invasion. 
Cell motility is crucial in the development of metastasis. The process of metastasis 
is commonly broken down into five key stages; firstly cancer cells must break-away from 
the primary tumour and invade through the extracellular matrix towards blood or lymph 
vessels. Once a cell reaches a vessel wall it must intravasate to enter the circulation. Once 
in circulation the cell experiences shear stress, making this an extremely selective stage 
with few cells surviving to form distant tumours. Tumour cells get trapped in thin 
capillaries and here are able to extravasate and invade through the surrounding tissue 
where, often after a period of dormancy, they proliferate to form a secondary tumour 
mass (Bendas 2011; Chiang & Massague 2008). Targeting tumour cells at the initial 
invasion stage will prevent subsequent metastasis. 
RNAi technology revolutionised biological research, providing a tool to transiently 
prevent the expression of a targeted protein. This has opened the doors to rapid 
functional characterisation of proteins. Collections of RNAi sequences targeting whole 
protein families or pathways, siRNA libraries, allow researchers to screen a larger number 
of targets in loss or gain of function screens, potentially RNAi’s most powerful application. 
Carrying out wide-scale high-throughput screening allows for identification of new 
biological pathway components and can give insight into the dynamic control of cellular 
processes (Bakal & Perrimon 2010; Echeverri & Perrimon 2006). We wished to employ 
this technology to carry out a high-throughput siRNA screen of the druggable genome to 
identify new regulators of lung cancer cell invasion. Using A549 cells, a non small-cell lung 
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cancer (NSCLC) cell line, we first thoroughly optimised a three-dimensional invasion assay 
to ensure its suitability for a screening set-up. We then carried out three pilot screens of a 
small siRNA library targeting the Phosphatome, in collaboration with Janssen 
Pharmaceutica. These pilot screens allowed us to test whether our assay was optimised 
for high-throughput conditions using a robotics set-up. 
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3.1 Choice of an Invasive Non Small-cell Lung Cancer cell line 
The two NSCLC cell lines A549 and H1299 were considered for this screen because 
they had been previously reported to be invasive. Further testing of these two cell lines 
confirmed their invasiveness within our assay. Both cell lines exhibited a similar level of 
invasion when stimulated with EGF. Therefore, A549 was chosen as the line with which all 
further optimisation work and the screen would be done (Lara et al., 2011; Data not 
shown).  
3.2 Optimization of Transfection Reagent and Method 
RNAi is commonly introduced into mammalian cells using lipid-based transfection 
reagents. Amongst commonly used transfection reagents are the cationic lipids which 
form complexes with siRNA sequences into positively charged packages. These packages 
are endocytosed, introducing the siRNA sequences into the cell. For a siRNA library screen 
the degree of transfection efficiency, the efficiency of target depletion, must be as high as 
possible. We therefore compared a number of available transfection reagents to assess 
which would provide optimal target knockdown with minimal reagent-based cell toxicity. 
It was also crucial to consider which reagent achieved sufficient knockdown with low 
siRNA concentrations. Using minimal siRNA concentrations minimizes the risk of off-
target effects, a key aspect to consider when optimising a high-throughput screen. The 
chosen product would also have to be amenable to our high-throughput robotic-based 
protocol. Two Invitrogen reagents were tested; Oligofectamine and Lipofectamine 
RNAiMax, alongside Polyplus from INTERFERin and HiPerFect by QIAGEN. To test these 
reagents siRNAs targeting Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were 
used. GAPDH is an abundant protein within the cell and therefore silencing such a highly-
expressed protein would provide a good test. siRNA concentrations of 10, 20 or 50 nM 
were tested. Non-Targeting 2 (Sc) (Dharmacon) siRNAs, sequences that are supposed not 
to target any mRNAs in the human genome, were used as a negative control.  
For each reagent the manufacturer’s instructions were followed. To assess the 
level of silencing, A549 cells were plated in 6 well plates 24 h before transfection with 10, 
20 or 50 nM GAPDH or non-targeting (NS) siRNAs using the relevant transfection reagent. 
After 72 and 96 h the protein was extracted from the cells using a HEPES-based lysis 
buffer. Protein extracts were then separated on a 10% SDS-PAGE and transferred onto a 
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nitrocellulose membrane. Transfection efficiency was then analysed using a HRP-coupled 
GAPDH antibody.  
The level of down-regulation obtained 72 h following transfection of 10 and 20 nM 
is shown in Figure 3.1A. Both Invitrogen reagents and the QIAGEN reagent, HiPerFect, 
performed well achieving good knockdown at 72 h. As the invasion assay would be 
carried out over a total of 96 h after transfection the level of silencing of GAPDH with 
these three promising reagents was also investigated at this time point. Again all three 
reagents, Oligofectamine, RNAiMAX and HiPerFect, performed well with low GAPDH 
levels at 96 h post-transfection (Figure 3.1B).  These three reagents were then compared 
in the invasion assay set-up. Briefly, 7 x103 A549 cells were plated in 96 well plates and 
transfected with GAPDH siRNA (20nM) 24 h later using the three reagents. The collagen 
was added on top of the cells 48 h after transfection and invasion into the collagen was 
stimulated using EGF (1.0 μg/ml) which was diluted in media and added above the 
polymerised collagen. The two Invitrogen reagents, Oligofectamine and RNAiMax, caused 
problems with the adherence of the collagen matrix to the well, resulting in a higher 
frequency of collagen detachment (data not shown). HiPerFect was therefore chosen for 
future assays. Reverse transfection and forward transfection protocols were compared 
and both gave adequate knockdown supporting the manufacture’s literature (data not 
shown). As reverse transfection lends itself well to robotisation we adopted this protocol 
for all our subsequent experiments. 
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Figure 3.1. Transfection Efficiency.  
A549 were transfected with siGAPDH at 10, 20 and 50 nM using Oligofectamine, RNAiMAX, 
HiPerFect, or INTERFERin. Cells were lysed and protein extracted after 72h (A) or 96 h (B). The 
protein lysates were quantified and separated by SDS-PAGE. Proteins were transferred by western 
blotting onto a nitrocellulose membrane which was probed with HRP coupled α-GAPDH (Abcam). 
(A) Assessment of transfection efficiency of four leading transfection reagents at 72 h. 
Oligofectamine, HiPerFect, RNAiMAX efficiently reduced GAPDH protein levels. β-Actin was used 
as a loading control (B) Confirmation of knockdown duration. Levels of GAPDH were still 
efficiently reduced 96 h after transfection. β-Tubulin was used as loading control  
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3.3 Method of Stimulating Invasion 
The basal level of invasion obtained by A549 cells within our 3D invasion assay was 
not sufficient to reliably detect changes in invasion by microscopy. Therefore a growth 
factor stimulant was applied to increase this basal invasion level, increasing the margins 
within which we were able to observe changes. In previous experience of this assay 
within our laboratory Epidermal Growth Factor (EGF) was used as a chemo-attractant to 
stimulate invasion. In vivo EGF is excreted by tumour cells and tumour associated 
macrophages to stimulate cell motility, angiogenesis and proliferation (Chiang & 
Massague 2008; Sahai 2005). However EGF is not the only growth factor released by 
tumour cells and surrounding stromal cells. We therefore wished to additionally test a 
range of other growth factors; PDGF, SDF-1, MCSF-1 and HGF. As these migratory signals 
are often released by surrounding cells rather than the tumour cells themselves, we also 
investigated whether invasion could be stimulated using a fibroblast cell line, CCL-211, or 
an endothelial cell line, HUVEC. 
To confirm the required concentration of EGF that is needed to stimulate sufficient 
invasion we performed the assay with titrated concentrations of EGF (Figure 3.2A). A549 
(7 x103) were plated in black 96-well plates 48 h before collagen was added. Once the 
collagen had polymerised EGF was added at a range of concentrations. Plates were then 
incubated at 37°C 10% CO2 for 48 h before being fixed using PFA and cells stained with 
SYTOX Green. Plates were images using a Zeiss Inverted Widefield microscope with 
spinning disc system. Images were then processed to determine average invasion 
distance per well. This was calculated by identifying the X, Y and Z coordinates of all cells 
detected within the image stacks (50 planes, 10 μM apart). Data was then normalised by 
removing the median Z distance from all cells identified, the average Z-median value for 
each well was found. Displayed in Figure 3.2A, it was confirmed that a suitably high 
stimulation of invasion was obtained at 1.0 µg/ml of EGF. Indeed, 1.5 µg/ml and 2.0 µg/ml 
were found not to offer statistically significant higher levels of invasion than 1.0 µg/ml. As 
1.0 µg/ml is already higher than endogenously found levels for EGF increasing this 
concentration further would not be physiologically relevant. 
To investigate whether alternative growth factors may provide a superior level of 
invasion, we tested HGF, PDGF, MCSF-1, and SDF1-α at concentrations ranging from 0.05 
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µg/ml to 2.0 µg/ml. Stimulation with growth factor concentrations below 0.25 µg/ml 
showed little change in invasion when compared to the untreated wells (data not shown). 
Figure 3.2B-E displays the data for all four additional growth factors tested at 0.25 µg/ml 
– 2.0 µg/ml. It can be seen that treatment with MCSF (C) and SDF-1α (E) did not markedly 
increase invasion compared to untreated cells, even at higher concentrations. Elevated 
levels of invasion were seen with increasing concentrations of HGF (D) applied to the 
collagen; with a significant increase in invasion compared to the untreated cells at 
concentrations above 0.5 μg/ml. A549 cells also responded well to treatment with PDGF 
(B), with levels of invasion mimicking those seen with EGF (A), statistically significant 
increases in invasion were observed with 1.0 – 2.0 μg/ml of PDGF.  
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Figure 3.2. Choice of chemoattractant to stimulate invasion.  
7x103 A549 cells were plated per well in 96-well plates for 48 h before a rat tail collagen matrix 
was laid above them. The indicated growth factor was then added at increasing concentrations 
from 0.25 – 2.0 μg/ml to stimulate invasion. 48 h later, plates were fixed stained and imaged to 
quantify the degree of invasion. (A) EGF and (B) PDGF stimulate invasion of A549 cells through a 
collagen layer. Addition of MCSF (C) or SDF-1 (E) to the collagen layer does not stimulate A549 
cell invasion. (D) HGF simulates A549 invasion less efficiently. All data shown is the average of at 
least three repeats. Error bars indicate SEM. Asterisks represent statistically significant values 
from a minimum of two biological repeat experiments with three technical repeats (*, P<0.05; **, 
P<0.01; ***, P<0.001, P<0.0001; ANOVA, Bonferroni’s multiple comparisons test). 
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In the physiological in-vivo environment a cocktail of growth factors is released by 
cells stimulating invasion. We tested combinations of EGF, HGF and PDGF, using the assay 
as described above, to assess whether these would be more efficient at promoting 
invasion. In Figure 3.3 it can be seen that EGF and PDGF used together significantly 
increased the level of invasion above that observed with EGF alone. The combination of 
EGF and HGF did not appear to improve the level of invasion but use of all three growth 
factors shows the highest level of invasion with around a 3 fold increase above that of un-
stimulated condition.    
 
 
 
 
 
 
 
 
Figure 3.3. The highest level of cell invasion can be achieved when EGF, HGF and PDGF are used 
in combination.  
7x103 A549 cells were plated in a 96-well plate for 48 h before a collagen matrix was laid above 
them. After 24 h growth factor solution in which all growth factors were present at 1 μg/ml was 
added above the matrix. The plates were incubated for another 48 h before being fixed, stained 
and images acquired. Images were then processed to quantify the degree of invasion. Data shown 
is the average of three repeats. Error bars indicate SEM. Asterisks represent statistically significant 
values from a minimum of two biological repeat experiments with three technical repeats (*, 
P<0.05; **, P<0.01; ***, P<0.005; ANOVA, Bonferroni’s multiple comparisons test) 
 
An additional aim of our optimisation experiments was to improve the 
physiological relevance of the assay. It has been previously shown that cells migrate or 
invade towards a chemo-attractant gradient. In vivo these chemo-attractants are released 
by other cells such as fibroblasts or endothelial cells. We tested both Human Umbilical 
Micro Vascular Endothelial Cells (HUVEC) and a fibroblast cell line CCL-211, plated on top 
of the collagen matrix in our assay, as a source of growth factor that could attract the 
A549 cancer cells. Previous experience in the laboratory had suggested that first 
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stimulating the HUVEC cells with interleukin -1 (IL-1) and VEGF increased the abundance 
of growth factors released by this cell line. Results displayed in Figure 3.4 show the level 
of invasion stimulated by a titration in cell number for both HUVEC (A) and CCL-211 cells 
(B). Over a series of repeats, neither cell line could produce levels of invasion similar to 
that obtained with EGF used at 1.0 µg/ml, despite high cell numbers being added (up to 4 
x 103). In fact, Figures 3.4A and B show that the level of invasion obtained using high 
numbers of stromal cells was reduced below that of the negative control. Taking into 
consideration all the above described optimisation tests, it was decided that a 
combination of EGF, PDGF and HGF all at 1μg/ml would be used for the screen as this 
would be the most physiological option. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4. Stimulation of Invasion using cells.  
7x103 A549 cells were plated in a 96-well plate for 48 h before a collagen matrix was laid above 
them. Once the matrix polymerised, the indicated stromal cells were then added at various 
concentrations above the matrix. The plates were incubated for another 48 h before been fixed 
stained and images acquired. Addition of HUVEC (A) or the fibroblast cell line CCL-211 (B) above 
the matrix does not induce A549 invasion. Representative graphs. Results are averages of 
quadruplicates with error bars indicating SEM. Asterisks represent statistically significant values 
from a minimum of two biological repeat experiments with four technical repeats (*, P<0.05; **, 
P<0.01; ***, P<0.001, P<0.0001; ****, ANOVA, Bonferroni’s multiple comparisons test).  
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3.4 Extracellular Matrix composition 
3D cell invasion in a tumour occurs as a cell moves through its extracellular matrix 
(ECM), remodelling its environment to allow passage. To mimic the in vivo conditions the 
majority of 3D assays use collagen or Matrigel-based matrices. Previous work with this 
assay in our laboratory has used Rat tail Type I collagen at 3 mg/ml mixed with DMEM 
and 1% FCS. There are many different sources of type I collagen ECM commercially 
available. To assess whether the matrix composition could be further optimised, another 
type of collagen, Porcine Collagen, was tested and compared to that extracted from rat 
tail. Both collagens were used at 3 mg/ml as previous experience suggested this 
concentration resulted in an appropriate density of matrix for our assay. As with previous 
optimisation experiments, 7 x 103 A549 were plated onto black 96-well plates and 
incubated at 37°C 10 % CO2. 48 h later the appropriate matrix was added and invasion 
stimulated by adding EGF (1.0 μg/ml) on to the polymerised collagen. Results from these 
experiments are represented in Figure 3.5A. It can be clearly seen that the un-stimulated 
level of invasion observed in porcine collagen was significantly lower than that seen in un-
stimulated rat tail collagen condition. When invasion is stimulated this difference is 
amplified, with a threefold increase in invasion seen through the rat tail collagen, and a 
0.4-0.5 fold decrease with porcine collagen, compared to the un-stimulated rat tail 
collagen control.  
Fibronectin and Laminin are two other ECM components; Laminin is bound by 
integrins to form focal adhesion complexes. A literature search suggested that the 
addition of Fibronectin or Laminin to a collagen matrix could improve invasion. Thus, to 
observe changes in invasion due to the presence of fibronectin and Laminin both were 
added to the collagen, either individually or together, to give a final concentration of 0.1 
µg/ml (the collagen concentration was unaltered). Figure 3.5B shows the change in the 
level of invasion in Rat tail collagen with or without the addition of Fibronectin, Laminin 
or both. All data is normalised to the un-stimulated Rat tail collagen only condition. 
Addition of Fibronectin did not significantly affect the level of invasion in the presence of 
growth factors. Addition of Laminin significantly reduced invasion in comparison to Rat 
tail collagen only. Presence of both additional ECM components did not change the 
degree of cell invasion compared to the rat tail collagen alone.  
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To confirm that collagen fibres formed in our matrix mimicked those found in 
endogenous collagen, we used second-harmonic imaging to observe the collagen 
structure. This form of microscopy utilises the natural fluorescence of certain structures 
when they are excited at a specific wavelength, collagen being one of those that naturally 
emit fluorescence. This avoids the incorporation of chemical dyes which could alter the 
collagen composition. Fibres were observed as anticipated and remodelling of collagen 
fibres around cells could be seen, Appendix Figure 10.1.  
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Figure 3.5. Composition of the extracellular matrix.  
7 x 103
 
A549 cells were plated in a 96-well plate for 48 h before ether a Rat tail collagen or porcine 
collagen matrix ± 0.1 µg/ml Fibronectin, Lamin or both was laid above them. EGF (1.0 µg/ml) was 
added to the matrix to stimulate invasion. Plates were incubated for another 48 h before being 
fixed stained and images acquired. (A) Representative graph comparing change in invasion when 
ether a Rat or Porcine collagen matrix is used. (B) Representative graph of the effect on invasion 
of addition of Fibronectin or Laminin to the collagen matrix. Representative graphs are the 
average of quadruplicate technical repeats. Error bars indicate SEM. Asterisks represent 
statistically significant values from a minimum of four technical repeats (*, P<0.05; **, P<0.01; 
***, P<0.001, ****, P<0.0001; ANOVA, Bonferroni’s multiple comparisons test) 
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3.5 Screening controls 
When carrying out a siRNA screen it is important to include various controls to 
normalise data, assess data reproducibility and reduce the occurrence of false positive 
and negative results. Such controls could be included within the assay plates themselves 
or on extra assay plates used at the beginning or end of each batch of the screen. As the 
intended screen would involve multiple 96 well plates and multiple batches of plates it 
was important for controls to be included on every plate. This would allow for exclusion 
of any plate where the behaviour of the controls was outside the norm. In our case we 
used the basic level of invasion as a control and discarded plates where the levels of 
invasion seen did not match what was expected. We also tested a number of siRNA 
controls. In addition to including non-targeting siRNA controls we wished to include 
functional controls, siRNAs which were known to increase or decrease motility when their 
target is silenced.  We tested a number of potential functional controls chosen based on 
their known roles as modulators of cell invasion through experiments conducted in our 
lab or literature search. Hence, siRNAs targeting the RSK1, 4.1B, ROCK1 were tested for 
increasing invasion. Similarly, siRNA against RSK4, RhoC and LIM kinase were tested for 
their negative impact on invasion.  
Figure 3.6A displays the results of the functional controls. As expected, depletion 
of RSK1 and ROCK increased A549 invasion. RSK4 silencing also resulted in the expected 
phenotype, reduced invasion. However the behaviour of some of the potential controls in 
our assay did not support the reported phenotype. Particularly, downregulation of LIM 
kinase appeared to reliably increase invasion in our set-up. Both RhoC and 4.1B silencing 
failed to give the expected invasive phenotype, while treatment with 4.1B siRNAs resulted 
in no phenotypic change and RhoC depletion consistently increased invasion (Figure 
3.6A). Due to the failure of 4.1B and RhoC we instead included two other control siRNAs. 
A triple receptor knockdown, a combination of siRNA targeting for EGFR, HGFR (MET) and 
PDGFR, the receptors for the three growth factors used to stimulate invasion, was used as 
a functional negative control. siRNAs against SRC was also added. Depletion of SRC was 
expected to decrease invasion.   
We also wished to identify a control that would serve as a transfection quality 
control during the running of our screen. In all screening experiments, transfection 
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efficiency would be assessed by inclusion of a control well in each plate treated with 
siRNAs against Kinesin family member 11 (KIF11). Knockdown of KIF11 prevents 
centrosome migration and arrest cells in mitosis leading to cell death after about 48-72 h 
(AMBION 2007). Figure 3.6B demonstrates that there are few cells remaining in the 
KIF11-silenced well compared to a confluent monolayer in the non-targeting SC control. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6. Selection of siRNA controls for 3D Invasion Screen. 
A549 cells were plates in black 96-well plates and reverse transfected with the following potential 
siRNA functional controls; RSK1, RSK4, RhoC, 4.1B, ROCK, LIMK or KIF11. 48 h after transfection a 
rat tail collagen layer was laid above the cells and EGF (1 μg/ml) was added above the 
polymerised collagen to stimulate invasion. After a further 48 h plates were fixed and cell stained 
before the plates were imaged using a Zeiss Inverted Widefield microscope with spinning disk 
system. Images were processed to quantify the degree of invasion. (A) Assessment of invasive 
phenotype for siRNA functional controls. Testing of RSK1, RSK4, RhoC, 4.1B, ROCK and LIMK 
confirmed the expected phenotypes with siRSK1, siRSK4 and siROCK. Knockdown of the other 
three siRNA controls did not display the predicted effects on cell motility. (B) Representative 
image demonstrating cell death induced by KIF11 silencing. Transfection efficiency was 
demonstrated by the percentage cell death in the KIF11 silenced wells compared to the control 
wells. Representative images are shown. (A) Results shown the average of three repeats. Error 
bars indicate SEM. Asterisks represent statistical significance calculated from a minimum of three 
biological replicates.   
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3.6 Phosphatome Pilot Invasion Screen 
In order to test whether decisions drawn from the optimisation experiments 
described above provided the best assay settings for screening, a pilot screen was carried 
out. Robotics were to be used to prepare siRNA complexes and to add reagents and cells 
to the plates, therefore this was a crucial step in confirming the suitability of both the 
robotics and the assay conditions. This work was carried out in collaboration with Janssen 
Pharmaceutica within their laboratories. It was decided that a small siRNA library would 
be screened: the phosphatome, supplied by AMBION (Silencer Select Human 
Phosphatome library). This collection contains 894 unique siRNA’s targeting 298 Human 
phosphatases. Each gene product is targeted by three separate oligonucleotide 
sequences, located on separate plates (Appendix Figure 10.2A).  
The pilot screen was carried out in triplicate. The control siRNAs used in each pilot 
are summarised in Table 3.1 and the full sequences for these siRNA can be found in Table 
2.5 in Chapter 2.2. NS#1 and NS#2 were used as non-targeting siRNA controls. 
Additional control plates were also screened in parallel: in all three repeats of the 
pilot screen, a plate containing the functional controls, LIMK, RSK1, RSK4, ROCK, SRC and 
triple receptor targeting siRNAs, as pools and deconvoluted sequences was added. Full 
plates of NS#1 and KIF11 were included in the later two pilot screens (2 and 3) so that 
phenomena such as edge effect and plate drift could be detected along with batch to 
batch variation. Pilot 2 and 3 also included an additional plate containing siRNAs for RSK1 
as both pooled and individual oligonucleotides, which was analysed by qPCR to assess the 
extent of target down-regulation. 
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Plate/Control 
siRNA 
Pilot 1 Pilot 2 Pilot 3 
Assay 
plates 
Full 
Plate 
Assay 
Plate 
Full 
Plate 
Assay 
Plate 
Full 
Plate 
RSK1 + - - + - + 
RSK4 + - - - - - 
ROCK + - - - - - 
SRC + - - - - - 
Triple Receptor + - - - - - 
NS#1 + + + + + + 
NS#2 + + + + + + 
KIF11 - - + + + + 
 
Table 3.1. Summary of siRNA controls used in the three pilot screens.  
Each 96-well assay plate contained room for 8 control siRNA’s. Additional plates were added to 
assess edge effects or in-batch variations. 
3.6.1 Phosphatome Pilot Invasion Screen 1 highlighted a number of issues 
with the screening protocol 
The first pilot screen (Pilot 1) was carried out to investigate whether the optimised 
conditions were indeed suitable for a high-throughput setting and to allow initial testing 
of the various robotics to be used.  This screen also allowed various analysis pipelines to 
be tested on larger data sets than those previously available during optimisation. This 
screen involved 12 library plates with 2 additional control plates; a Functional control 
plate and a full NS#1 plate. Briefly, assay plates were prefilled with 40 μl OptiMEM 
containing the transfection reagent HiPerFect. siRNA was transferred from daughter 
plates into assay plates using disposable 96-well tip heads on the CyBi-well robot and 
plates were incubated to allow complexes to form before 7 x 103 A549 cells were added 
to each well using a Multi-drop. Plates were incubated at 37°C 10 % CO2 for 48 h before 
addition of the collagen matrix and 25 μl of DMEM containing EGF (1 µg/ml), HGF (1 
µg/ml) and PDGF-1 (1 µg/ml) was added to stimulate invasion. All plates were then 
incubated for a further 48 h to allow for invasion to occur before being fixed and stained. 
Plates were imaged by spinning-disk confocal imaging using an Opera high-content 
microscope (PerkinElmer). The average Z distance invaded was found for each target by 
first normalising each well to the average of the non-targeting siRNA controls (NS#1 and 
NS#2) on each plate. These values were then averaged between the three siRNAs for each 
target resulting in a final invasion value for each target. Figure 3.7A displays the resulting 
spread of data.  
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Figure 3.7. Phosphatome Pilot Invasion Screen 1.  
(A) Overview of the spread of data for fold-change in invasion obtained following the down 
regulation of the 298 targets of the AMBION phosphatome library. (B) Behaviour of controls 
during pilot 1 of the Phosphatome screen. The controls were arranged on every plate of the 
screen. In Pilot Screen 1 black 96-well plates were pre-plated with OptiMEM containing 
transfection reagent before siRNA was added using a CiBi well robot. A549 cells were then added 
to the plate so that they were reverse transfected. 48 h later a collagen matrix was laid above the 
cells and a combination of EGF, HGF and PDGF (all at 1 μg/ml) was added above the polymerised 
collagen. Plates were incubated for a further 48 h before being fixed, stained and imaged using 
the Opera high content microscope. A Matlab code and Mathematica notebook were used to 
quantify the average distance of invasion. The fold change values were calculated against the 
behaviour of the non-specific control on each plate. These are plotted in (A). The fold change 
values for the functional controls were averaged between plates and plotted (B). Error bars 
indicate SEM. Asterisks represent statistically significant values (*, P<0.05; **, P<0.01; ***, 
P<0.001, ****, P<0.0001; ANOVA, Bonferroni’s multiple comparisons test). 
 
The major issue identified in Pilot 1 was the poor reliability of phenotypes 
displayed by the controls (Figure 3.7B). Depletion of RSK1, LIMK and ROCK1 was expected 
to result in an increase in invasion based on previous experience in the lab and/or 
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EGFR, MET and PDGFR were expected to inhibit cell invasion. However, there were large 
variations in the results seen for these conditions between plates (Figure 3.7 B) and the 
effects observed did not always match the expected phenotype. Silencing RSK4 increased 
invasion as did siRNA SRC, which resulted in a significant increase rather than the 
expected decrease in motility. All control siRNAs appeared to increase invasion in 
comparison to the average of the non-targeting siRNA controls.  
These results raised doubts as to the reliability of transfection conditions within 
our assay. Using the KDalert system we compared the percentage knockdown of GAPDH 
obtained between identical transfection conditions to Pilot 1 and slightly altered 
conditions. We tested the effect of increasing the concentration of siRNAs from 30 to 50 
nM. Another concern was that complex formation was taking place in 50 µl which is a 
reasonably large volume and so we tested increased HiPerFect concentrations (I= 0.25 %, 
II=0.5 %, III=0.75 %, IV=1.0 %) to assess whether this would improve our results. Appendix 
Figure 10.3 shows that in conditions 30_II (used in Pilot 1); the efficiency of target 
silencing obtained is about 76 %. However with increased HiPerFect concentration this 
could be increased to 83 %. Increasing the siRNA concentration to 50 nM further 
improved the knockdown efficiency. However using 50 nM siRNA would be expected to 
also increase the risk of off target effects and so it was decided to continue using 30 nM 
for the rest of this project. A HiPerFect concentration of 0.75 % was chosen as adequate 
as the knockdown efficiency did not noticeably increase when using this agent at 1.0 %. It 
was also decided that the HiPerFect reagent would be added after the siRNAs were 
transferred into the assay plates, as this would allow for better control of complex 
formation timings. 
A number of further issues were identified by this first pilot screen (data not 
shown). The homogeneity of the collagen mix was shown to be insufficient and this 
introduced variability between plates due to different matrix densities influencing the 
ease with which cancer cells could penetrate the matrix. Another problem was the 
formation of bubbles within the collagen, introduced during the mixing process. This 
complicated the image acquisition and resulted in fields or whole wells having to be 
excluded from analysis. Moreover, traces of media remaining in the wells before collagen 
addition caused further concern as the concentration and homogeneity of the collagen in 
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the well may be influenced by this. In order to prevent these issues in further pilot 
screens a different multi-drop system was used which allowed for slower dispensing while 
the collagen mixing process was revised to enable more thorough homogenisation.  
Bacterial contamination was another issue, though only a few wells were affected. 
These wells were often situated around the edges of the plate where handling may have 
caused contamination. In subsequent pilot screens, antibiotics-containing medium was 
added 24 h after transfection and steps were taken to improve the sterility of the 
procedure. 
3.6.2 Phosphatome Pilot Invasion Screens 2 & 3 resolved previous issues 
To confirm that the above mentioned modifications to robotics and assay 
conditions improved the high-throughput screen protocol, the phosphatome siRNA 
screen was repeated as Pilots 2 and 3. Both were performed on the same day a few hours 
apart. The general protocol remained the same, with changes to the procedure described 
above and below. 
Changes were made to the controls: as described an additional assay plate was 
included filled only with RSK1 siRNA-treated cells, present as pools or deconvoluted 
sequences. This plate was removed from the screen protocol 48 h after transfection and 
qPCR was performed to quantify the efficiency of target knockdown. Additionally, full 
NS#1 and KIF11 siRNA plates were added. These plates would be used to control for edge 
effect. Functional controls were removed from the assay plates and replaced with three 
wells each of NS#1 and NS#2 plus two wells of KIF11. The presence of NS#1 and NS#2 in 
triplicate allowed for the behaviour of these non-targeting siRNAs to be assessed and for 
exclusion of outlying NS wells before normalisation of targets. 
The qPCR results for Pilots 2 and 3 showed a knockdown level of 95 % with the 3 
siRNA oligonucleotides targeting RSK1 used either as a pool or deconvoluted sequences 
(Figure 3.8A).  The full NS#1 and KIF11 plates confirmed that there was no edge effect or 
plate drift; this is seen by the little variation in colour between wells on the heat maps 
displayed in Figure 3.8C.  An example of edge effect can be seen in Figure 3.8B. To 
confirm that growth factor addition was indeed stimulating invasion in this screen, half a 
plate was used for siRNA- and growth factor-untreated controls. The effect of growth 
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factor stimulation can be seen in the heat map in Figure 3.8D. The lighter colour of the 
bottom half of the plate, representing the growth factor un-stimulated cells without any 
target knockdown, confirms that the level of invasion was lower there than in the growth 
factor stimulated top half of the plate and therefore that growth factor stimulation 
increased invasion as was desired. Moreover, the improvement in sterility brought to the 
assay after Pilot 1 were sufficient in ensuring that contamination was not an issue in Pilots 
2 and 3. 
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Figure 3.8. Controls for Phosphatome Pilot Invasion Screens 2&3.  
(A) qPCR for RSK1 from pilot 2 &3  to confirm adequate transfection efficiency. 7 x 103 A549 cells 
were plated and reverse transfected with RSK1 siRNA. After 48 h total RNA was extracted and the 
samples analysed by qPCR to quantify the amount of RSK1 mRNA remaining by comparison to two 
housekeeping genes PGK1 and TFRC. (B) Example of edge effect. Example heat map shows lower 
invasion in the outer wells, as seen by the lighter colour. (C) Confirmation of the absence of edge 
effect or plate drift. Representative image taken from Pilot 2. (D) Confirmation of stimulation by 
growth factors. Only the upper wells were stimulated, these can be seen in darker grey showing a 
greater degree of invasion than the lower unstimulated wells. Representative image taken from 
Pilot 2. 
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Analysis of the Opera confocal images was carried out using a Matlab code and 
processed using a Mathematica notebook. The fold changes in invasion were calculated in 
reference to the median of the NS#1 and NS#2 values of each respective plate. It should 
be noted that the level of A549 invasion when transfected with NS#2 was higher than 
with NS#1, which is why it was decided to use a median of the two average values on 
each plate rather than choosing one over the other (Appendix Figure 10.4). The spread of 
fold change in invasion obtained for all downregulated targets for Pilot screens 2 and 3 is 
displayed in Figure 3.9A & B. Values in Pilots 2 and 3 range only from ~0.25 – 3.0 fold. The 
data is spread relatively evenly either side of 1.0, the control value. In contrast, pilot 1 
(Figure 3.7) produced a much larger data spread, ranging from ~0.0 – 7.5 fold with the 
majority of data lying above the control. 
The values for the three different siRNAs targeting each gene, normalised to the 
NS#1 and NS#2 controls as described above, were compiled and submitted to Redundant 
siRNA Activity (RSA) analysis. This method models the probability of a gene genuinely 
affecting the tested function, based on the collective activities of the multiple siRNAs 
targeting that gene. This method was employed to rank hits in our screens. The algorithm 
firstly ranks all individual siRNAs/wells according to their scores. The rank distribution of 
all siRNAs for each gene is then examined and a p value assigned. A gene for which all 
siRNAs have a moderate impact on function will therefore rank higher than a gene with 
one highly impacting siRNA but the others less active (Chiang et al. 2007). While the RSA 
analysis was carried out on all pilot screens, the ranks were only compared between 
Pilots 2 and 3 as the protocol variations between the first and later two screens may 
introduce analytical artefacts. However, the overlap between Pilots 2 and 3 was low: 28% 
for the top 50 genes ranked increasing invasion when downregulated and 36% for those 
50 genes decreasing invasion upon knockdown. Table 3.2 displays the 11 overlapping hits 
selected by this analysis. For these genes, 2 or more of the 3 individual siRNAs led to fold 
changes in invasion >1.5 (increase) or <0.5 (decrease). Validation experiments on these 11 
hits were then undertaken to confirm the effects observed in the screens. 
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Figure 3.9. Phosphatome Pilot Invasion Screens 2 & 3.  
(A, B)  Overview of the spread of data for fold-changes in invasion obtained following the down 
regulation of the 298 targets of the AMBION phosphatome library, in Pilot 2 (A) and Pilot 3 (B). 
In Pilot Screens 2 and 3 black 96-well plates were pre-plated with OptiMEM before siRNA was 
added using a CiBi well robot, HiPerFect reagent diluted in OptiMEM was then added to all wells 
and complexes allowed to form. A549 cells were then added to the plates so that they were 
reverse transfected. 48 h later a collagen matrix was laid above the cells and a combination of 
EGF, HGF and PDGF (all at 1 μg/ml) was added above the polymerised collagen. Plates were 
incubated for a further 48 h before being fixed, stained and imaged using the Opera high-content 
microscope. A Matlab code and Mathematica notebook were used to quantify the average 
distance of invasion. Mean invasion for each RNAi condition was normalised against the median 
of the non-specific controls on each plate of the screen. These values were then averaged 
between the three siRNAs against each target and plotted in ascending order to show the spread 
of the data.   
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Gene Name 
Fold change in invasion 
Pilot 2 Pilot 3 AVG 
DUSP4 Dual specificity phosphatase 4 1.41 2.15 1.78 
DUSP5 Dual specificity phosphatase 5 2.6 2.09 2.34 
INPP1 Inositol polyphosphate-1-phosphatase 1.6 1.87 1.73 
PPP2R5C Protein Phosphatase 2 regulatory subunit B gamma 1.16 1.64 1.4 
PPP2R1B Protein Phosphatase 2 regulatory subunit A Beta 1.36 2.24 1.8 
PPAP2B Phosphatidic acid phosphatase type 2B 0.26 0.41 0.34 
PTPN9 Protein Tyrosine Phosphatase, non receptor type 9 0.43 0.6 0.51 
SACM1L SAC suppressor of actin mutations 1-like 0.35 0.24 0.3 
CIB2 Calcium and integrin binding family member 2 0.3 0.49 0.4 
HTPAP Phosphatidic acid phosphatase type 2 domain 0.51 0.49 0.5 
C21orf6 PWD Domain containing 2B 0.49 0.29 0.39 
 
Table 3.2. List of 11 Hits modulating A549 cell invasion speed.  
Hits identified in the phosphatome invasion screen that increased (red) or decreased (black) 
invasion distance upon depletion using siRNA. These hits lie within the top 50 hits for increasing 
and decreasing invasion in both Pilot 2 and 3. 
3.7 Validation of the hits from Phosphatome Pilot Invasion Screen 2 
and 3  
To confirm that Pilots 2 & 3 had produced reliable results and that the analysis 
had not resulted in the inclusion of false positives within our top 11 hits, these hits were 
validated. Validation was performed manually, using the optimised invasion assay 
conditions, again using A549. Validation siRNAs used were pools of four sequences 
purchased from an alternate provider, Dharmacon. This enabled us to confirm that the 
changes in invasiveness seen during the screen were not a consequence of off-target 
effects specific to the AMBION siRNAs. Plates were run containing all 11 hits, a non-
targeting siRNA control, NS, and MARK4, a gene that our laboratory has demonstrated to 
decrease invasion upon knockdown. The first set of validation plates were only stimulated 
with EGF (Figure 3.10A). The 5 hits from the screen which increased invasion are shown in 
light grey, those that decreased invasion in dark grey. A number of issues were 
highlighted by these results. There were large variations between wells for the same 
condition which lead to large error bars making it difficult to determine the significance of 
the results.  Variations between repeats were also seen. From the 11 hits only three, 
PPP2R1B, PTPN9 and SACM1L, validated across all experiments. Figure 3.10A shows  
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Figure 3.10. Validation of the Phosphatome Invasion Screen.  
(A) Validation Invasion Assays with EGF alone. (B) Validation Invasion Assays with EGF, HGF and 
PDGF. (C) Comparison of average fold-change in invasion with EGF or Multiple growth factor 
stimulation. 7 x 103 A549 cells were plated and reverse transfected with the appropriate siRNA. 
After 48 h a collagen matrix was laid upon the cells and EGF (1 µg/ml) or a combination of EGF, 
PDGF and HGF (all at 1 µg/ml) was added to stimulate invasion. After a further 48 h the plates 
were fixed, stained and images acquired. Fold change in invasion was calculated for each 
condition. In A and B the control non-targeting siRNA is shown in black, those hits which increased 
invasion in the screen in light grey, and those which decrease invasion in the screen are shown in 
dark grey. All data shown is the average of three repeats. Error bars indicate SEM. Asterisks 
represent statistically significant values from a minimum of three biological repeats (*, P<0.05; **, 
P<0.01; ***, P<0.001, ****, P<0.0001; ANOVA, Bonferroni’s multiple comparisons test). 
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clearly that depletion of DUSP4 and DUSP5 appears to reliably decrease invasion in the 
manual validation experiments. However, these results do not validate the screen as they 
oppose those seen in the screen itself. A higher validation rate was expected especially as 
this hit list had been compiled from the top 50 hit lists of two repeats rather than a single 
occurrence. 
Subsequently we performed validation in the presence of all three growth factors 
as performed during the initial screen (Figure 3.10B). The use of all three growth factors 
did improve the reproducibility between technical repeats although there was still some 
variation between biological replicates. When all three growth factors were used none of 
the siRNAs resulted in an average increase in invasion. As with EGF alone, depletion of 
DUSP4 and DUSP5 appears to decrease invasion though to a lesser extent. From those 
hits which are expected to decrease invasion, seen in dark grey in Figure 3.10B, PPAP2B 
and CIB2 validated with a significant decrease seen in both cases. No significant change is 
observed amongst the other decreasing hits.  
Gene 
Validated 
EGF EGF, PDGF, HGF 
DUSP4 X X 
DUSP5 X X 
INPP1 X X 
PPP2R5C X X 
PPP2R1B  X 
PPAP2B X  
PTPN9  X 
SACM1L  X 
CIB2 X  
HTPAP X X 
C21orf6 X X 
 
Table 3.3. Validation of 11 hits from Pilot Screens 2 and 3.  
Summary of the validation results for the 11 hits from Pilot screens 2 and 3 both with EGF alone 
and with a combination of growth factors; EGF, HGF and PDGF. 
 
In Figure 3.10C, the average fold change between repeats with EGF alone or all 
three growth factors is displayed. It appears that the phenotype observed with some hits 
is altered by the type of growth factor stimulation applied. For example PPP2R1B 
increases invasion when only EGF is used, whereas a decrease in motility is observed 
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when all three growth factors are applied. Table 3.3 summarises which hits validate in the 
two validation assays used. With ether choice of invasion stimulant, however, the 
validation rate is still less than 30%. 
When analysing Pilots 2 and 3 the number of cells detected in each well was 
observed in an effort to exclude wells where siRNA treatment-induced cell death 
occurred. However to confirm that changes in cell viability or proliferation did not 
influence our readout, Crystal Violet assays were carried out following down regulation of 
our 11 hits (Figure 3.11A). A549 cells were reverse transfected with the relevant siRNAs 
prior to incubation at 37°C, 10 % CO2 for 48 or 72 h. Plates were then fixed with 4% PFA 
and stained with a crystal violet solution. Toxicity was seen upon silencing of CIB2 and 
DUSP5 and a small decrease in cell number was seen with PPP2R1B and INPP1 down 
regulation. No statistically significant changes were observed. For the three hits that 
validated in the EGF alone experiments, a further toxicity experiment was performed to 
assess the level of Caspase activity, indicative of apoptosis. A substrate-based assay was 
used to measure the activity of caspase 3 and 7. Cleavage of the substrate by active 
caspases 3 and 7, results in luminescence emission that is proportionate to the level of 
caspase activity. Figure 3.11B shows that caspase 3/7 activity was increased 24 hours 
after knockdown of PPP2R1B as compared to the NS control, although this was not 
statistically significant. 
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Figure 3.11. Toxicity of Phosphatome Screen hits.  
(A) Validation of toxicity associated with silencing of the Phosphatome hits. A549 cells were 
plated and reverse transfected with siRNA’s against the 11 hits. Plates were incubated for 48 h at 
37°C and 10 % CO2 before being fixed with 4% PFA and stained with 0.075% crystal violet solution. 
Washed plates were dried and crystal violet precipitates re-suspended in 10% Acetic Acid. 
Absorbance was then measured using a plate reader and data normalized against the control 
wells to provide fold-change in cell density as a read out of proliferation/toxicity. (B) Caspase 
activity for validating hits. A549 cells were plated and reverse transfected with siRNAs against the 
11 hits. Plates were incubated for 48 h at 37°C and 10 % CO2 before the Caspase 3/7 reagent 
(Promega) was added to each well and plates were incubated for 1 h in the dark at room 
temperature. The luminescence was then read using the PHERAstar luminescence microplate 
reader.  Values were normalized against that of the non-targeting control wells to provide fold-
changes in caspase 3/7 activity. Data shown is the average of three repeats. All error bars indicate 
SEM. Asterisks represent statistically significant values from a minimum of three biological repeat 
experiments with three technical repeats (*, P<0.05; **, P<0.01; ***, P<0.001, ****, P<0.0001; 
ANOVA, Bonferroni’s multiple comparisons test). 
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3.8 Discussion 
Lung cancer is a worldwide disease responsible for 1 in 5 cancer deaths. It is highly 
metastatic with the majority of patients presenting with secondary tumours. Improved 
understanding of the mechanisms behind tumour metastasis would allow the 
development of improved diagnostics and treatments. In this thesis we wished to 
perform an RNAi-based high-throughput screen to identify novel genes involved in cell 
invasiveness, a key attribute for cancer cells to metastasise. We took a 3D invasion assay 
previously used within our laboratory (Lara et al. 2011), and performed thorough 
optimisation of every component to develop the assay further and adapt the protocol for 
screening. 
Initial work confirmed that the non-small-cell lung cancer cell lines A549 was 
invasive through a matrix of rat tail collagen (Lara et al. 2011). There may have been merit 
in using a metastatic cell line such as A549 M1M1 for the screen (Catena et al. 2011). 
These cells may have a higher basal level of invasion than the parental A549. Hits that 
would decrease invasion may be revealed more easily using this model.  This was not 
tested as the project instead moved forward to characterise the role in motility of a 
previously identified target (Lara et al. 2011). 
For a siRNA screen it is crucial that a high knockdown efficiency is achieved. We 
assessed this by comparing the level of GAPDH knockdown achieved by a range of leading 
transfection reagents; Invitrogen Oligofectamine, Invitrogen Lipofectamine RNAiMAX, 
Polyplus INTERFERrin and QIAGEN HiPerFect. A consistently high level of knockdown was 
observed by western blot over a 96 hours timeframe with HiPerFect, RNAiMAX and 
Oligofectamine (Figure 3.1). HiPerFect induced neither toxicity nor issues with subsequent 
steps of the invasion assay whereas the two Invitrogen reagents affected adhesion of the 
collagen matrix to the wells. HiPerFect was therefore chosen to be used for the siRNA 
screen. It was concluded that reverse transfection would be the easiest method for use in 
a screening setting allowing for cells to be plated and transfected at the same time 
removing a day from the protocol.  
Previous work with this assay had used EGF as a stimulant for invasion; we 
confirmed this previous observation concluding that 1.0 μg/ml was sufficient to stimulate 
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a threefold increase above basal invasion (Figure 3.2A). We tested additional growth 
factors and identified PDGF and HGF as good stimulators of invasion. With both growth 
factors, a significant increase in invasion above the control was seen above 1.0 μg/ml 
(Figure 3.2B, D). The two other growth factors tested, SDF-1 and MCSF did not stimulate 
invasion above background (Figure 3.2C, E). Ideally, endothelial cells or fibroblasts would 
have been used to stimulate invasion as occurs in vivo however this proved unsuccessful 
(Figure 3.4A & B). It is likely that the concentration of chemo-attractant released by these 
cells was too low to diffuse adequately through the collagen layer and stimulate the 
NSCLC cells below. Use of high stimulating cell number appeared to decrease rather than 
increase invasion. We would propose this is due to cell death amongst the stimulating 
cells causing release of cellular contents that may discourage invasion of the tumour cells. 
It could be argued that other cell lines may have performed better in driving chemo-
attraction, but time constraints prevented testing this hypothesis. As our aim was to 
make our invasion assay as in vivo-like as possible it was decided that a combination of 
growth factors (EGF, HGF and PDGF) should be used. This would also decrease the chance 
of identifying hits regulating invasion downstream of a single growth factor but rather 
highlight targets that have a general effect on cell invasiveness. When tested, it was 
found that using a combination of these three provided a higher level of invasion that 
when they are used alone or as pairs (Figure 3.3). 
Steps were also taken to ensure that the matrix composition through which cells 
would invade was optimal. Rat tail Type 1 Collagen had been used previously within our 
laboratory. Porcine Type 1 Collagen was tested as a potential alternative; however the 
level of invasion obtained was lower than that seen with the Rat tail collagen (Figure 
3.5A). This may be due to the difference of pH between these two products as porcine 
collagen is less acidic than the rat tail collagen. The benefit of Fibronectin and Laminin 
addition to the Rat Tail collagen was negligible to the outcome of the assay in 
contradiction to the published literature (Figure 3.5B) (Brekhman & Neufeld 2009). As 
addition of these components to the matrix would increasing the cost and complexity of 
the set-up without benefit, it was therefore decided that Rat Tail Type 1 collagen alone 
would be used for subsequent screening efforts. Matrigel which contains Laminin, 
collagen IV, along with a cocktail of growth factors such as EGF, insulin-like growth factor, 
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FGF and others is a commonly used extracellular matrix in cell motility assays. Matrigel 
was not tested as part of this work even though it may have been considered a better 
imitation of a physiologically relevant extracellular matrix. However, the presence of a 
range of growth factors within this matrix was not desired as we wished to stimulate 
invasion towards a chemoattractant gradient. Additionally, previous work with this matrix 
in our laboratory did not show that this environment was able to promote invasion of 
A549 cells in comparison to that seen through a rat tail collagen matrix.   
In the setup of a high-throughput screen, the identification of adequate controls is 
essential to quality assurance and subsequent data analysis. As this was a siRNA screen 
we tested a number of siRNAs as potential functional controls. These were genes that 
were known, when silenced, to result in an increased or decreased cell invasion. Silencing 
of RSK1, 4.1B, ROCK1 were expected to increase invasion whereas depletion of RSK4, 
RhoC and LIM Kinase should result in a decrease in invasion. Both siRNAs against RSK1 
and ROCK resulted in the expected increase, and RSK4 depletion in a decrease, in 
invasion. However, despite repeated testing, silencing of LIM Kinase, RhoC and 4.1B did 
not display the expected phenotypes (Figure 3.6A). Indeed, siRNA against LIM Kinase or 
RhoC increased invasion whereas depletion of 4.1B had no effect on cell motility. It was 
decided that RSK1, RSK4 and ROCK would be included as functional controls. LIM Kinase 
was also chosen despite displaying the opposite phenotype to the one commonly 
reported as the observed effects were consistently reproduced. In addition to these four 
controls, siRNAs against SRC and a combination of three siRNAs against the receptors for 
the three stimulating growth factors (EGFR, PDGFR, and HGFR) were included as 
functional controls to decrease invasion upon silencing.  
Pilot screen 1 was carried out to provide initial feedback as to the suitability of 
assay conditions, robotics and the controls for high-throughput screening. All data was 
normalised to the median value of NS#1 and NS#2 on a plate by plate basis. To quantify 
the effect of each target on invasion, the distance of invasion for the three siRNAs for 
each target was averaged (Figure 3.7A). An acceptable level of transfection efficiency was 
confirmed with greater than 75% cell death in KIF11 transfected control wells (data not 
shown). Pilot 1 highlighted a number of problems with the set-up of the assay. Despite 
rigorous testing the functional controls did not behave as desired (Figure 3.7B). There was 
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large variation in performance of controls between plates and when averaged across 
plates there was an increase in invasion with all controls. We were unable to find a clear 
explanation for the poor phenotype observed. One explanation could be the use of 
Dharmacon siRNAs for control optimisation and AMBION siRNA’s during the screen itself. 
Though it would be unlikely that all the AMBION siRNAs failed to silence their targets, it 
could be that off target effects occurred. Ideally all library plates screened would contain 
two functional controls demonstrated to reliably increase/decrease invasion upon 
knockdown. This would confirm the robustness and consistency of the assay throughout a 
large siRNA screen. However as we failed to identify reliable functional controls these 
were replaced by multiple wells of NS#1 and NS#2 in Pilot Screens 2 and 3. Additional 
problems included issues with collagen composition and contamination. These were 
corrected in Pilots 2 and 3 by improving sterility and a change to the robot used to add 
collagen to the plates. 
The repeat pilot screens allowed us to again asses the suitability with the changes 
made after Pilot 1 but also to look at how reproducible our findings were by comparing 
the results of two repeats with identical conditions. Changes made to the robotics and 
timings as described in section 3.7.1 and 3.7.2 were successful in improving the 
robustness of the assay. Transfection efficiency was confirmed not only by the cell death 
seen in KIF11 depleted wells (Figure 3.6B) but also qPCR of RSK1 knockdown (Figure 
3.8A). No problems with contamination or edge effect were observed (Figure 3.8C) and a 
good level on invasion was observed upon application of growth factors (Figure 3.8D). 
The spread of data obtained in the repeat pilot screens was more evenly distributed 
around the control (Figure 3.9) than in pilot 1 where the majority of conditions appeared 
to result in increased (Figure 3.7). As there were no issues highlighted by the numerous 
controls the level of variation observed between Pilots 2 and 3 was unexpected and the 
poor validation rate (3 out of 11 hits) added to our concerns regarding the reproducibility 
of this assay. We have not identified clear issues with the performance of Pilots 2 and 3 
that may explain the poor overlap between these screens. The multiple NS1 and NS2 
wells on each plate allowed for accurate normalization using the median NS value on a 
plate by plate basis. The behaviour of NS did not massively differ between plates or pilots. 
As mentioned all other controls, qPCR and full NS plates did not highlight any additional 
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issues. It was queried whether the poor overlap was due to analytical errors. However, 
this has not been demonstrated to be true. These two screens were analysed using 
Redundant siRNA activity analysis (RSA analysis) (Konig et al. 2007). This is a robust 
analysis method which allows for ranking of siRNA targets based on the individual 
behaviour of the three or four siRNAs against a particular target. Analysis of this screen by 
just averaging the behaviour of the three siRNAs for each target would lead to a higher 
false-positive and false-negative rate as an outlying siRNA could have a dramatic effect on 
the average value. Use of RSA analysis avoided this potential problem.  
Despite the attempts at assay optimisation described in this thesis, when tested in 
a small scale screening set-up, the 3D invasion assay did not provide an acceptable level 
of reproducibility. It was therefore concluded that the invasion assay set-up was not 
suitable for a large-scale screen without further optimisation and testing. Proposed 
changes included investigating whether a 72 h invasion period rather than 48 h is better 
suited, improving the robotisation of steps in the protocol such as the aspiration of media 
and addition of fixative, and use of a more invasive cell line. If these alterations improved 
the reproducibility of the assay to an acceptable level we would then screen a large siRNA 
library with the hope of identifying novel invasion regulators. It was decided, however, 
that within the scope of this PhD it would be more fruitful to further characterise a 
previously identified (Lara et al. 2011) novel cell motility regulator, MARK4 . 
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4.1 Introduction  
Cell motility requires the dramatic changes in both the actin and microtubule 
cytoskeletons. The microtubule cytoskeleton is a highly dynamic filamentous network, 
composed of tubulin heterodimers. Tubulin filaments cycle between phases of 
polymerisation and depolymerisation by stages of catastrophe and rescue, regulated by 
the activity and binding of a number of proteins. Microtubule associated proteins (MAPs) 
stabilise microtubule polymerisation by binding to the filaments. Plus-end binding 
proteins are split into two classes; mitotic centromere-associated kinesins (MCAKs) and 
plus-end-binding proteins (+TIPs), these aide or prevent the incorporation of new tubulin 
dimers. During cell motility these filaments must be rearranged or regrown in order for 
the cell to move forward, this is co-ordinated by MAPs. 
Regulation of the proteins, which control microtubule stability, is crucial to 
maintain a dynamic state. This regulation is carried out by different families of kinases 
and phosphatases.  
One such family is the microtubule affinity regulating kinase family (MARKs). The 
first of the four members of the MARK family was identified in 1995 (Gerard Drewes et al. 
1995) as the key kinase responsible for phosphorylating the microtubule associated 
protein (MAP) TAU. TAU is found bound to microtubules to stabilize polymerisation. 
MARKs phosphorylate TAU triggering its detachment from the microtubule, thus leaving 
the filament in a more dynamic state (Drewes et al. 1998; Mandelkow & Mandelkow 
1995). The majority of work on this kinase family has focused on their role in neurone 
development and maintenance. They have also been shown to be required for cell cycle 
progression due to the importance of microtubule organisation in the separation of 
chromosomes. Due to the importance of MARKs in the regulation of MAPs, and therefore 
of microtubule stability, MARK1-4 have been implicated in the development and 
progression of a number of diseases including Alzheimer’s, autism, and cancer (Drewes et 
al. 1998; Maussion et al. 2008; Kato et al. 2001; Beghini et al. 2003). We identified the 
fourth member of the MARK family, MARK4, as playing a role in cell motility. Upon 
silencing of MARK4 there is a significant decrease in A549 cell motility as observed during 
a 2D migration screen of the kinome (Lara et al. 2011). The objective of this thesis was to 
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validate this finding and further characterise the role of MARK4 in motility and other 
metastatic processes with a view to assessing its potential as a novel therapeutic target.   
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4.2 Depletion of MARK4 in NSCLC cell lines decreases migration 
A siRNA screen of the kinome was previously carried out within our laboratory  to 
identify novel modulators of cell motility by screening using a 2D migration assay (Lara et 
al. 2011). From the hits identified, MARK4 depletion was found to significantly decrease 
cell motility. Here, we validated this observation using the original screening cell line, 
A549, and three additional non small-cell lung cancer (NSCLC) cell lines, H1299, H460 and 
EKVX. This work was done with the kind assistance of Dr Romain Lara. Briefly, 1 x103 cells 
were plated in black 96-well plates and transfected with non-targeting control (NS) or 
MARK4 siRNAs 24 h later. Plates were then incubated for a further 24 h before being 
imaged for 18 h in an environmentally controlled ImageXpress high content screening 
microscope. One image was taken every 10 min and using the videos produced cells were 
manually tracked using a MetaXpress 2.0 tracking plugin.  In A549 cells a significant 
decrease in migration was seen upon downregulation of MARK4, confirming earlier 
results. Figure 4.1A displays the migration maps of a representative experiment clearly 
showing a decrease in motility in MARK4 depleted A549. The phenotype was reproduced 
in the additional NSCLC cell lines H1299, H460 and EKVX with a consistent and significant 
reduction in migration (Figure 4.1B). Knockdown of MARK4 was achieved using a pool of 
four siRNA oligonucleotides targeting different regions of the MARK4 mRNA sequence. 
We also tested the sequences individually (deconvolution) to confirm that the observed 
phenotype was not the result of the activity of a single oligonucleotide. Three of the four 
siRNAs (siRNA2-4) used against MARK4 significantly decreased A549 migration to a similar 
degree as the pool (Figure 4.1C). MARK4 knockdown using the first sequence (siRNA 1) 
decreased migration by only 20%, which was not found to be statistically significant.  
Silencing of MARK4 was confirmed using qPCR. Briefly, cells were transfected with 
non-targeting control (NS) or MARK4 siRNAs 24 h before RNA was extracted from the cells 
using the RNeasy mini kit. MARK4 expression was then quantified through qPCR using 
specific MARK4 primers (Table 2.6), and the analysis software qBase. Expression was 
measured against that of two housekeeping genes, GAPDH and HPRT, and normalised 
against the non-targeting control (Appendix Figure 10.5A). Commercially available 
antibodies for MARK4 were tested however none could be validated as detecting known 
silencing of MARK4 or indeed MARK4 overexpression, Data not shown. 
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Figure 4.1. Silencing of MARK4 decreases cell migration. 
1 x 103 cells were plated in black 96-well plates 24 h before being transfected with either control 
non-targeting (NS) or MARK4 siRNAs. Plates were incubated for 48 h at 37°C, 10% CO2 before 
being imaged in an environmentally controlled ImageXpress high-content screening microscope 
for 18 h, with 1 image acquired every 10 minutes at two sites per well. Cell migration was tracked 
manually using MetaXpress 2.0 software (A) Representation maps of migration tracks of control 
and MARK4 silenced A549 cells. Track maps were produced in Mathematica. (B) The decrease in 
migration upon MARK4 depletion validated in additional non-small cell lung cancer cell lines. 
MARK4 was silenced in three non-small cell lung cancer cell lines; H1299, H460 and EKVX. (C) 
Knockdown of MARK4 using each of the four siRNAs reduced migration. A549 were transfected 
with individual oligonucleotides against MARK4 or a pool of all four sequences. (C) Data shown is 
the average of three repeats. (B) Data shown is the average of quadruplicate technical repeats. 
Error bars indicate SEM. Asterisks represent statistically significant values from a minimum of two 
biological repeat experiments (*, P<0.05; **, P<0.01; ***, P<0.001; ANOVA).  
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4.3 Invasion through a collagen matrix is reduced in MARK4 silenced 
cells 
In vivo cells employ a number of motility methods; 2D migration along collagen 
fibres, amoeboid migration, and 3D invasion through the extracellular matrix (Friedl & 
Gilmour 2009; Friedl & Wolf 2010). We wished to test whether MARK4 silencing only 
decreased 2D migration or whether 3D invasion was also affected. Using the optimised 
3D invasion assay from the phosphatome screen we observed the effect of MARK4 
silencing in A549 and H1299 cells. Cells were plated in black 96-well plates and 
transfected 24 h later with control non-targeting (NS) or MARK4 siRNA. 24 h after 
transfection a collagen layer containing 1% FCS was placed above the cells and invasion 
was stimulated using EGF. Plates were incubated for 48 h before PFA was used to fix cells 
and SYTOX green added to stain nuclei. Plates were then imaged and processed to 
quantify the degree of invasion in each condition. The effect of silencing MARK4 was even 
more marked in a 3D invasion setting than in 2D. In A549, an 80% reduction in cell 
motility was seen (Figure 4.2A) while in H1299 cells, a decrease in invasion was observed 
with a significant reduction of 70% (Figure 4.2B).  
4.4 Changes are observed in cell cytoskeleton 
MARK4 is known to associate with microtubules and be involved with the 
regulation of microtubule associated proteins which control microtubule dynamics. We 
stained the cell cytoskeleton to observe whether silencing of this kinase resulted in any 
change to cytoskeleton structure. Both the microtubule and actin networks were 
visualised by immunofluorescence using a Cy3-labelled Beta tubulin antibody and Alexa 
Fluor 488 Phalloidin, respectively (Figure 4.3A). A difference in cell size and shape was 
observed between the two conditions, with decreased MARK4 expression increasing cell 
size. This change was quantified using the Multi Wavelength cell scoring analysis within 
the MetaXpress 2.0 software. A reduction in cell motility following MARK4 silencing 
correlated with an increase in tubulin stained area in A549 and H1299 (Figure 4.3B).  
To validate this change we again deconvoluted the four siRNAs used against 
MARK4 (Figure 4.3C). Although the increase in tubulin area was not as great when the 
individual siRNAs were used compared to that seen with the pooled siRNAs, an increase 
was still observed with three of the four oligonucleotides (siRNAs 2-4). 
4. Phenotypic changes in NSCLC cell lines when MARK4 expression is altered 
138 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2. Cell invasion is decreased in MARK4 depleted cells.  
7 x 103 cells were plated in black 96-well plates 24 h before being transfected with either control 
non-targeting (NS) or MARK4 siRNAs. Plates were incubated for 24 h at 37°C, 10% CO2 before 
collagen was placed above the cells and invasion stimulated using EGF (1 μg/ml). After a further 
incubation for 48 h, plates were fixed with PFA and cells stained using SYTOX green. Plates were 
then imaged using Zeiss Inverted Widefield microscope with spinning disk system. Images were 
analysed to determine the degree of invasion (A) siRNA-mediated depletion of MARK4 in A549 
cells reduces invasion in response to EGF. Data shown is an average of three repeats. (B) 
Representative graph showing a decrease in invasion upon depletion of MARK4 in H1299 cells. 
Data shown is an average of quadruplicate technical repeats. Error bars indicate SEM. Asterisks 
represent statistically significant values from a minimum of three biological repeat experiments 
with three technical repeats (*, P<0.05; **, P<0.01; ***, P<0.001, ****, P<0.00001; Students t-
test, two sample equal variance, two tailed distribution). 
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Figure 4.3. Change in cell morphology upon depletion of MARK4.  
1 x103 cells were plated in 96-well plates and transfected 24 h later. 48 h after siRNA transfection 
plates were washed with PBS, and cells fixed using PFA. The cells were permeabilised using 0.1% 
Triton X-100 in PBS. Plates were then blocked with 3% BSA (w/v) in TBS-T. Cells were stained 
overnight using either Alexa Fluor 488-conjugated Phalloidin or Cy3-conjugated Beta Tubulin to 
stain actin or microtubules respectively. Images were collected using an ImageXpress High 
content Screening Microscope and the MetaXpress software (Molecular Devices). Area covered by 
tubulin was quantified using the Multi Wavelength Cell Scoring analysis module within the 
MetaXpress software. (A) Representative images of tubulin and actin staining in control and 
MARK4 depleted A549 cells. (B) Change in tubulin area upon MARK4 depletion, in A549 and 
H1299 cells. (C) Change in tubulin staining intensity upon MARK4 depletion, both with pooled 
and individual siRNA oligonucleotides. Cells were transfected with individual oligonucleotides 
against MARK4 or a pool of all four sequences. All data shown is the average of three repeats. 
Error bars indicate SEM. Asterisks represent statistically significant values from a minimum of 
three biological repeat experiments with three technical repeats (*, P<0.05; **, P<0.01; ***, 
P<0.001, ****, P<0.0001; (B) Students t-test, two sample equal variance, two tailed distribution. 
(C) ANOVA, Bonferroni’s multiple comparison test).  
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4.5 The tubulin polymerisation is altered with a decrease in MARK4 
expression 
An increase in tubulin area suggests that the control of the microtubule network 
has been altered and that polymerisation of the microtubule filaments is changed. MARK 
family members are known to phosphorylate microtubule associated proteins, MAPs. 
When phosphorylated, these MAPs detach from the filaments, leaving them more 
unstable and therefore prone to catastrophe resulting in depolymerisation. We used two 
different methods to investigate whether the rate of microtubule polymerisation was 
increased or decreased in the absence of MARK4.  
A plasmid construct for the +TIP protein End Binding protein 3 (EB3) coupled to 
Green Fluorescent Protein (GFP) (EB3-GFP) was used to visualise microtubule 
polymerisation. This protein binds to the growing ends of microtubules and, when 
imaged, GFP comets can be seen as the microtubules grow, moving EB3 forward with 
them. By tracking the particles visible from the GFP signal, the speed of microtubule 
polymerisation can be calculated. This construct was transfected into A549 24 h before 
they were re-plated into 8-well chamber slides and reverse-transfected with non-
targeting (NS) or MARK4 siRNA. After a further 24 h individual cells were imaged at 40x 
magnification using a Zeiss LSM-780 inverted confocal microscope, 1 image per second 
for 2 min. The resulting images were processed using ImageJ and the EB3-GFP comets 
tracked using the plugin wrMTrck (Pedersen 2011). Comet speed was calculated using the 
distance travelled across frames, Appendix Figure 10.6 shows examples of the comets 
travel within a cell. In Figure 4.4A representative images of the comets in the two 
conditions can be seen. When quantified, comet speed was significantly elevated in cells 
treated with MARK4 siRNA (Figure 4.4B) indicating an increase in the rate of tubulin 
polymerisation.  
 Further studies to investigate microtubule polymerisation produced contrasting 
results. The drug nocodazole is commonly used for microtubule polymerisation studies. 
When cells are treated with nocodazole, microtubule depolymerisation is triggered and 
the filament network is broken down. A549 were plated on coverslips and transfected 
with control or MARK4 siRNA. 24 h after transfection the cells were treated for 16 h with 
nocodazole. We then observed the speed at which the network was rebuilt in cells 
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treated with siRNA MARK4 upon removal of the drug. This was done by fixing cells with 
PFA at 0, 2, 5, 10, 20 and 30 min after removal of the drug, then staining the microtubule 
network using a Cy3 conjugated antibody against Beta-Tubulin. Figure 4.5A shows that 
there are no filaments present at 0 minutes in both conditions. It should be noted that 
the actin cytoskeleton is not broken down and therefore the cell shape is maintained. By 
30 minutes (Figure 4.5A right hand panel), it can be seen in both conditions that the 
microtubule network is re-established. The area covered by tubulin was quantified at 0, 
10 and 30 min. The additional time points were not analysed as little tubulin regrowth 
could be seen until 10 minutes after nocodazole wash out. Fold change in tubulin area 
was calculated using the area at 0 minutes as the control. The fold change in area covered 
was lower over 30 min in MARK4 silenced cells than the control (NS) (Figure 4.5B). 
Suggesting that tubulin polymerisation is occurring at a decreased rate in the transfected 
cells.  
 
 
 
 
 
 
 
 
 
Figure 4.4. Change in tubulin polymerization and stability.  
(A) Representative image of microtubule growth. (B) Quantification of the speed of microtubule 
growth. A construct expressing EB3-GFP was transfected into cells plated 24 h previously in 10 cm 
dishes using the plasmid transfection reagent Attractene. Plates were then incubated for 24 h 
before being re-plated into 8-well chamber slides and reverse transfected with control (NS) or 
MARK4 siRNA. 24 h later cells were imaged using a Zeiss LSM-780 inverted confocal microscope 
using the Zen Black software (Zeiss). Comet speed was analysed using FIJI ImageJ (NIH, USA) and 
the plugin wrMTrck. Data shown is the average of three repeats. Error bars indicate SEM. 
Asterisks represent statistically significant values from a minimum of three biological repeat 
experiments with three technical repeats (*, P<0.05; **, P<0.01; Students T Test) 
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Figure 4.5. The tubulin network regrows slower in MARK4 depleted cells after nocodazole 
treatment.  
(A) Representative images of A549 cells before and 30 min after Nocodazole washout. (B) 
Quantification of tubulin regrowth. A549 cells were plated onto Poly-L-Lysine coated coverslips 
and transfected 24 h later with control (NS) or MARK4 siRNA. 24 h later cells were treated with 10 
μM Nocodazole for 16 h. Nocodazole was then washed out by rinsing cells with PBS and addition 
of normal media for 0, 2, 5, 10, 20 and 30 min. Cells were fixed at each time point with PFA and 
permeabilised using 0.1% Triton X-100 for 5 min. Unspecific interactions were blocked with 3% 
BSA in TBS-T and the tubulin network stained by incubation with Cy3-conjugated Beta-Tubulin 
antibody overnight. Coverslips were mounted onto slides and imaged using an EVOS FL Cell 
Imaging System upright microscope. Tubulin re-growth was quantified using FIJI ImageJ (NIH) by 
thresholding the area covered by tubulin. Data shown is the average of three repeats. Error bars 
indicate SEM. Asterisks represent statistically significant values from a minimum of three 
biological repeat experiments with three technical repeats (*, P<0.05; **, P<0.01; ***, P<0.001, 
****, P<0.0001; ANOVA, Bonferroni’s multiple comparisons test). 
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4.6 Overexpression of MARK4 also alters cell motility but does not 
affect cell cytoskeleton  
Observations had shown the effects of decreasing MARK4 expression in NSCLC cell 
lines on cell motility which we propose is due to changes to tubulin polymerisation. When 
studying the effects of down-regulating a protein it can be informative to observe the 
changes when this protein is overexpressed. We hypothesised that, when overexpressing 
MARK4, we may see the opposite effects on cell motility to that seen upon its depletion. 
We obtained plasmids with a pCDNA3 backbone containing MARK4 with either a N-
terminal HA or GFP tag from Dr Bernhard Trinczek (Trinczek et al. 2004a). The majority of 
work with MARK4 overexpression was done in H1299 as they are easy to transfect with 
plasmid and maintain expression for a week without the need for antibiotic selection.  
Initially we confirmed that MARK4 was overexpressed in H1299 96 h after 
transfection. Protein lysates were collected from cells transfected with pCDNA3 (empty 
vector, EV) or pCDNA3 GFP-MARK4 (WT M4) 96 h after transfection and separated by 
SDS-PAGE before proteins were transferred onto a PVDF membrane.  The time point of 96 
h was chosen as this was the time period over which we required expression to be 
maintained to carry out phenotypic studies. By probing for the GFP tag we confirmed 
expression of MARK4 at the expected size of ~80 kDa (Figure 4.6A). Overexpression of 
MARK4 was also verified using RT-qPCR for each experiment with transiently transfected 
cells (Appendix Figure 10.5B). Briefly RNA was extracted from cells 48 h after transfection 
with plasmid using the RNeasy mini kit (QIAGEN). RNA was converted to cDNA using the 
High Capacity cDNA Reverse Transcription Kit (Applied Biosystems) and expression of 
MARK4 quantified using the Fast SYBR® Green PCR Master Mix (Applied Biosystems) and 
the Applied Biosystems 7900HT Real-time PCR System. Expression was calculated using 
the qBase software in reference to two housekeeping genes GAPDH and HPRT. 
Overexpression was consistently shown throughout the experiments. 
We first wished to determine whether cell motility was affected by overexpression 
of MARK4, as it was impaired by MARK4 silencing. pCDNA3 MARK4-GFP was transfected 
into H1299 24 h before they were re-plated into black 96-well plates. A 2D migration 
assay was then performed 24 h later, as described before. We observed a significant 1.4 
fold increase in cell migration upon MARK4 overexpression (Figure 4.6B). As before, cell 
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invasion through a 3D collagen matrix was also investigated. Again cells were transfected 
with plasmid 24 h before being re-plated into 96-well plates. Collagen was then laid above 
the cells 24 h after re-plating and invasion stimulated using EGF (1 μg/ml). Cells were 
allowed to invade for 48 h before plates were fixed and the degree of invasion 
determined. Similar to the results obtained by the 2D migration assay, we observed an 
increase of 1.55 fold upon MARK4 overexpression (Figure 4.6C). This data confirms that 
MARK4 plays a crucial role in cell motility as modulating MARK4 levels alters cell motility 
in the corresponding direction. Motility assays were also performed using the HA tagged 
MARK4 construct to confirm the change in motility was due to overexpression of MARK4 
rather than the GFP tag (data not shown).  
We believe that the decrease in NSCLC cell motility upon MARK4 depletion was a 
result of changes in tubulin structure and dynamics (Figures 4.3, 4.4 and 4.5). However, 
immunofluorescence staining of the microtubule network in H1299 overexpressing 
MARK4 using a Cy3-conjugated Beta-Tubulin antibody did not show any changes in 
tubulin area (Figure 4.7A). Additionally, we studied tubulin polymerisation rates using the 
EB3-GFP construct. HA-MARK4 was transfected into A549 at the same time as the EB3-
GFP construct and cells were re-plated 24 h later. After a further 24 h, microtubule 
growth was imaged as described earlier. A549 cells rather than H1299 were used for this 
study as no comets could be detected within the H1299 cells. We propose this is due to 
excessive overexpression in the H1299 cell line leading to an extremely high GFP signal. 
No difference in tubulin polymerisation speed was detected upon overexpression of 
pcDNA3 HA-MARK4 (Figure 4.7B). 
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Figure 4.6. Effect of  overexpressing MARK4 on cell motility. 
(A) Confirmation of overexpression of MARK4. H1299 cells were transfected with pCDNA3 (EV) 
or pCDNA3 WT GFP-MARK4 (WT M4) in 6-well plates. 48 h after transfection cells were harvested 
using Laemmli lysis buffer and separated using a 10% SDS-PAGE gel. An anti-GFP antibody was 
used to visualise overexpression of the construct. Lamin was used as a loading control. (B) 
Overexpression of MARK4 increases cell migration. H1299 cells were transfected with pCDNA3 
(Empty Vector) or pCDNA3 WT GFP-MARK4 plasmid in 15 cm dishes. 24 h later cells were re-
plated into 96-well plates. Cells were imaged, 24 h after re-plating,  for 18 h with an image taken 
every 10 min using an environmentally controlled ImageXpress high-content screening 
microscope. Cells were manually tracked using MetaXpress 2.0 software. (C) Cell invasion is 
increased by overexpression of MARK4. H1299 cells were transfected as described above and re-
plated into black 96-well plates 24 h later.  The collagen matrix was added 48 h later and EGF 
added to stimulate invasion. Cells were allowed to invade for 48 h before plates were fixed and 
imaged. The degree of invasion was calculated using ImageJ and the 3D Object plugin. All data 
shown is the average of three repeats. Error bars indicate SEM. Asterisks represent statistically 
significant values from a minimum of three biological repeat experiments with three technical 
repeats (*, P<0.05; **, P<0.01; ***, P<0.001, ****, P<0.0001; Students T Test).  
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Figure 4.7. Overexpressing MARK4 does not affect cytoskeleton structure. 
(A) Tubulin area is unaffected by MARK4 overexpression. H1299 cells were transfected as 
described above and re-plated into black 96-well plates. 48 h after transfection plates were 
processed for beta-tubulin staining as described in Methods. (B) Microtubule growth is not 
altered by overexpression of MARK4. EB3-GFP construct and either pCDNA3 (Empty vector) or 
pCDNA3 HA-MARK4 (MARK4) were transfected into A549 cells plated 24 h previously in 10 cm 
dishes using the plasmid transfection reagent Attractene. Plates were then incubated for 24 h 
before being re-plated into 8-well chamber slides and reverse transfected with control (NS) or 
MARK4 siRNA. 24 h later cells were imaged using a Zeiss LSM-780 inverted confocal microscope 
using the Zen Black software (Zeiss). Comet speed was analysed using FIJI ImageJ (NIH, USA) and 
the plugin wrMTrck. All data shown is the average of three (A) or two (B) repeats. Error bars 
indicate SEM.  
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4.7 Discussion 
MARK4 was one of 70 hits identified within our laboratory as a potential 
modulator of cell motility during a 2D migration RNA interference screen targeting the 
kinome using the NSCLC cell line A549 (Lara et al. 2011). To confirm that downregulation 
of MARK4 results in decreased cell motility we used four NSCLC cell lines (A549, H1299, 
H460 and EKVX) and performed 2D migration assays. We found that in all four cell lines 
depletion of MARK4 resulted in reduced cell motility (Figure 4.1). We then utilised the 3D 
invasion assay that had been optimised as part of this thesis, and established that MARK4 
silencing also reduced cell invasiveness though a collagen matrix (Figure 4.2).  
Immunofluorescence analysis of the microtubule and actin cytoskeletons showed 
an increase in cell size after silencing of MARK4 expression. We quantified the increase in 
tubulin area and found it to occur in both A549 and H1299 upon depletion of MARK4 
(Figure 4.3). Both the changes in motility and cell size were confirmed as on target RNAi 
effects by deconvoluting the pool of four RNAi sequences used (Figure 4.1, 4.3). MARK4 is 
known to phosphorylate a number of microtubule associated proteins (MAPs) to regulate 
microtubule dynamics. Phosphorylation of the MAPs Tau, MAP2 and MAP4, by MARK4 
results in their detachment from the microtubule filaments. As bound MAPs function to 
provide stability to the microtubule, their removal increases the dynamic nature of the 
filament (Naz et al. 2013; S Illenberger et al. 1996; Trinczek et al. 2004a; Drewes et al. 
1998; Ebneth et al. 1999). Using the plasmid construct EB3-GFP we were able to image 
microtubule polymerisation. EB3 is a +TIP protein that autonomously tracks growing ends 
of the microtubule. Hence, confocal imaging of the movements of this protein can be 
used to visualise microtubule growth. Using this technique, we detected a significant 
increase in the speed of EB3-GFP comets after treatment of A549 cells with MARK4 siRNA 
(Figure 4.4). This suggests an elevated rate of microtubule polymerisation. In the absence 
of MARK4, according to the literature, MAPs would not be removed from the microtubule 
filaments, increasing their stability. This would reduce the occurrence of catastrophe 
(depolymerisation). Resulting in the formation of longer fibres which would explain the 
increased area covered by the tubulin network within MARK4 depleted cells. However 
there is little evidence to explain why this may encourage the incorporation of new 
tubulin dimers at an increased rate.  
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In addition to using the EB3-GFP construct to observe microtubule polymerisation 
we also treated control or MARK4 silenced A549 with the drug Nocodazole which induces 
the complete loss of the microtubule network. We then observed the speed of re-growth 
of the tubulin fibres after removal of the drug. There was a reduction in microtubule 
regrowth, though the change was not statistically significant (Figure 4.5). Although this 
would appear to contradict the findings using the EB3-GFP construct we propose that the 
experimental conditions are too dissimilar to be directly compared. Indeed, regrowth of 
the network after nocodazole treatment requires nucleation of all fibres from the MTOC. 
This process has different requirements than those underlying the growth of an 
established microtubule network. Without MARK4 it maybe that the speed of nucleation 
is reduced slowing the formation of new filaments, though further investigation would be 
required to assess this. 
Increasing protein levels of MARK4 resulted in a significant increase in cell motility 
both within the 2D migration assay (Figure 4.6 B) and within a 3D collagen matrix (Figure 
4.6 C). This data confirms that MARK4 protein levels have a significant effect on cell 
motility. However, no changes in cell area were detected (Figure 4.7 A) and tubulin 
polymerisation rates, assessed using the EB3-GFP construct, were not affected by 
increased MARK4 levels. We would propose that in the presence of excess MARK4 
microtubule dynamics are increased as MAPs are readily removed from the filaments by 
MARK4. This allows for rapid reorganisation of the filaments promoting motility. However 
polymerisation rates of the filaments themselves are unaffected in overexpressing cells. 
In overexpressing cells MARK4 activity is likely to be controlled via feedback mechanisms. 
These feedback mechanisms will prevent total loss of MAPs from the filaments which 
would trigger depolymerisation of the network. We have carried out further 
investigations to identify these potential feedback routes.  
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5.1 Introduction  
A number of signalling pathways and processes have been shown to be required 
for a cell to be mobile. One such process Epithelial-mesenchymal transition (EMT) is 
observed in motile cells. Cells lose expression of key adhesion molecules such as E-
Cadherin and increase expression of a number of mesenchymal markers when stimulated 
to invade (See Introduction Section 1.2.1) (Fang et al. 2011; Valastyan & Weinberg 2011). 
Having identified the alteration of MARK4 expression levels as significantly altering the 
motility of two non-small cell lung cancer cell lines we wished to elucidate the 
mechanisms behind MARK4’s role in cell motility beginning with assessing the expression 
of known EMT markers.  
Known to phosphorylate a number of microtubule associated proteins (Gerard 
Drewes et al. 1995), MARK4 has also been linked to a number of other kinases and 
phosphatases (Naz et al. 2013; Drewes 2012; Al-Hakim et al. 2008; Brajenovic et al. 2004; 
Trinczek et al. 2004b). We investigated the effect of depletion of a number of suspected 
MARK4 interacting proteins on cell motility in the presence of MARK4 silencing or 
overexpression.  This data allowed us to determine whether certain interacting proteins 
may be positioned upstream or downstream of MARK4. A recent siRNA screen of 
microtubule binding proteins by Nishimura et al. identified a relationship between 
MARK2 and Rac1 GTPase (Nishimura et al. 2012). Although studies of Rac1 activity in 
response to changes in MARK4 expression were unsuccessful we did observe differences 
in Rho GTPase activity. 
These studies enabled us to start uncovering possible mechanisms through which 
MARK4 regulates cell motility, and the feedback mechanisms which control the activity of 
this kinase. 
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5.1 Changes in the expression of key EMT markers in response to 
MARK4 silencing or overexpression do not indicate EMT 
Epithelial-Mesenchymal transition is a key process during development as part of 
tissue differentiation and cell rearrangement. It has also been observed to occur within 
some cancer types, increasing the motility of cancer cells and therefore the dispersion of 
tumour cells throughout the body. EMT is characterised by the loss of cell-cell and cell-
matrix adhesion due to decreases in the expression of key adhesion molecules such as E-
Cadherin and a change in β-catenin expression and localisation. A corresponding increase 
is then seen in a number of mesenchymal markers such as N-cadherin and Vimentin. 
These changes are seen in response to external stimulation from a number of growth 
factors such as FGF and EGF that increase the transcription and activity of the EMT 
transcription factors Snail, Slug, ZEB1 and TCF-1.  
To establish whether the changes in cell motility we had observed in response to 
altered MARK4 expression were due to EMT, we quantified the mRNA expression of six 
key markers; β-Catenin, E-Cadherin, N-Cadherin, Vimentin, TCF-1 and Snail. Briefly, H1299 
cells were transfected with non-targeting (NS) and MARK4 siRNA 48 h before RNA was 
harvested from the cells using the RNeasy mini kit from QIAGEN. Expression of the chosen 
markers was then quantified by qPCR (See Methods Table 2.6). The expression of our 
genes of interest was normalised against that of two housekeeping genes, GAPDH and 
HPRT, using the software qBase and fold changes calculated against the NS control. As it 
leads to decreased motility; we predicted that no change in EMT markers would occur in 
response to MARK4 depletion. The data presented in Figure 5.1 confirmed this with no 
significant changes observed in β-Catenin, E-Cadherin, N-Cadherin, Vimentin or Snail 
expression (A, B, C, D & F) in response to silencing of this kinase. However, a significant 
increase in mRNA expression of the transcription factor TCF-1 was observed in H1299 
cells transfected with siRNA MARK4 (Figure 5.1E). 
Expression of EMT markers was also investigated in H1299 cells overexpressing 
MARK4. Due to the observed increase in motility, it was hypothesised that an increase in 
mesenchymal markers would be seen. Briefly, H1299 cells were transfected with pCDNA3 
(EV) or pCDNA3 HA-MARK4 (MARK4) 48 h before RNA was extracted as previously 
described. Expression of the six EMT markers was then quantified using qPCR. E-Cadherin   
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Figure 5.1. The expression of epithelial mesenchymal transition markers is not significantly 
altered by depletion of MARK4.  
The expression of key EMT markers was quantified in H1299 cells after transfection with non-
targeting (NS) or MARK4 siRNAs. Specific primers against β-Catenin (A), E-Cadherin (B), N-
Cadherin (C), Snail (D), TCF-1 (E) and Vimentin (F) were used. Expression was normalised against 
the expression of two housekeeping genes, GAPDH and HPRT, using the software qBase. All data 
shown is the average of three repeats. Error bars indicate SEM. Asterisks represent statistically 
significant values from a minimum of two biological repeat experiments (*, P<0.05; **, P<0.01; 
***, P<0.005; Students t-test). 
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Figure 5.2. Significant changes in the expression of key EMT markers are seen with increased 
MARK4 expression.  
The expression of key EMT markers was quantified in H1299 cells after transfection with control 
(pCDNA3, EV) or pcDNA3 HA-MARK4 (MARK4) plasmids. Specific primers against β-Catenin (A), E-
Cadherin (B), N-Cadherin (C), Snail (D), TCF-1 (E) and Vimentin (F) were used. Expression was 
normalised against the expression of two housekeeping genes, GAPDH and HPRT, using the 
software qBase. All data shown is the average of three repeats. Error bars indicate SEM. Asterisks 
represent statistically significant values from three biological repeat experiments (*, P<0.05; **, 
P<0.01; ***, P<0.005; Students t-test). 
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was decreased upon overexpression of MARK4 (Figure 5.2B), suggesting loss of adhesion, 
typical of EMT. However, a significant decrease was also detected in the mesenchymal 
markers N-cadherin (Figure 5.2C) and, although this was not significant, in Vimentin 
expression. The mRNA levels of two EMT transcription factors, Snail & TCF-1 were also 
decreased (Figure 5.2D & E). The decrease in these mesenchymal markers does not 
support a change to a more mesenchymal phenotype upon MARK4 overexpression.   
5.2 Invasion screen to identify key counterparts of MARK4 in its role 
in cell motility 
We wished to establish the mechanism by which MARK4 was affecting cell 
motility. MARK4 had previously been associated with a number of interacting partners, 
these included microtubule associated proteins Tau, MAP2 and MAP4. Additionally a 
Tandem Affinity Purification (TAP-Tag) for MARK4 had suggested a number of other 
binding proteins (Brajenovic et al. 2004). To confirm whether these interacting proteins 
were involved in MARK4’s role in cell motility we carried out a small siRNA screen. This 
screen allowed us to study the effect on cell motility of silencing a selected list of 
interacting proteins in H1299 cells in the presence of MARK4 overexpression or depletion.  
Through this we hoped to establish whether removing these proteins exaggerated or 
reversed the effects of modulating MARK4 levels and therefore their involvement in our 
core observations. The chosen targets are detailed in Table 5.1, also detailed is a brief 
explanation for the inclusion of each target and reference to the relevant publication.  
Initially we confirmed that proliferation was not affected by silencing of the 13 
chosen targets. H1299 cells were transfected with non-targeting (NS), MARK4, or target 
(1-13) siRNA in 96-well plates. 48 h after transfection plates were fixed with PFA and cells 
were stained with Crystal Violet. Changes in proliferation were quantified by dissolving 
the crystal violet staining in acetic acid and reading the absorbance at 595 nm. Significant 
decreases in cell density were only observed with targets 12 and 13; MAP4 and Tau. All 
other targets did not significantly alter proliferation/survival (Figure 5.3A).  
We wished to observe the effects of silencing these binding partners on the 
increase in cell motility that occurs upon overexpression of MARK4. H1299 cells were 
transfected in 15 cm dishes with either pCDNA3 (Empty vector) as a control or pCDNA3 
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HA-MARK4. Cells were then re-plated into black 96-well plates 24 h later and reverse 
transfected with control non-targeting (NS) siRNA, siRNA MARK4 or siRNA against one of  
the 13  
Table 5.1. Targets included in the MARK4 Interactor screen. 13 proteins which are suggested to 
interact with MARK4 were chosen to be included in a small siRNA invasion screen. The table 
details target number, target name, and reference suggesting a link to MARK4. 
 
 No.  Interactor  Information 
1 PPP2R1A 
Shown to dephosphorylate MAPs and to interact with MARK4 
(Brajenovic et al. 2004; Liu et al. 2002) 
2 14-3-3η (YWHAH) TAP-Tag proposed interaction (Brajenovic et al. 2004) 
3 CAB39 
Shown to be essential for the activation of MARK4 (Lizcano et al. 2004; 
Brajenovic et al. 2004) 
4 ARHGEF2 
Microtubule associated exchange factor for Rac and Rho GTPases 
(Brajenovic et al. 2004; Yamahashi et al. 2011) 
5 PPP2CB 
Shown to dephosphorylate MAPs and to interact with MARK4 
(Brajenovic et al. 2004; Liu et al. 2002) 
6 PKCλ (PRKCI) 
TAP-Tag suggested interaction with MARK4, Known involvement in cell 
polarity (Brajenovic et al. 2004) 
7 PARD6A 
TAP-Tag proposed interaction, Adapter protein that actively participates 
in cell polarization and cell division (Brajenovic et al. 2004) 
8 USP21 
Regulates centrosome and microtubule-associated functions via binding 
through MARK4 (Naz et al. 2013) 
9 STRADA 
Identified during TAP-MARK4, Shown to be essential for the activation 
of MARK4 (substrate of LKB1) MARK4 (Lizcano et al. 2004; Brajenovic et 
al. 2004) 
10 STK11 
Also known as LKB1, Activates MARK4 (Brajenovic et al. 2004; Naz et al. 
2013; Lizcano et al. 2004) 
11 MAP2 
Phosphorylated by MARK resulting in its detachment from MT (Trinczek 
et al. 2004b; Ebneth et al. 1999) 
12 MAP4 
Phosphorylated by MARK resulting in its detachment from MT (Trinczek 
et al. 2004b; Ebneth et al. 1999) 
13 TAU 
Phosphorylated by MARK resulting in its detachment from MT (Trinczek 
et al. 2004b; Gerard Drewes et al. 1997) 
- MARK4 Positive control 
- NS Non-targeting siRNA control  
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chosen targets. 48 h later collagen (3 mg/ml) was laid above the cells and EGF (1 μg/ml) 
added to stimulate invasion. Cells were allowed to invade for 48 h before the plates were 
fixed with 4% PFA and stained using SYTOX green. The plates were imaged using a Zeiss 
Inverted Widefield microscope with spinning disk system. Images were analysed using 
ImageJ to determine the degree of invasion.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3. Screen of potential interactors of MARK4.  
(A) Effect on survival of knockdown of chosen targets. H1299 cells were transfected with control 
(NS) or the target siRNAs (See Table 5.1) in 96-well plates. After 48 h plates were fixed with 4% 
PFA and stained with crystal violet. Crystal violet precipitates were dissolved in 10% Acetic Acid 
and the absorbance read at 595 nm to quantify changes in survival. Data were normalised to the 
control (NS). (B) Confirmation that invasion is increased upon MARK4 overexpression. H1299 
cells were transfected in 15 cm dishes with control plasmid (pCDNA3, Empty Vector) or pCDNA3 
HA-MARK4 (MARK4). Cells were then re-plated into black 96-well plates 24 h later. Collagen was 
laid upon the cells after a further 24 h and invasion stimulated by adding EGF (1 μg/ml). Cells were 
allowed to invade for 48 h before the plates were fixed with 4% PFA and cells stained using SYTOX 
green. Plates were then imaged using a Zeiss Inverted Widefield microscope with spinning disk 
system. Images were analysed to determine the degree of invasion using ImageJ. Data shown is 
an average of three repeats Error bars indicate SEM. Asterisks represent statistically significant 
values from a minimum of three biological repeat experiments (*, P<0.05; **, P<0.01; ***, 
P<0.001, ****, P<0.0001; (A) One-way ANOVA, Bonferroni’s multiple comparisons test, (B) 
Students t-test (unpaired, two tailed)). 
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Before analysing the effects of silencing the 13 targets, we confirmed our original 
observation that overexpression of MARK4 increases invasion of H1299 cells through a 
collagen matrix (Figure 5.3B). 
We analysed the targets which, when silenced, caused a difference in cell motility 
between the control Empty Vector transfected cells and those overexpressing MARK4. 
Silencing of target 13, Tau, significantly increased invasion (5.0 fold over the NS control) in 
the absence of MARK4 over-expression (Figure 5.5A). However when TAU was depleted in 
the presence of MARK4 overexpression, the increase in invasion seen is lower than in 
control cells and in fact appears to rescue or reduce the effect of MARK4 over-expression 
on motility (Figure 5.5B, Target 13). This could suggest that the effect on motility of 
silencing Tau is reversed by overexpression of MARK4 but also that the absence of Tau 
reduces the effect of increasing MARK4 expression.  
Depletion of 14-3-3η (YWHAH, target 2) reduced invasion in the control cells, this 
also occurred in MARK4 overexpressing cells, rescuing the effect of increasing MARK4 
expression (Figure 5.4). The same effect was also seen upon deletion of PARD6A and 
MAP2 (Targets 7 and 11), as silencing of either target reversed the effect of 
overexpressing MARK4. The results seen for these three targets indicate that they could 
be placed downstream of MARK4 in its role in cell motility. Moderate rescue of the 
MARK4 overexpression phenotype was seen upon depletion of PPP2R1A (Target 1), 
ARGHEF2 (Target 4), STRADA (Target 9) and STK11 (Target 10), again implicating these 
proteins as downstream effectors of MARK4. Depletion of Targets 5, 6 and 8 did not 
attenuate or enhance the effect of overexpressing MARK4 on cell invasion (Figure 5.4B).  
Silencing of CAB39 and MAP4 (Targets 3 and 12) in cells overexpressing MARK4 
gave a further increase in invasion (Figure 5.5B). siRNA CAB39 significantly increased 
invasion in the control cells also (Figure 5.4A), although this was heightened upon MARK4 
overexpression. An increase in invasion was also seen after siRNA MAP4 in control cells, 
although this change was not significant due to high variation between repeats (Figure 
5.4A). Potentiation of the effects of MARK4 overexpression suggests the involvement of 
both targets in regulating MARK4, perhaps directly controlling its activity or affecting the 
expression and activity of MARK4’s downstream effector proteins.  
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Figure 5.4. Screen of potential interactor's of MARK4.  
H1299 cells were transfected in 15 cm dishes with control (pCDNA3, Empty Vector) (A) or pCDNA3 
HA-MARK4 (MARK4) (B) plasmids. Cells were then re-plated into black 96-well plates 24 h later 
and reverse transfected with control (NS) or targeting siRNAs (See Table 5.1). Collagen was laid 
upon the cells 24 h after siRNA transfection and invasion stimulated by adding EGF (1 μg/ml) 
above the collagen layer. Cells were allowed to invade for 48 h before plates were fixed with 4% 
PFA and cells stained using SYTOX green. Plates were then imaged using Zeiss Inverted Widefield 
microscope with spinning disk system. Images were analysed to determine the degree of invasion 
using ImageJ. Data were normalised to the Empty Vector siNS control and are shown in two 
separate graphs for ease of display. Data shown is the average of three repeats.  Error bars 
indicate SEM. Asterisks represent statistically significant values from a minimum of three 
biological repeat experiments (*, P<0.05; **, P<0.01; ***, P<0.001, ****, P<0.0001; One-way 
ANOVA, Bonferroni’s multiple comparisons test). 
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We also tested the effect of silencing these targets in a double knockdown with 
MARK4. This allowed us to identify whether silencing of a downstream target of MARK4 
could reverse the effect of depleting MARK4. Published literature would suggest that 
MARK4’s absence could increase the number of MAPs bound to microtubule filaments. By 
silencing the expression of these MAPs the effect of MARK4 depletion would be negated. 
Silencing of other MARK4 interacting partners may give the same result or enhance the 
effect of depleting MARK4. H1299 cells were plated and reverse transfected with control 
non-targeting (NS) siRNAs (60 nM) or MARK4 siRNAs plus target siRNAs (Final siRNA 
concentration 60 nM). 48 h after transfection collagen was laid above the cells and 
invasion stimulated with EGF (1 μg/ml). Cells were allowed to invade for 48 h before the 
plates were fixed with 4% PFA and stained using SYTOX green. Plates were imaged as 
before and invasion quantified using ImageJ.  
 
 
 
 
 
 
 
 
Figure 5.5. Knockdown of MARK4 interacting proteins does not rescue the effect of depletion of 
MARK4 on cell invasion. 
H1299 cells were transfected with double siRNA mixtures containing control (NS,/NS 60 nM) or 
target siRNAs  plus MARK4 siRNA (60 nM final concentration) (See Table 5.1 for targets). Collagen 
was laid upon the cells 24 h after siRNA transfection and invasion stimulated by adding EGF (1 
μg/ml) above the collagen layer. Cells were allowed to invade for 48 h before plates were fixed 
with 4% PFA and cells stained using SYTOX green. Plates were then imaged using Zeiss Inverted 
Widefield microscope with spinning disk system. Images were analysed to determine the degree 
of invasion using ImageJ. Data were normalised to the double siNS control. All data shown is the 
average of three repeats. Error bars indicate SEM. Asterisks represent statistically significant 
values from a minimum of three biological repeat experiments (*, P<0.05; **, P<0.01; One-way 
ANOVA, Bonferroni’s multiple comparisons test). 
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The silencing of all targets in the presence of MARK4 depletion led to a decrease in 
H1299 cell invasion (Figure 5.5). Although some variation in the reduction of motility was 
seen between targets, none rescued the decrease in motility that occurred upon silencing 
MARK4. Previous findings had shown a decrease in invasion when H1299 were 
transfected with 14-3-3η (Target 2), PARD6A (Target 7) and MAP2 (Target 11) (Figure 
5.3A). Within the double knockdown experiments a significant decrease in motility was 
seen with transfection of two of these three targets; 14-3-3η and PARD6A (Figure 5.5). 
With both, the reduction in motility observed was similar to that seen without the 
additional MARK4 knockdown (Figure 5.4A). This would suggest that the reduction in 
motility seen may not be due to the combined effect of both siRNAs. No rescue of the 
MARK4 phenotype was detected, however silencing of MAP2 (Target 11) and Tau (Target 
13) with MARK4 did not significantly decrease invasion (Figure 5.5). Silencing of Tau alone 
was found to increase invasion (Figure 5.4A). We would therefore suggest that this small 
reduction in motility when Tau and MARK4 siRNAs are combined may be due to the 
opposing effects of both knockdowns. This cannot be concluded for MAP2 as knockdown 
of this protein alone reduced invasion (Figure 5.4A). 
5.3 PP2A acts to reduce MARK4 activity  
Protein phosphatase 2A (PP2A) is a serine/threonine phosphatase whose activity 
is crucial for the regulation of several key cellular processes. PP2A is composed of a core 
enzyme made up of a structural and catalytic subunit, which combines with an additional 
variable regulatory subunit to form a heterotrimeric haloenzyme (Xu et al. 2006). The 
combination of subunits determines the enzyme’s targets and functions. Two subunits of 
PP2A were identified as potential binding partners of MARK4 during a tandem affinity 
purification of the kinase. The structural subunit PPP2R1A and the catalytic unit PPP2CB 
were both pulled down with TAP-MARK4 (Brajenovic et al. 2004). Within our siRNA screen 
of MARK4 interacting proteins (Section 5.3) we found that silencing of the structural 
subunit rescued the effect of MARK4 overexpression on cell motility (Figure 5.4, Target 1). 
No reversal or exaggeration of the change to cell motility upon MARK4 overexpression or 
silencing was observed upon knockdown of the catalytic subunit PPP2CB (Figure 5.4 & 
5.5, Target 5).  
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In addition to being implicated as a binding partner of MARK4, Drewes et al in 
1997 demonstrated that PP2A dephosphorylates MARKs, reducing their activity, as 
demonstrated by the reduced phosphorylation of a MARK4 target sequence (Gerard 
Drewes et al. 1997). PP2A is also known to regulate the binding of MAP2, MAP4 and Tau 
to microtubules, and is often referred to as the microtubule associated phosphatase (Liu 
et al. 2002; Sontag et al. 2012). Due to these publications and our findings with regards to 
the effect of silencing  
 
 
 
 
 
 
 
 
 
 
Figure 5.6.  MARK4 activity is regulated by PP2A. 
H1299 cells were transfected with control (EV) and pCDNA3 HA-MARK4 plasmids 48 h before 
proteins were harvested. (A) A decrease in the inactivating phosphorylation of PP2A occurs 
upon MARK4 overexpression. Proteins were separated on a 10% SDS-PAGE gel and transferred 
onto a PVDF membrane. Antibodies against pY307 PP2A and total PP2A were used. Detection of 
HSP90 was used as a loading control. The blot shown is representative of two independent 
repeats. (B) MARK4 binds to PP2A. Protein extracts were subjected to immunoprecipitation using 
anti-PP2Aα/β, anti-HA, unspecific antibody (anti-Flag, Control) or beads without antibody (Beads). 
Magnetic Protein G beads were then added to pull down the protein antibody complexes. 
Immune complexes were then washed and eluted into 2x Laemmli buffer and separated on a 10% 
SDS-PAGE gel. Proteins were transferred onto a PVDF membrane and the presence of MARK4 
visualised using an anti-HA antibody. The blot shown is representative of three independent 
experiments.  
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PP2A subunits on cell motility we wished to assess PP2A activity in cells overexpressing 
MARK4. The NSCLC cell line H1299 were transfected with pCDNA3 (control, EV) or 
pCDNA3 HA-MARK4 (HA-M4) 48 h before proteins were harvested using Laemmli Buffer. 
Lysates were boiled to denature proteins and equal volumes were separated on a 10% 
SDS-PAGE gel. Proteins were then transferred onto a PVDF membrane and protein 
expression visualised using specific antibodies against PP2A phospho-Y307 and total PP2A 
α/β. Detection of HSP90 was used as a loading control. We observed a decrease in the 
phosphorylation of tyrosine 307 (Y307) on PP2A upon MARK4 overexpression (Figure 
5.6A). As this phosphorylation inactivates PP2A, its reduction therefore suggests an 
increase in activity of this phosphatase. As a known negative regulator of MARK4 activity 
we would suggest that this increase in PP2A activity could be an attempt by the cell to 
reduce the activity of the overexpressed kinase. 
In addition to observing changes in the activity of PP2A we also confirmed the 
direct interaction between MARK4 and PP2A. Co-immunoprecipitation of the two 
proteins was carried out using the following method. H1299 cells in 15 cm dishes were 
transfected with pCDNA3 (Empty vector control, EV) or pCDNA3 HA-MARK4. 48 h after 
transfection cells were lysed using Mg2+ lysis buffer (MLB) supplemented with protease 
inhibitors. 500μg of protein extract was then subjected to immunoprecipitation overnight 
at 4°C using 2-5μg anti-PP2Aα/β (Abcam), anti-HA (Sigma), unspecific antibody (anti-Flag, 
Control) or beads without antibody (Beads). Magnetic Protein G beads were then added 
to pull down the protein antibody complexes. Immune complexes were then washed with 
MLB and eluted into 2x Laemmli buffer, boiled, then, with the original protein lysates 
(50μg), separated on a 10% SDS-PAGE gel. Proteins were transferred onto a PVDF 
membrane and the interaction between PP2A and MARK4 visualised using an anti-HA 
antibody. We successfully observed the interaction between PP2A and MARK4 in three 
biological repeat experiments (Figure 5.6B), confirming the findings of Brajenovic et al. 
(Brajenovic et al. 2004). We were unable, however, to confirm the interaction using the 
anti-HA antibody to immunoprecipitate MARK4.  
5.4 Involvement of GSK3α/β with MARK4 
In addition to studying the activity of PP2A we also investigated glycogen synthase 
kinase 3 (GSK3) and its role in regulating MARK4 activity. GSK3 is a serine/threonine 
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kinase found as two isoforms, GSK3α or GSK3β, and is involved in many cellular processes 
including cell motility, survival and proliferation. MARKs have been suggested to be 
regulated by glycogen synthase kinase 3 in two contrasting publications. In 2005, GSK3β 
was shown to phosphorylate MARK2 at serine 212 leading to its activation and 
downstream phosphorylation of Tau (pTau) (Kosuga et al. 2005). However 
phosphorylation of this site on MARK2 (Ser-212) was later deemed to be inhibitory. Timm 
et al showed a marked decrease in pTau upon transfection of constitutively active 
GSK3βS9A into cells, even when constitutively active MARK2 is introduced into cells. In 
vitro kinase assays using bacterially expressed MARK2 and GSK3β also demonstrated a 
reduction in MARK2 activity when pre-incubated with GSK3β (Timm, Balusamy, et al. 
2008). As this site is conserved within the other MARK family members (MARK4; Ser218) 
a similar regulation is thought to take place for all MARK isoforms.  
As with PP2A if GSK3 is involved in the deactivation/inhibition of MARK4 we 
hypothesised that we would see an increase in activity of GSK3β, as a negative feedback 
following MARK4 overexpression. Having transfected H1299 cells 48 h previously with 
pCDNA3 (Control empty vector, EV), pCDNA3 HA-MARK4 (HA-M4) or pCDNA3 GFP-
MARK4 (GFP-M4) we harvested protein from the cells using Laemmli buffer. Lysates were 
boiled to denature proteins before equal volumes were separated on a 10% SDS-PAGE 
gel. Proteins were transferred onto a PVDF membrane by western blotting and expression 
visualised using antibodies against pGSK3 α/β, total GSK3 α/β, GFP and HA. Detection of 
HSP90 expression was used as a loading control. We observed an increase in the 
inhibitory phosphorylation of GSK3 upon overexpression of MARK4 with either construct 
(Figure 5.7). Due to the position of the band seen with the phospho-GSK3 α/β antibody 
we conclude that there was a change in phosphorylation of Serine 21 on GSK3 α. No 
second band (phosphorylation of pGSK3β on Ser9) was observed.  
Although little evidence is published to support this, it is generally accepted that 
the inhibitory phosphorylation of Ser 218 within MARK4 may trigger degradation of the 
kinase via further downstream modifications and interactions. As increased degradation 
may trigger changes at a transcriptional level we wished to investigate changes in MARK4 
transcription in response to GSK3 α/β silencing. Attempts to overexpress GSK3 were 
unsuccessful due to problems obtaining plasmids expressing the correct proteins and 
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forms. H1299 cells transfected with pCDNA3 (empty vector control) or pCDNA3 HA-
MARK4 (MARK4) or A549 cells were transfected with non-targeting (NS), GSK3α or GSK3β 
siRNA (transfections in H1299 were carried out 24 h after transfection with plasmid). RNA  
 
 
 
 
 
 
 
 
 
 
Figure 5.7.  GSK3 activity is altered upon overexpression of MARK4.  
H1299 cells were transfected with a control empty vector (pCDNA3, EV) or pCDNA3 MARK4 (HA or 
GFP tag, HA M4, GFP M4) plasmid. Proteins were harvested 48 h after transfection and separated 
on a 10% SDS-PAGE gel, transferred onto a PVDF membrane and the expression of pGSK3αβ, 
GSK3α/β, GFP and HA visualised using specific antibodies. Detection of HSP90 was used as a 
loading control. Blots are representative of two independent experiments. 
 
was extracted from the cells 48 h after siRNA transfection using the RNeasy mini kit. 
MARK4 mRNA levels were then quantified using qPCR. Expression was measured against 
the expression of two housekeeping genes, GAPDH and HPRT using the software qBase. 
Data was then normalised against the non-targeting siRNA control (NS). Appendix Figure 
10.7 shows a significant increase in MARK4 mRNA levels when GSK3α is silenced and this 
is similarly seen to occur when MARK4 is overexpressed. We also observed a significant 
increase in MARK4 mRNA expression in A549 after GSK3α knockdown. GSK3β silencing 
had no significant effect on mRNA expression levels in either cell line.  
5.5 Effect on Rho GTPase activity 
Another key family involved in the regulation of cell motility is the Rho GTPase 
family. The balance of location and activity of this family’s key members; Rac1, Cdc42 and 
RhoA, is key in the control of actin polymerisation through the regulation on nucleation-
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promoting factor proteins (NPFs) (Welch & Mullins 2002; Pollard 2007). They are also 
involved in actomyosin contraction by controlling myosin II via myosin light chain (MLC) 
(Sanz-Moreno et al. 2008; Ridley et al. 2003). Rho GTPases are controlled by the activity 
of Rho guanine nucleotide exchange factors (GEFs), Rho GTPase-activating proteins 
(RhoGAPs) and Rho guanine nucleotide-dissociation inhibitors (GDIs). GEFs increase Rho 
GTPase activity by stimulating GTP association whereas RhoGAPs and GDIs are inhibitory.  
MARK4 has been associated with a known GEF, ARHGEF2 (GEFH1), which is 
referred to as the microtubule-regulated Rho GEF. This interaction was identified through 
the TAP-MARK4 carried out by Brajenovic et al in 2004 (Brajenovic et al. 2004). Silencing 
of this target in H1299 empty vector transfected cells (Figure 5.4A, Target 4), increased 
invasion above the non-targeting control, although only a small reduction in the motility 
of cell overexpressing MARK4 was detected upon GEFH1 knockdown, (Figure 5.4B, Target 
4 compared to NS Figure 5.4B). GEFH1 has also been linked to MARK2. Indeed, 
phosphorylation of GEFH1 by MARK2 at serine 885  and serine 959 inhibits its ability to 
stimulate RhoA preventing RhoA dependent actin polymerisation (Yamahashi et al. 2011). 
MARK2 was also identified as acting downstream of Rac1 (Nishimura et al. 2012). 
Silencing of MARK2 altered microtubule (MT) orientation and filament lifetime and 
reduced cell motility. Through the use of constitutively active Rac1 constructs this group 
concluded MARK2 is a downstream target of Rac1, promoting the orientation of MT at 
the leading edge of migrating cells (Nishimura et al. 2012).  
We investigated whether the activity of Rac1 and RhoA were altered when MARK4 
expression was modulated. Studies of Rac1 activity were unsuccessful, however we did 
observe differences in Rho GTPase activity. H1299 cells were plated in 15 cm dishes and 
transfected with either non-targeting (NS) or MARK4 siRNA, pCDNA3 (empty vector 
control, EV) or pCDNA 3 GFP-MARK4 (GFP-M4). 48 h after transfection cells were 
harvested with Magnesium lysis buffer (MLB). Active Rho was pulled down by incubation 
of 500μg of lysate with Rhotekin GST-agarose slurry for 45 min at 4°C. The agarose beads 
were pelleted and bound Rho released by addition of Laemmli buffer. 10% input lysate 
and the Active Rho fraction were separated on a 10% SDS-PAGE gel and proteins 
transferred to a PVDF membrane. The amount of total Rho and active Rho was visualised 
using an antibody against Rho A, B & C. Silencing of MARK4 did not dramatically alter the 
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amount of active (GTP bound) Rho pulled down (Figure 5.8A). However the most marked 
effect was after over expression of MARK4, where activity of Rho was greatly decreased 
(Figure 5.8B). This result would support the findings of Yamahashi et al who found MARK2 
inhibited GEFH1 by phosphorylation, resulting in reduced RhoA activity, (Yamahashi et al. 
2011). We wished to confirm whether this change in Rho activity was indeed mediated 
through GEFH1 phosphorylation by MARK4 when the kinase is overexpressed. However, 
as suggested by Yamahashi et al, use of commercially available antibodies for pGEFH1 
Ser885/959 proved unsuccessful. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.8.  The activity of Rho GTPase is altered when MARK4 expression is modulated.  
H1299 cells were transfected with either control (NS) or MARK4 (M4) siRNAs (A) or empty vector 
(EV) or pCDNA3 GFP-MARK4 (GFPM4) plasmids (B). 48 h after transfection cells were lysed with 
Mg2+ Lysis/Wash Buffer (MLB). Active Rho GTPase was pulled down using a construct of GST 
tagged Rhotekin Rho Binding Domain bound to glutathione-agarose beads and eluted 2x Laemmli 
buffer. Proteins from the original lysates (Total Rho) and the eluted proteins were then separated 
on a 10% SDS-PAGE gel, transferred to a PVDF membrane and Rho detected using a Rho A, B, C 
antibody. Blots shown are representative of three independent biological repeats.  
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5.6 Interplay between MARK family members 
Within this thesis we have focused on the involvement of MARK4 in cell motility, 
chemoresistance and proliferation. As described MARK4 is one of four members of the 
MARK family, all of which are implicated in control of microtubule stability. The initial 
screen carried out by our laboratory did not highlight the other MARK family members, 1-
3, as significantly altering the motility of A549 cells, (Lara et al. 2011). The MARK family 
have been shown to play a role in determining cell polarity (Tang et al. 2013; Bright et al. 
2009; Naz et al. 2013; Gerard Drewes et al. 1997; Cohen et al. 2004). This would indicate 
the involvement of this family in the control of directed cell migration, which requires 
polarisation of the cell. MARK2 has been directly implicated in affecting cell motility in 
several publications (Yamahashi et al. 2011; Nishimura et al. 2012) through interacting 
with the Rho GTPase family.  
We wished to confirm whether silencing of the three other MARK family members 
also decreased motility. A549 were plated in 96-well plates 24 h before they were 
transfected with non-targeting (NS) or MARK1, MARK2 or MARK3 siRNAs with a final 
concentration of 30 nM. 24 h after transfection, cells were imaged for 18 h in 
environmentally controlled conditions using an ImageXpress high throughput screening 
microscope. One image was taken every 10 min and using the videos produced, cells were 
manually tracked using the MetaXpress Track point application in MetaXpress 2.0 and the 
degree of migration was determined using a published Mathematica notebook (Katso et 
al. 2006). We observed a decrease in cell migration upon silencing of each of the three 
other MARK family members (Figure 5.9A), although high variation was observed with 
siMARK1.  
We also investigated whether there was compensation between the MARK family 
members. We quantified changes in MARK4 and MARK2 mRNA levels upon depletion of 
the MARK1-4 in A549 and H1299 using qPCR. RNA was extracted 48 h after transfection 
with control (NS) or the relevant MARK siRNA. Specific primers against MARK4 and 
MARK2 were used to quantify changes in expression relative to expression of two 
housekeeping genes, GAPDH and HPRT. Silencing of MARK1-3 did not significantly affect 
MARK4 mRNA expression (Figure 5.9B). A small increase was observed, however, after 
knockdown of MARK1 and MARK3, although this only occurred in A549. As role for 
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MARK2 in cell motility had been previously reported in published literature and we had 
drawn parallels between MARK4 and MARK2’s  downstream signalling effects MARK2 
mRNA levels were also quantified (Yamahashi et al. 2011; Nishimura et al. 2012). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.9.  The effect of MARK4 family members silencing on MARK4 and MARK2 mRNA 
expression.  
(A) Depletion of all MARK family members reduces migration. A549 cells were transfected with 
non-targeting (NS), MARK1, MARK2 or MARK3 siRNAs 24 h after being plated in black 96-well 
plates. After a further 24 h, cells were images in an environmentally controlled ImageXpress high-
throughput screening microscope for 18 h, with one image acquired every 10 min. Cells were then 
manually tracked using the MetaXpress Track Points application in MetaXpress 2.0. A 
Mathematica notebook was then used to determine the average distance of migration. (B) 
MARK4 expression is not altered by the silencing of other MARK family members. (C) MARK4 
silencing reduces MARK2 mRNA expression. A549 and H1299 cells were transfected with non-
targeting (NS) or MARK1, MARK2, MARK3 or MARK4 siRNA (30 nM) 48 h before RNA was 
extracted. Expression of MARK4 (B), or MARK2 (C) was quantified using qPCR for the indicated 
targets. Data were normalised against the expression of two housekeeping genes, GAPDH and 
HPRT using the qBase software. All data shown is the average of three repeats. Error bars indicate 
SEM. Asterisks represent statistically significant values from a minimum of three biological repeat 
experiments with three technical repeats (*, P<0.05; **, P<0.01; ***, P<0.001, ****, P<0.0001; 
ANOVA, Bonferroni’s multiple comparisons test). 
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MARK2 mRNA levels were significantly decreased in both cell lines after silencing of 
MARK4 (Figure 5.9C). Although this could be due to off target effects of the MARK4 
siRNAs, comparison of the MARK2 mRNA sequence and the siRNA sequences did not 
highlight this possibility as being likely. In contrast, silencing of MARK1 and MARK3 did 
not significantly alter MARK2 expression (Figure 5.9C). 
5.7 Discussion 
Within Chapter 4 we describe significant changes in cell motility when MARK4 
expression is altered. Silencing of this kinase reduced motility in 2D or through a 3D 
collagen matrix by up to 80%, whereas overexpression resulted in an increase in motility. 
Though we identified changes in microtubule dynamics, supported by MARK4’s known 
involvement in the regulation of microtubule associated proteins Tau, MAP2 and MAP4, 
we were yet to provide further mechanistic findings. Within this chapter we attempted to 
address this, investigating MARK4’s effect on epithelial mesenchymal transition (EMT) 
and the involvement of a number of potential interacting proteins in MARK4’s role in cell 
motility. 
EMT is a crucial process during embryogenesis, wound healing and metastasis. 
Some tumour cell types are known to adopt a mesenchymal phenotype, increasing 
motility. This transition is therefore seen as a potential initiation event in the metastatic 
cascade. It should be noted however that certain forms of cell motility, such as amoeboid 
movement, do not require EMT. EMT is characterised by the loss of expression of typical 
epithelial markers and an increase in mesenchymal markers. Using qPCR we quantified 
the changes in the epithelial markers E-Cadherin and β-Catenin, the mesenchymal 
markers N-Cadherin, Vimentin and two EMT transcription factors; Snail and TCF-1. We did 
not detect significant changes in epithelial or mesenchymal markers upon silencing of 
MARK4 which was not unexpected as cells depleted of MARK4 exhibit reduced motility 
which would not suggest EMT (Figure 5.1). However H1299 cells overexpressing MARK4 
do show increased motility, indicative of a more mesenchymal phenotype. Although we 
did observe a decrease in E-Cadherin and β-Catenin mRNA with increased MARK4 
expression, there was no corresponding increase in the level of the mesenchymal 
marker’s investigated (Figure 5.2). This data would suggest that EMT is not triggered upon 
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MARK4 overexpression. However, the decrease in E-Cadherin expression could contribute 
towards the observed increased motility. As a key molecule within cell-cell and cell-matrix 
adhesions, reduced levels of E-Cadherin would increase a cell’s ability to detach from 
other cells and matrices, encouraging motility. Further studies using immunofluorescence 
staining of E-Cadherin and other focal adhesion components such as FAK would identify 
reduced adhesions in these cells. It may also be useful to study the levels at the mRNA 
and protein level of a wider range of EMT markers.  
Changes were seen in the expression of TCF-1 mRNA, significantly decreased upon 
MARK4 overexpression, and increased after MARK4 silencing (Figure 5.1 and 5.2). This 
would suggest another role for this transcription factor beyond the stimulation of EMT. T-
cell factor-1 (TCF-1, also known as transcription factor 7, TCF7) has been linked with EMT 
through its formation of a complex with β-catenin in the nucleus. This complex has been 
shown, through stimulation of Axin2, to stabilise Snail, a crucial regulator of EMT (Yook et 
al. 2006). A positive correlation between MARK4 expression and the expression of the TCF 
family has been previously identified. It was this correlation which led to MARK4’s 
identification in 2005 through Kato et al.’s studies of Tcf/LEF1 expression in 
hepatocellular carcinoma (Kato et al. 2001). 
 To begin uncovering the mechanism behind MARK4s role in cell motility we took 
the approach of silencing 13 previously identified potential MARK4 interacting proteins in 
the presence of MARK4 overexpression or depletion. This enabled us to suggest whether 
some of the interacting proteins tested were involved in the pro-migratory role of 
MARK4. Table 5.1 lists the interacting proteins we tested and references to the 
publications which suggested their involvement with MARK4. Figures 5.4 and 5.5 present 
our findings. Depletion of some targets repressed the effect of overexpressing MARK4; 
decreasing invasion in the control cells and preventing any increase upon the additional 
overexpression of MARK4, namely 14-3-3η (Target2), PARD6A (Target 7), MAP2 (Target 
11). Others rescued the observed increase in invasion upon overexpression of the kinase; 
PPP2R1A (Target 1), ARGHEF2 (Target 4), STRADA (Target 9) and STK11 (Target 10). These 
findings allow us to suggest that these proteins may sit downstream of MARK4. In the 
case of STK11 (also known as LKB1), this kinase is known to activate MARK4 along with 
many other AMPK family members (Lizcano et al. 2004). Our findings would support this 
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as the absence of STK11 would remove the effect of MARK4 overexpression potentially by 
preventing its activation by STK11. Further investigation would be required to confirm 
whether these seven proteins are indeed downstream targets of MARK4. Direct 
interactions could be confirmed using co-immunoprecipitation and co-localisation studies 
using immunofluorescence. Studying the activity of these proteins when MARK4 protein 
levels are altered would provide further evidence to support their involvement in this 
mechanism. It could be concluded that those interacting proteins which did not alter the 
known increase in motility upon MARK4 overexpression (PPP2CB, PKCλ and USP21) are 
not involved in MARK4’s role in the control of cell motility. This does not disprove their 
interaction with MARK4 but only demonstrate their lack of requirement in the phenotypic 
change we investigated. Knockdown of CAB39 and MAP4 using RNAi enhanced the 
increase in invasion when MARK4 was overexpressed. It is suggested that CAB39 (also 
known as MO25) is required for the activation of MARK4 through activation of LKB1 
(STK11) (Brajenovic et al. 2004; Lizcano et al. 2004). Our findings here do not support this 
reported involvement however, as the expected rescue of the MARK4 phenotype is not 
observed. We would propose that STK11 is activated by other factors alongside CAB39 
and therefore, no effect on MARK4 activity is seen downstream of the absence of CAB39. 
MARK4 is also activated by other kinases such as MARKK which do not require CAB39 
(Tang et al. 2013). We proposed that MARK4 overexpression increased invasion by 
increasing the turnover of MAPs binding and releasing from microtubules, increasing the 
dynamic instability allowing for more rapid remodelling of the cytoskeleton during 
invasion. In this model, it would be logical to expect a further promotion of cell invasion 
upon additional silencing of one such MAP, consistent with the results we obtained for 
MAP4.  
Ideally all findings of this small siRNA screen would be followed up with 
confirmation of direct or indirect interaction and activity studies. However due to time 
restraints only some targets were investigated further, these were chosen based on the 
effects observed within the screen, and the body of literature supporting a potential 
interaction. The phosphatase PP2A is involved in a large number of signalling pathways,.  
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Figure 5.10. Proposed model for MARK4’s downstream signalling. 
MARK4 overexpression results in the inactivation of GSK3. MARK4 interacts with and activates 
CDC42 which in turn activates the Par6/PKCζ complex. This complex phosphorylates GSK3 at 
serine 21/9 inactivating this kinase. Inactivation of GSK3 leads to increased activation of FAK by 
phosphorylation at serine 772. Active FAK increases cell spreading and motility through its 
involvement in focal adhesions. (B) PP2A activity is increased when MARK4 is overexpressed as 
part of a negative feedback loop. Overexpression of MARK4 leads to an increase in the 
phosphorylation at Y307 of PP2A, activating the phosphatase. PP2A is known to dephosphorylate 
MAPs such as Tau increasing their affinity for binding microtubules. GSK3 is activated by PP2A 
preventing the proposed phosphorylation of FAK. Both GSK3 and PP2A have been shown to 
inactivate MARK family members by de-phosporylation. The actions of PP2A would therefore 
reduce the effects of MARK4 overexpression. (C) Rho activity is reduced when MARK4 expression 
is increased. GEFH1 is inactivated through phosphorylation by MARK expression preventing the 
activation of Rho GTPase. 
A 
C 
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modulating the activity of a range of proteins by dephosporylation. As a so called of the 
filaments microtubule associated phosphatase, PP2A has been shown to dephosphorylate 
MAPs (Sontag et al. 2012; Liu et al. 2002). It has also been implicated in the regulation of 
MARK activity (Gerard Drewes et al. 1997). The small siRNA screen which we conducted 
(Figure 5.4) identified depletion of PPP2R1A (Target 1) as reversing the increase in 
invasion, stimulated by overexpression of MARK4. We found an increase in PP2A activity 
following MARK4 overexpression (Figure 5.6A). In accordance with the literature we 
propose this increase in activity is a direct response to the increased expression of MARK4 
and is a feedback mechanism within the cell to reduce MARK4 activity (Figure 5.10B). We 
confirmed, via co-immunoprecipitation a direct interaction between PP2A and HA-MARK4 
(Figure 5.6B). Heightened PP2A activity will also result in dephosporylation of its target 
MAPs, reversing MARK4’s activity, this will increase the number of MAPs bound to 
microtubules and therefore the stability of the filaments (Figure 5.10 B). This proposed 
mechanism does not however explain why depletion of PP2R1A within our small siRNA 
screen rescued the MARK4 invasion phenotype.  
Though not included within our small screen, GSK3α/β has been frequently 
associated with the regulation of MARK4. GSK3 is also known to play key roles within the 
regulation of cell motility. We observed an increase in the inhibitory phosphorylation of 
GSK3α, pSer21, in cells overexpressing MARK4 (Figure 5.7). The antibody used was 
targeted against GSK3α/β pSer21/9, however only one band was seen following analysis 
of protein extracts by SDS-PAGE/Western blotting. Due to the perceived molecular weight 
of this band, it was concluded to represent pGSK3α Ser21. This could be confirmed using 
siRNA silencing of GSK3α. GSK3β inactivation has been previously associated with an 
increase in motility. Two publications previously highlighted increase in pSer9/21 GSK3 at 
the leading edge of migrating cells (Etienne-manneville & Hall 2003; Bianchi et al. 2005). 
Using wound healing assays Etienne-Manneville et al. found this inactivating 
phosphorylation to be induced by Cdc42 activated Par6-PKCζ (Etienne-manneville & Hall 
2003). The impact of this inactivation on cell motility is proposed by Bianchi et al. to be 
through an increase in activation of FAK, a key component of focal adhesion complexes. 
This increased FAK activity results in enhanced cell spreading and migration (Bianchi et al. 
2005). Although these findings were concluded to involve GSK3β rather than GSK3α, we 
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would propose these findings to warrant further investigation into the role of GSK3α in 
our system. The first required step would be the confirmation of the change in GSK3α 
rather than GSKβ activity upon changes in MARK4 expression. Changes in the activity of 
FAK by observation of phosphorylation at Ser772 would confirm the involvement of this 
kinase downstream of MARK4. Interestingly Cdc42 was pulled down with TAP-MARK4 in 
the tandem affinity purification carried out by Brajenovic et al (Brajenovic et al. 2004). If 
MARK4 could be shown to activate Cdc42 to stimulate its downstream activation of the 
Par6-PKCζ complex which phosphorylates GSK3 this would provide further evidence in 
support of MARK4’s involvement in this signalling pathway. This proposed mechanism is 
described in Figure 5.10A. Interestingly, PP2A is known to dephosphorylate GSK3, 
activating this kinase (Hernández et al. 2010; Qian et al. 2010). This would be another 
potential feedback mechanism in response to MARK4 overexpression (Figure 5.10B). This 
could be studied using a time course to observe a loss of pGSK3 with an increase in PP2A 
activity. 
MARK4 was proposed to interact with ARHGEF2 (GEFH1), a member of the 
guanine nucleotide exchange factor (GEF) family, responsible for activating Rho GTPase 
activity (Brajenovic et al. 2004). This GEF has also been previously linked to MARK2 which, 
it is proposed, inactivates it via phosphorylation of Ser885/959 (Yamahashi et al. 2011). 
Although we were unable to observe the inhibitory phosphorylation of GEFH1 upon 
MARK4 overexpression we did see a corresponding decrease in Rho activity (Figure 5.8B). 
No clear change was noted after silencing of MARK4 (Figure 5.8A). A decrease in Rho 
activity with increasing MARK expression suggests that like MARK2, MARK4 is involved in 
control of Rho activity (Figure 5.10 C). In the absence of satisfactory antibodies for the 
suggested phosphorylation sites on GEFH1 site, directed mutagenesis of these sites would 
be required to confirm the regulation was indeed through inactivation of this GEF 
(Yamahashi et al. 2011). Confirmation of a direct interaction between GEFH1 and MARK4, 
as was seen confirmed with MARK2, would require co-immunoprecipitation of this 
complex. We were unable to confirm this or observe changes in Rac1 activity in response 
to modulation of MARK4 expression. MARK2 has been suggested to act downstream of 
this Rho GTPase family member (Nishimura et al. 2012) but we are yet to investigate 
whether MARK4 is also a target. 
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Taken together our findings would suggest similar roles for MARK4 and MARK2. 
We confirmed that silencing of all three other MARK family members decreased cell 
NSCLC cell invasion. We found no significant compensation of MARK4 mRNA expression in 
the absence of MARK1-3, though a 30% reduction in MARK2 expression was observed 
upon depletion of MARK4 (Figure 5.9). We would propose that the crossover in function 
between these highly homologous proteins is high. However we note that removal of any 
individual MARK is enough to affect cell motility, suggesting no compensation in function. 
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6.1 Introduction  
One hallmark of a cancer cell is uncontrolled or increased proliferation. The cell 
cycle is broken down into four stages; G1, cell begins to increase in size and prepare for 
DNA synthesis, S, DNA replication occurs, G2, continued cell growth, and finally M 
(Mitosis) where cell division occurs to produce two daughter cells (Harper & Brooks 
2005). Cell cycle checkpoints regulate progression through these stages. They prevent 
damaged cells continuing the cycle and instead trigger degradation. A number of common 
chemotherapy drugs target the cell cycle, inducing DNA damage or preventing division to 
trigger cell death as the cell passes through a checkpoint. Cyclin’s and cyclin dependent 
kinases (Cdk) regulate the cell cycle and are themselves controlled by a wide range of 
binding partners (Walworth 2000). In cancer cells the regulatory control of the cell cycle is 
often disrupted by the loss of increased expression of these proteins.  
The two main causes for death of Lung cancer patients are metastasis and 
resistance to chemotherapy. Resistance to therapy can be developed as a result of 
previous treatment or an innate feature of the tumour cells. Having studied MARK4’s role 
in metastatic progression we examined whether modulating MARK4 expression may also 
affect NSCLC cells sensitivity to chemotherapeutics. When considering MARK4 as a 
potential novel therapeutic target to reduce metastasis in lung cancer patients it is also 
important to study its effect on the efficacy of standard treatments. 
In addition to examining cell proliferation and chemosensitivity we additionally 
looked at the effect of MARK4 silencing on another stage of the metastatic cascade, one 
in which tumour cells are highly susceptible to apoptosis. When tumour cells enter the 
blood or lymphatic systems to disseminate around the body, the lack of adhesion to other 
cells or the substratum can trigger anoikis. Anoikis is the process of cell death triggered 
when adherent cells are placed in suspension. 
The results of this section will highlight the potential for therapeutic targeting of MARK4 
to modulate additional aspects of lung cancer biology. 
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6.1 Survival in circulation may also be affected by MARK4 protein 
levels 
In addition to investigating MARK4’s involvement in cell invasion, we wished to 
explore whether MARK4 affected the fate of tumour cells at other levels. When a tumour 
cell enters the circulation anoikis can be triggered. Lack of adhesion in addition to 
exposure to immune cells and shear stress means this second stage of metastasis is highly 
selective. By determining the effect of MARK4 depletion on anoikis we could further 
determine its suitability as a therapeutic target. 
siRNA-mediated silencing of MARK4 alone did not induce toxicity in adherent cells 
(data not shown). To assess the susceptibility of MARK4-depleted cells to anoikis A549 
cells, transfected 24 h earlier with non-targeting (NS) and MARK4 siRNA, were plated in 
low-adhesion plates. These plates prevent cells forming adhesions to the plastic keeping 
the cells in suspension. After 18 h in low adhesion, cells were returned to normal 
adhesion plates and allowed to adhere for a further 8 h. The survival was measured using 
crystal violet staining of the adhered cells.  
In the absence of MARK4 expression we observed a significant increase in anoikis 
(Figure 6.1A). The increase in cell death was confirmed using a Caspase 3/7 activity assay. 
Both caspase 3 and 7 are activated during apoptotic cell death. By adding a substrate 
which is cleaved by active caspase 3 and 7 to produce a luminescent signal, a level of 
caspase activation and, by inference, apoptosis can be quantified. The substrate was 
added to the low adhesion plates after the 18 h incubation period, without moving the 
cells back to normal adhesion plates. Figure 6.1B confirms cell death is increased in 
MARK4 silenced cells with a 60% increase in caspase 3/7 activity compared to the non-
targeting control (NS). Hence, in addition to reducing the invasive ability of a tumour cell, 
depletion of MARK4 may reduce the likelihood of tumour cells surviving in circulation. 
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Figure 6.1. Effect of depletion of MARK4 on A549 cell survival in suspension. 
5x103 A549 were plated in 96-well well plates and transfected with control (NS) or MARK4 siRNAs 
24 h later. 48 h after transfection, cells were trypsinised; half were transferred into a low 
adhesion 96-well plate and the other half to a standard 96-well plate. Plates were incubated 
overnight at 37°C, 10% CO2. (A) Anoikis assay using A549 cells. To determine survival, after 18 h 
in low adhesion, cells were then transferred into a normal adhesion plate and allowed to adhere 
for 8 h before plates were fixed with PFA and stained with crystal violet. The crystal violet staining 
was dissolved in 10% (v/v) Acetic acid and the absorbance measured to quantify survival.  (B) 
Capsase Glo assay using A549 cells. Caspase 3/7 reagent was added to the low adhesion plate 
without cells being returned to normal adhesion plates. Plates were incubated for 1 h in the dark 
at room temperature. Luminescence produced by cleavage of the substrate by active caspases 3 
and 7 was quantified using the PHERAstar luminescence microplate reader. All data shown is the 
average of three repeats. Error bars indicate SEM. Asterisks represent statistically significant 
values from a minimum of three biological repeat experiments with three technical repeats (*, 
P<0.05; **, P<0.01; ***, P<0.005; Students t-test, two sample equal variance, two tailed 
distribution). 
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6.2 Lower expression of MARK4 increases NSCLC cell resistance to 
Cisplatin an Paclitaxel probably due to reduced cell division 
NSCLC patients are treated with combinations of chemotherapy drugs including 
Cisplatin and Paciltaxel (Taxol). To investigate whether MARK4 expression affects the 
efficiency of these two common chemotherapy drugs we treated two NSCLC cell lines 
with increasing concentrations of both drugs in the presence and absence of MARK4 
expression. Cells were plated in 96-well plates and transfected after 24 h with control 
(NS) or MARK4 siRNA. After a further 24 h either Cisplatin was added at increasing 
concentrations from 1 to 40 μM (to both cell lines) or Taxol at 1 to 50 nM (A549) or 25-
500 nM (H1299). Both cell lines were treated with drug for 48 h before plates were fixed 
and stained with crystal violet. The degree of staining was quantified and the effect of 
drug calculated by normalising to the DMSO control of each siRNA treatment. In A549 a 
significant difference in survival was observed, with cells treated with MARK4 siRNA more 
resistant to Cisplatin (Figure 6.2A) and Taxol (Figure 6.2B) treatment. The increase in 
resistance was noted at all concentrations though due to variation between experiments 
this was only significant at certain concentrations. An increase in resistance to Taxol was 
also observed in MARK4 silenced H1299, with a significant increase in survival at all 
concentrations (Figure 6.2D). However when H1299 were treated with Cisplatin, although 
a trend towards higher resistance in siRNA MARK4 cells could be seen, no significant 
differences were found (Figure 6.2C).  
An increase in resistance to chemotherapy in response to MARK4 down-regulation 
would indicate that this protein may not be an ideal therapeutic target despite the 
accompanying reduction in tumour cell motility and survival in suspension.  
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Figure 6.2. MARK4 silencing affects the sensitivity of NSCLC cell lines to chemotherapy.  
3 x 103 A549 or H1299 cells were plated in triplicate in 96-well plates and incubated for 24 h 
before being transfected with either control (NS) or MARK4 siRNA. 24h after transfection cells 
were treated with the indicated concentrations of Cisplatin or Paclitaxel (Taxol). After a further 48 
h incubation plates were fixed with PFA. Cells were stained with Crystal violet. Staining intensity 
was measured as described in Methods. Response to drug treatment was assessed by normalising 
to the DMSO control wells. Sensitivity to Cisplatin treatment is reduced in MARK4 depleted 
A549 (A) and H1299 (C) cells. Resistance to Paciltaxel is also increased upon silencing of MARK4 
in A549 (B) and H1299 (D). All data shown is the average of three repeats. Error bars indicate 
SEM. Asterisks represent statistically significant values from a minimum of three biological repeat 
experiments with three technical repeats (*, P<0.05; **, P<0.01; ***, P<0.001, ****, P<0.0001; 
ANOVA, Bonferroni’s multiple comparisons test). 
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6.2.1 Changes in chemoresistance are due to altered cell cycle progression  
The reason behind the increase in resistance to the two tested chemotherapeutics 
upon silencing of MARK4 was unclear. Both drugs have different modes of action. 
Cisplatin intercalates DNA forming distortion and damage to the DNA’s structure. While 
this damage may be repaired, if the damage becomes substantial, apoptosis can be 
triggered (Galluzzi et al. 2012; Eastman 1987). The action of cisplatin is increased in 
dividing cells as DNA crosslinks are more likely to trigger apoptosis during cell division. 
Rather than inducing DNA damage, Paciltaxel targets the microtubules. By hyper-
stabilizing the microtubule filaments the dynamic behaviour of the microtubules is 
inhibited. This impairs re-organisation of the filaments during mitosis preventing normal 
cell division. This triggers apoptosis as the cell is unable to divide correctly (Xiao et al. 
2006). Although both drugs act via different mechanisms, both trigger apoptosis in rapidly 
dividing cells.  
As MARK family members have been previously suggested to play a role in cell 
division we first investigated the consequence of MARK4 depletion on proliferation.  A549 
were transfected with control or MARK4 siRNA and incubated for 48 h to allow cells to 
proliferate. Proliferation was quantified by staining the plates with crystal violet solution 
and quantifying the staining density. Figure 6.3A shows that silencing of MARK4 leads to a 
significant reduction in A549 cell proliferation.  
To confirm that the decrease in proliferation observed in Figure 6.3A was due to 
reduced cell division we quantified the percentage of cells in each phase of the cell cycle 
using the Click-iT® EdU cell proliferation assay by FACS. As before A549 were plated and 
transfected with control or MARK4 siRNA 24 h later. Following incubation for a further 48 
h, EdU was added to the media for 1 h to allow for its incorporation into the cells’ DNA. 
Cells were then trypsinised and processed as described in the manufacturer’s protocol. 
The degree of EdU incorporation was analysed using the FACSDiva software v6.12 on a 
FACSCanto A flow cytometer. We found that in MARK4-silenced cells there was a 
significant decrease in S phase (Figure 6.3B), and an increase in the percentage of cells in 
G1, suggesting cell cycle delay and a degree of G1 arrest. However observations in culture 
confirmed that MARK4-depleted cells do divide. Taken together, these data indicate that 
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there is a decrease in the rate of cell division upon MARK4 down-regulation that may 
explain the diminished effectiveness of both Paciltaxel and Cisplatin. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.3. Cell division is reduced in MARK4-silenced A549 cells. 
(A) Proliferation is reduced in the absence of MARK4. 3 x 103 A549 cells were plated in 96-well 
plates and transfected 24 h later with non-targeting control (NS) or MARK4 siRNAs. Plates were 
then incubated for 48 h. Plates were then fixed with PFA and stained with crystal violet. The 
intensity of staining was then quantified and normalised against the empty vector control. 
Asterisks represents statistically significant values from three biological repeat experiments (*, 
P<0.05, Students T Test) (B) The percentage of cells in S and G1 phase is altered upon depletion 
of MARK4. A549 cellswere plated in 6 well plates and transfected with control or MARK4 siRNA 24 
h later. 48 h after transfection EdU (10 μM) was added to the culture media for 1 h before cells 
were trypsinised, pelleted and washed with 1% BSA in PBS. Cells were then stained using the 
Click-iT EdU cell proliferation assay kit following the manufacturer’s protocol. Cell cycle was then 
assessed using a FACSCanto A flow cytometer. The degree of incorporation of EdU indicates the 
cell cycle stage of the cell. Data was analysed using FlowJo v7.6.5. All data shown is the average of 
three repeats with error bars indicating SEM. Asterisks represent statistically significant values 
from a minimum of three biological repeat experiments with three technical repeats (*, P<0.05; 
ANOVA, Bonferroni’s multiple comparisons test).  
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6.2.2 Tumour suppressor protein TP53 protein levels are increased upon 
MARK4 silencing  
Progression between stages of the cell cycle is controlled by a family of proteins 
known as the cyclin dependent kinases (CDKs) whose activity is governed by a wide range 
of modulators. A potential cause of cell cycle delay in MARK4 silenced cells could be 
changes to the expression of these cell cycle controllers. One such protein is TP53 (p53). 
When p53 expression is supressed and kept at a low level, cell cycle progression is 
allowed to occur. However upon DNA damage or cell stress, p53 expression and activity 
increases. While this may result in apoptosis or DNA repair, it may also trigger cell cycle 
arrest. P53 can prevent entry into S phase by activation of p21. Active p21 inhibits Cdk2, 
the activity of which is required for the transition through the G1 to S checkpoint. P53 
activation of p21 and 14-3-3σ also triggers G2 arrest by inactivating Cdc2 (Vogelstein et al. 
2000; Laronga et al. 2000). As the FACS data indicated a degree of G1 arrest (Figure 4.8), 
we wished to investigate any changes in p53 and p21 expression upon MARK4 silencing. 
Protein lysates obtained from A549 cells transfected with non-targeting (NS) or MARK4 
siRNA (either as a pool of four oligonucleotides or as individual siRNA’s) were separated 
by SDS-PAGE. Proteins were transferred onto a nitrocellulose membrane by Western 
blotting. Using antibodies against p53 and p21, we observed a dramatic increase in 
expression of both proteins upon MARK4 depletion (Figure 4.9A). The increase in p53 
expression was seen upon transfection with all four MARK4-targeting oligonucleotides, 
although the increase was higher with siRNA’s 1 and 3.  
As p53 is normally activated by cell stress we investigated whether there was a 
further increase in p53 expression with a combination of cell stress and MARK4 siRNA. 
Protein lysates were prepared from A549 transfected with control or MARK4 siRNA, a 
mock transfection control was also included (MO). Cells were either treated with DMSO 
(control) or with 40 μM Cisplatin for 24 h before protein harvest. Again an increase in p53 
and p21 expression was observed upon MARK4 knockdown (Figure 4.9B). However, in the 
cisplatin treated cells, in which much higher p53 expression is seen than in the DMSO 
treated cells, no further increase is observed upon MARK4 depletion (Figure 4.9B).  Also 
shown in Figure 4.9B are the ubquitinated forms of p53. P53 is ubquitinated upon binding 
to Mdm2, a key regulator of p53 expression. Mdm2 expression is triggered by p53, which 
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in turn reduces p53 expression through ubiquitination. No changes in Mdm2 expression 
were detected upon MARK4 siRNA transfection (data not shown). However, a reduction 
in ubquitinated p53 was seen in Figure 4.9B, suggesting a possible stabilisation of this 
protein.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.4. The expression of some key apoptotic and cell cycle proteins is altered in the 
absence of MARK4.  
A549 cells were plated in 6-well plates and transfected with control or MARK4 siRNAs 24 h later. If 
required cells were treated with drug 24 h later. Protein extracts were separated on a 10% SDS-
PAGE gel and transferred to a nitrocellulose membrane. Proteins were detected using antibodies 
against p53 and p21. Detection of GAPDH was used as a loading control. Blots shown are 
representative of two independent experiments. (A) Increase in p21 and p53 protein levels is not 
an off target siRNA effect. A549 were transfected with control (NS) or MARK4 (M4) siRNAs either 
as a pool or using four individual oligonucleotides. A large increase in p53 protein levels is 
observed upon silencing of MARK4. (B) When cells are treated with cisplatin in addition to 
MARK4 silencing p53 is not further increased above the control. Cells were transfected 24 h later 
with mock (MO), control (NS) or MARK4 (M4) siRNAs, each condition present in duplicate. 24 h 
after transfection one well of each condition was treated with 40 μM Cisplatin and incubated for a 
further 24 h before protein was harvested. Cisplatin treatment increases p53 expression, no 
additional increase was seen upon silencing of MARK4. 
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6.2.3 Increases in p53 protein levels are contributed by changes in TP53 
transcription 
Changes in protein levels can be the result of two changes. Firstly, an increase in 
the stability of the protein or decrease in the rate of degradation (increasing half-life of 
the protein) can lead to protein accumulation. Protein levels can also be raised by an 
increase in transcription of the encoding gene or in translation of the existing mRNA pool. 
To assess whether the observed increase in p53 protein levels was an increase in 
expression rather than a change in half-life we used Real-time Quantitative PCR (qPCR) to 
quantify changes in mRNA levels of p53 following MARK4 silencing. All protein-based 
observations had been made 48 h after transfection. We therefore harvested RNA from 
the transfected cells at this time-point using the RNeasy®Mini Kit. The expression levels of 
p53 and MARK4 mRNA were then quantified using the Fast SYBR® Green PCR Master Mix 
and specific primers against these mRNA sequences. Expression levels were calculated by 
normalising against the expression of two house-keeping genes, GDPH and HPRT using 
the software qbasePLUS.  
A non-significant increase of 20% in p53 mRNA expression levels upon siRNA 
MARK4 was detected (Figure 4.10A). Although this may suggest elevated transcription of 
the TP53 gene, the reduction in ubquitinated forms of p53 seen in Figure 4.9 B may 
indicate that a decrease in degradation could be responsible for the increase in total 
protein seen. RNA was also extracted at 24 and 72 h but no differences were reliably 
observed between control and MARK4 silenced conditions. Although no significant 
change in p53 mRNA expression was noted upon MARK4 depletion we also looked at the 
effect on MARK4 mRNA levels upon p53 silencing. This would allow us to implicate 
MARK4 as downstream of the transcription factor p53, perhaps in the process of cell cycle 
control. P53 silencing in A549 cells led to a significant 40% decrease in the expression of 
MARK4 mRNA (Figure 4.10B). This would suggest that either p53 acts as a transcription 
factor for MARK4 or that downstream signalling from p53 influences MARK4 
transcription. 
 
 
6. Effect of MARK4 depletion on survival and cell cycle progression 
187 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
Figure 6.5. MARK4 and p53 mRNA expression is altered by silencing of either protein.  
A549 cells were transfected with control (NS) or the indicated siRNA 24 h after plating in 6-well 
plates. 48 h after transfection RNA was harvested using RNeasy kit following the manufacturer’s 
instructions. qPCR was then used to quantify expression of the relevant mRNA. Relative 
expression was calculated using expression levels of two housekeeping genes; HPRT and GAPDH, 
and the software qBase. (A) MARK4 depletion increases p53 expression after 48 h. Cells were 
transfected with MARK4 siRNA and the effect on p53 mRNA expression assessed by qPCR. (B) 
Silencing of p53 decreases MARK4 mRNA expression levels. Cells were transfected with MARK4 
or p53 siRNAs. MARK4 expression was analysed by qPCR. All data shown is the average of three 
repeats. Error bars indicate SEM. Asterisks represent statistically significant values from a 
minimum of two biological repeat experiments (*, P<0.05; **, P<0.01; ***, P<0.005; One-way 
ANOVA, Bonferroni’s multiple comparisons test). 
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6.3 Effect of overexpressing MARK4 on cell cycle and chemoresistance 
We observed a decrease in cell cycle upon depletion of MARK4, confirmed by a 
decrease in the percentage of cells in S phase suggesting a delay in cell cycle progression 
perhaps due to G1 arrest. This change in the rate of division is proposed as an explanation 
for the increase in resistance of MARK4-silenced cells to cisplatin and Taxol. Here, we 
wished to assess whether, as opposed to MARK4 silencing, increasing MARK4 protein 
levels sensitised to therapy and accelerated cell cycle progression. 
Using a GFP-tagged MARK4 plasmid we overexpressed MARK4 in H1299 cells prior 
to plating them into 96-well plates with control cells transfected with the empty pCDNA3 
vector only. These cells were then treated with cisplatin for 48 h before plates were fixed 
with PFA and stained with crystal violet. The degree of staining was quantified, as before, 
to determine the survival to cisplatin treatment. Figure 6.6A clearly shows that there is no 
difference in sensitivity to chemotherapy with increased MARK4 expression. Confirmation 
of overexpression is demonstrated in Figure 4.6A and Appendix Figure 10.5B.   
Having observed no difference in cisplatin resistance we did not predict a change 
in proliferation. However, again using crystal violet assays, we determined that cells 
overexpressing MARK4 did proliferate at a significantly increased rate (Figure 6.6B). The 
effect of cisplatin is amplified in rapidly dividing cells as DNA damage is more likely to 
induced apoptosis in a dividing cell. However no increase in sensitivity to cisplatin was 
observed (Figure 6.6A). 
 
 
 
 
 
 
 
6. Effect of MARK4 depletion on survival and cell cycle progression 
189 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.6. Overexpressing MARK4 does not affect chemoresistance despite an increase in 
proliferation. 
(A) Cisplatin resistance is not altered by overexpression of wild type or dominant negative 
mutant MARK4. H1299 cells were transfected with pCDNA3 (Empty vector) or pCDNA3 WT GFP-
MARK4 (MARK4) in 15 cm dishes and then re-plated into 96-well plates 24 h later. 24 h after cells 
were re-plated. Cisplatin was added at the indicated concentrations and plates were incubated for 
48 h before being fixed with PFA and stained with crystal violet. (B) Proliferation is increased 
upon MARK4 overexpression. 3 x 103 H1299 cells transfected with either the empty vector 
control or pCDNA3 GFP-MARK4 were plated in 96-well plates and incubated for 48 h. Plates were 
then fixed with PFA and stained with crystal violet. The intensity of staining was then quantified 
and normalised against the empty vector control. All data shown is the average of three repeats 
Error bars indicate SEM. Asterisks represent statistically significant values from a minimum of 
three biological repeat experiments with three technical repeats (*, P<0.05; **, P<0.01; ***, 
P<0.001, ****, P<0.0001; Students T Test) 
  
0.0
0.2
0.4
0.6
0.8
1.0
1.2
DMSO 10 30
Su
rv
iv
al
 (
Fo
ld
)
Cisplatin (µM)
Empty Vector
WT MARK4
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1.8
2.0
Empty Vector MARK4
P
ro
lif
er
at
io
n
 (
Fo
ld
)
Vector
A 
B 
**** 
6. Effect of MARK4 depletion on survival and cell cycle progression 
190 
 
6.4 Discussion  
Anoikis is increased in the absence of MARK4 expression. This was confirmed by 
an increase in activity of caspases 3 and 7 showing activation of the apoptotic cascade. 
This proved that the decrease in survival in suspension seen is not a decrease in MARK4 
silenced cells ability to adhere to the final assay plate. Tumour cell dissemination via the 
blood of lymphatic system is already a highly selective stage of the metastatic cascade, 
further increasing the likelihood of tumour cell death would be a desirable effect of 
cancer therapeutic.  
In addition to a change in survival in suspension we also investigated how MARK4 
silencing affected A549 and H1299 cell survival downstream of treatment with two 
chemotherapy drugs, Cisplatin and Paciltaxel. With both drugs we observed enhanced 
resistance of our cell lines in the absence of MARK4 expression (Figure 6.2). While this 
increase was only significant at certain concentrations of both drugs in each cell lines, the 
trend towards increased resistance was consistent. Hence, MARK4 silencing increases 
resistance to drugs that induce cell death via different mechanisms, DNA damage or 
disruption to microtubules, and our data suggest this may be linked to a decrease in cell 
division (Eastman 1987; Galluzzi et al. 2012; Wani et al. 1971; Orr et al. 2003). We 
observed a reduction in the rate of cell division in MARK4 depleted cells using crystal 
violet assays (Figure 6.3A). Further investigations using flow cytometry to measure DNA 
content confirmed these findings as silencing of MARK4 significantly increased the 
percentage of cells in G1 while reducing the number in S phase, highlighting a delay in cell 
cycle progression.  
As briefly described, cell cycle progression is controlled via a number of 
checkpoints between and within the different stages of division. In addition to controlling 
progression these checkpoints also ensure genomic stability as cells are prevented from 
progressing through the cycle with DNA damage or incorrect DNA segmentation 
(Walworth 2000). The MARK family have previously been suggested to be involved in cell 
cycle via their regulation of microtubule stability (Tassan & Le Goff 2004). It has been 
shown cells treated with microtubule disrupting agents such as nocodazole, vincristine 
and colchicine display G1 or G2 arrest (Blajeski et al. 2002).  This arrest is thought to occur 
by triggering the mitotic checkpoint when microtubules fail to attach correctly to the 
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kinetochores during cytokinesis. After prolonged treatment with these agents, cells have 
been shown to continue cell division and progress into G1. However at this point G1 
arrest occurs via a p53-mediated increase in p21 activity which inhibits Cdk2 and Cdk4-
cyclin complexes causing G1 arrest. P53 is activated due to the presence of DNA damage 
occurring because of abnormal chromosome segregation and cytokinesis (Woods et al. 
1995; Notterman et al. 1998; Casenghi et al. 1999; Blajeski et al. 2002; Amundson et al. 
1998). Here, we propose that in the absence of MARK4 microtubule polymerisation is 
disrupted potentially leading to DNA damage response. Indeed, we observed an increase 
in p53 protein levels (Figure 6. 4A & B) following MARK4 silencing and a corresponding 
increase in p21 expression. This would suggest that G1 arrest upon MARK4 silencing 
occurs via p53 activation and the resulting inhibition of Cdk2. Cisplatin treatment, to 
induce cell stress in addition to MARK4 depletion, did not further increase p53 protein 
levels above that of the cisplatin treated siRNA control (Figure 6.4B) suggesting that 
MARK4 depletion is of its own right a substantial source of cellular stress. 
No significant increase in p53 transcription was detected suggesting that the 
observed increase in p53 protein was due to altered stability rather than an increase in 
transcription (Figure 6.5A). In support of this hypothesis, the levels of ubquitinated forms 
of p53 were lower after MARK4 silencing. However, this was not accompanied by an 
increase in MDM2, a key downstream regulator of p53 (data not shown). MDM2 
expression is stimulated by p53, and their binding triggers ubiquitination of p53 leading to 
its degradation. Taken together, our data would suggest that p53 is activated and 
stabilised by MARK4’s absence.  
Additional RT-qPCR results indicated that p53 could also act upstream of MARK4, 
controlling its expression. The mRNA expression levels of MARK4 are significantly reduced 
after depletion of p53 using p53 RNAi (Figure 6.5B). Consultation of literature suggested 
that p53 could be a transcription factor for MARK4. P53 is known to bind to a consensus 
sequence within promoter regions of its targets. This sequence; RRRCWWGYYY where R = 
purine (G or A), W = T or A and Y = pyrimidine (C or T) (El-Deiry et al. 1992; Ma et al. 
2007). We found a potential consensus binding site AGACAAGCTT upstream of the 
MARK4 transcription start sight. This could suggest that p53 is a transcription factor for 
MARK4 and in p53’s absence there is a decrease in MARK4 expression. However further 
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experiments would be required to test this hypothesis. Chromatin Immuno-precipitation 
(ChIP) for p53 against the MARK4 promoter region would confirm p53 binding within this 
region. Additionally, mutation of the identified binding site in addition to ChIP would 
prove this was the site of binding. It must be noted that additional transcription factors 
may be responsible for MARK4 expression; sequence analysis using the QIAGEN ChIP-
qPCR transcription factor search tool proposes HEN-1, ARP-1, GATA-1-3, Elk-1, Pax-5 and 
MIF-1.  
In conclusion, we observed an increase in cell death upon RNAi MARK4 when cells 
were placed in suspension. However, depletion of this kinase appears to offer resistance 
to the two chemotherapeutics tested, Cisplatin and Paciltaxel. We propose this is due to 
reduced proliferation in these cells due to G1 arrest. This correlates with increased p53 
expression and corresponding increase p21 expression. We provide preliminary evidence 
that p53 expression may affect transcription of MARK4, although further experiments 
would be required to confirm p53’s role as a transcription factor for MARK4. Also, while 
overexpression of MARK4 in H1299 did not result in any change in Cisplatin resistance, it 
led to an increase in proliferation was detected. 
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7.1 Introduction  
We have identified MARK4 as a regulator of cell motility in the non-small cell lung 
cancer cell lines, A549 and H1299. Based on the data we have collated, we would predict 
that high expression of MARK4 in tumours would increase the probability of metastasis. 
Raised expression of this kinase has previously been detected in hepatocellular carcinoma 
compared to surrounding non-cancerous liver cells (Kato et al. 2001). Expression is also 
elevated in gliomas and within immortalised glioblastoma cell lines. In this cancer type 
changes to the loci of MARK4 on chromosome 19 have been observed. However, the 
increased expression of this kinase is not thought to be due to amplification of the gene 
itself (Beghini et al. 2003; Magnani et al. 2011).  
One contributing factor to the high mortality rate within lung cancer patients is 
delayed diagnosis and high probability of metastasis. With increasing importance being 
placed on improving the speed of diagnosis and personalised medicine, much research is 
focusing upon the identification of biomarkers which indicate more aggressive 
carcinomas at the point of diagnosis. Considering this and the previously observed 
elevated expression in other cancer forms we wished to establish whether MARK4 
expression is raised in lung cancer tissue above that of normal lung tissue. We also 
wanted to establish whether expression levels could be indicative of poor survival or be 
altered with increased stage, grade or tumour size. To examine this we used commercially 
available lung cancer tissue microarrays (TMA). Of the TMAs we tested, some contained 
matched primary and metastatic tissues, others a range of primary lung tumour types and 
normal lung tissue. This work was performed in collaboration with Dr Francesco A. Mauri 
(Histopathology, Imperial College London, Hammersmith Hospital, London, UK) and with 
the help of Dr Romain Lara. 
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7.1 MARK4 is expressed in lung cancer tumour tissue 
We confirmed the specificity of the MARK4 antibody (Sigma Aldrich, SAB1300394) 
on formalin fixed paraffin-embedded pellets of A549 cells treated with non-targeting or 
MARK4 siRNAs. Reduced staining was detected in cells depleted of MARK4. Figure 7.1A 
shows representative images of lung tumour tissues stained with this antibody. The 
degree of staining score was calculated by multiplying the percentage staining (0-100%) 
by the intensity of staining (1-3), giving a final score of 0-300.   
To assess whether MARK4 expression was higher in lung cancer than in normal 
tissue we purchased a Lung cancer TMA from US Biomax, BC041114. This TMA contained 
90 tumour samples (32 Squamous Cell, 36 Adenocarcinoma, 4 Bronchioalveolar 
carcinoma, 4 Large Cell carcinoma, 8 Small cell lung cancer, 6 Atypical/Undifferentiated 
carcinoma.) and 10 normal lung tissue samples. IHC was performed using the  anti-MARK4 
antibody at 1:50 dilution. No expression of MARK4 was detected in the normal tissue 
samples included within this array. In contrast, MARK4 was detected within 36% of 
primary tumour samples (Figure 7.1B), suggesting a possible role for MARK4 in lung 
cancer tumourgenesis. 
 To investigate whether MARK4 was expressed within a specific lung cancer 
subtype we analysed the positive samples within the data. Of those positively stained, we 
found that the majority were Adenocarcinoma samples (53.33%) while 36.66% were 
Squamous Cell carcinoma and only 10% of other subtypes (Figure 7.1C). This was 
confirmed by examining the percentage of positively and negatively stained samples in 
the two majority forms of lung cancer present in this array (Squamous cell and 
Adenocarcinoma) as compared to that in the other subtypes (Bronchioalveolar 
carcinoma, Large Cell carcinoma, Small cell lung cancer, Atypical/Undifferentiated 
carcinoma) (Figure 7.1D). 
7.2 No significant change in MARK4 expression was detected between 
primary and metastatic tissue.  
Our in vitro data would suggest that the expression of MARK4 in primary tumours 
may be indicative of their metastatic potential, with high expression promoting cell 
motility and lower expression reducing tumour dispersal and survival of cells in the   
7. Is MARK4 expression indicative of cancer progression and survival 
196 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.1. MARK4 expression in lung cancer tissue samples. 
Tissue microarray BC041114 was purchased from Biomax US. This lung carcinoma and normal 
tissue microarray contained 90 cases of lung carcinoma and 10 normal tissue, duplicate cores per 
case. Expression of MARK4 was established using immunohistochemistry (IHC) staining using a 
MARK4 antibody at a dilution of 1:50. (A) Representative IHC images of MARK4 expression. 
Staining was scored for percentage coverage (0-100%) and intensity of staining (1-3). This was 
multiplied together to give a score from 0-300. (B) Percentage of staining in normal and primary 
lung cancer tissue. Percentage of positive staining within primary tumours and normal tissue 
samples (total n=180, 20 samples excluded). (C) MARK4 staining in four lung cancer sub-types. 
Percentage of positive and negative staining in the non small-cell lung cancer sub-types; 
Squamous cell carcinoma (n=32), Adenocarcinoma (n=36) and other forms of lung cancer 
(Bronchioloalveolar, Small cell, Large Cell, Atypical carcinoma) (n=22). 
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Figure 7.2. No consistent change in MARK4 expression is seen between primary and matched 
metastatic lung tumour tissues.  
Two commercial tissue microarrays, LC814 and LC817 and an in-house TMA (TMA_HH) contain 
biopsy cores from matched primary and metastatic tumour tissues. Expression of MARK4 was 
established using immunohistochemistry (IHC) staining using a MARK4 antibody at a dilution of 
1:50. Expression was compared between primary (I) and metastatic (II) cores (A); No change; I=II 
(Dark grey), Increase; I<II (Light grey), Decrease; I>II (Mid grey). No trend towards an increase of 
decrease in MARK4 expression was seen between the matched samples in any of the three TMA’s, 
(B). Data was pooled from all three TMAs for statistical analysis. Error bars indicate SEM. Asterisks 
represent statistically significant values (*, P<0.05; **, P<0.01; ***, P<0.001, ****, P<0.0001; 
ANOVA, Bonferroni’s multiple comparison test) 
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circulation. Also, one would predict that MARK4 expression would be higher in metastatic 
tissue than primary. Using three tissue microarrays we investigated the difference in 
MARK4 expression between matched primary and metastasis biopsy samples. LC814 and 
LC817 were obtained from US Biomax. LC814 contained 40 cases of primary lung tumours 
(NSCLC; 17 Adenocarcinoma samples, 17 Squamous cell, and 6 SCLC) and 40 matched 
local lymph nodes metastatic lesions. The second commercial array, LC818, contained 16 
cases of lung squamous cell carcinoma, 16 lung adenocarcinoma, 1 lung 
bronchioloalveolar carcinoma and 6 lung small cell carcinoma all with matched lymph 
node metastasis cores. TMA_HH was compiled in-house and is made up of isogenically 
matched primary and metastatic tumour samples from 58 lung cancer patients. 
Figure 7.2A shows that in all three TMA’s the number of cases in which expression 
did not change between primary and metastatic samples was higher than those in which 
there was a change in expression. In all three arrays the percentage of cases in which 
MARK4 expression increased in the metastatic tissue was higher than the percentage in 
which expression was lower than in the primary tissue, Figure 7.2A (light grey versus mid 
grey (I<II vs. I>II)). However when all data from the three TMA’s was pooled this change 
was not found to be significant (Figure 7.2B).   
7.3 MARK4 expression is altered in advanced lung cancer and 
increased in larger tumours. 
Using the commercial TMAs available to us we assessed MARK4 expression as a 
function of tumour stage, size and grade. Tumour stage is used to describe to what 
degree the cancer has spread; Stage 0; carcinoma in situ, Stage 1 (I); localised to one 
organ or part of the body, Stage 2 (II); early locally advanced, Stage 3 (III); late locally 
advanced and finally Stage 4 (IV); metastatic, advanced cancer. Many tumours are 
classified using the TNM staging system. The size of the primary tumour (T), the presence 
of local lymph node metastasis (N) and the presence of distant metastasis (M) is indicated 
by increasing numbers e.g. T1, T2, T3 for increasing tumour size. The third method of 
classification that is commonly used is grading. Tumours are graded as follows: GX; 
cannot be assessed, G1; Well differentiated (low grade), G2; Moderately differentiated 
(Intermediate grade), G3; Poorly differentiated (High grade), G4; Undifferentiated (High 
grade).  
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Figure 7.3. No consistent change in MARK4 expression is seen between primary and matched 
metastatic lung tumour tissue.  
Expression of MARK4 was established using immunohistochemistry (IHC) staining using a MARK4 
antibody at a dilution of 1:50. Both positively and negatively stained primary tumour samples 
were included in this analysis. (A) MARK4 expression is significantly reduced in late stage lung 
cancer tissue. TMA’s LC817, LC10013, LC915 and BC041114 were stained for MARK4 expression 
and the results pooled. Expression over increased tumour stage was analysed. (B) MARK4 
expression is decreased in high grade lung carcinoma. MARK4 expression was compared 
between grade 1, 2 and 3 (I, II, IIIa & IIIb) tumour tissue from TMA’s LC814, LC817, BC041114. (C) 
No correlation between MARK4 expression and tumour size was seen. Pooled expression data 
from TMA’s LC817, LC915 & BC041114 for tumours of increase size, classified using the TNM 
system. Error bars indicate SEM. Asterisks represent statistically significant values (*, P<0.05; **, 
P<0.01; ***, P<0.001, ****, P<0.0001; One-way ANOVA, Bonferroni’s multiple comparison test). 
 
To investigate MARK4 expression over increasing tumour stage we pooled data 
from positively stained primary tumour samples from the LC817, LC10013, LC915 and 
BC041114 TMAs (total n = 299). MARK4 expression was significantly lower in the stage 3 
Lung cancer tumours sampled than stage 1 (Figure 7.3A). This finding would not support 
our in vitro findings as within NSCLC cell lines increased MARK4 expression increased cell 
motility. We would therefore have hypothesised that later stage tumours would have 
higher MARK4 levels as, based on our data, this would promote tumour spread. No 
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significant change was seen between stage 1 and 2. A decrease in expression with 
increasing tumour grade was also seen using data from TMA’s LC814, LC817 and 
BC041114 (n=192) (Figure 7.3B), although the decrease seen was not significant. No 
correlation between MARK4 expression and tumour size was observed (n=256) (Figure 
7.3C). 
7.4 Kaplan-Meier analysis indicates that MARK4 expression significantly 
affects survival in lung cancer patients.  
Based on our data regarding the role of MARK4 expression on lung cancer cells 
motility and proliferation we would hypothesise that reduced MARK4 expression may 
improve patient survival. Survival would be improved due to reduced metastasis 
formation and proliferation of the tumour. We utilised an online database of gene 
expression and survival data of 1,715 lung cancer patients (www.kmplot.com) to establish 
the influence of MARK4 expression on patient survival (Gyorffy et al. 2013). The Kaplan-
Meier Plotter contains data from GEO (Affymetrix microarrays only), The European 
Genome-phenome Archive (EGA) and The Cancer Genome Atlas (TCCA). Using the mean 
expression of two MARK4 probes; 221560_at and 55065_at, we searched this database 
for survival of patients with high or low MARK4 expression. Figure 7.4 shows that there 
was a significant difference in survival between patients with low and high MARK4 
expression with those with reduced expression having improved survival. This result is 
consistent with the hypothesis we formed based upon our in vitro results. 
7.5 Discussion  
We have established MARK4 as a playing a key role in motility of NSCLC cells. To identify 
whether MARK4 plays a role in the progression of lung cancer in the clinic we compared 
the expression of this kinase within a number of TMAs containing primary lung cancers, 
matched metastatic and normal tissue. MARK4 was not detected in normal lung biopsy 
samples (Figure 7.1B), whereas expression was detected in 36.67% of lung carcinoma 
samples. Positive staining was seen in 52.78% of adenocarcinoma samples, although 
expression was also high in squamous cell carcinoma with 34.38% of samples staining 
positively (Figure 7.1C & D). This data could suggest a role for MARK4 expression in 
tumourgenesis, especially within adenocarcinoma.  
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Figure 7.4. Low MARK4 mRNA expression improves survival.  
Kaplan Meier Plotter collates gene expression and survival data from 1715 lung cancer patients 
from GEO, EGA and TCGA. We analysed the expression of MARK4 within this data-set using the 
mean expression of two MARK4 probes (221560_at and 55065_at). Survival is significantly 
improved in patients with low MARK4 expression compared to those with high expression 
(Gyorffy et al. 2013).  
 
Our in vitro data indicated that raised MARK4 expression increases cell motility. 
We therefore hypothesised that MARK4 expression would be higher at metastatic sites 
than in primary tumours. We examined expression between isogenically-matched 
primary and metastatic tumours. Although the majority of matched tissues showed no 
change in expression between primary and metastasis (I=II), the percentage in which 
expression was raised in the metastatic lesion (I<II) did exceed that of cases in which it 
was decreased (I>II). However this difference was not significant (Figure 7.2A & B). This 
data gives no conclusive evidence that MARK4 expression influences the development of 
metastasis in lung cancer patients.  
Further analysis of commercial TMAs LC814, LC817, LC915, LC10013 and 
BC041114 suggested that MARK4 protein expression is reduced in late stage lung cancer 
and in higher grade tumours (Figure 7.3). These clinical findings are not consistent with 
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our in vitro data as we found that MARK4 silencing reduces cancer cell invasiveness, 
survival in the circulation and proliferation.  
Taken together the Lung cancer TMAs did not provide conclusive evidence that 
MARK4 expression is indicative of the formation of metastasis or is raised in metastatic 
tissue. Although the antibody was optimised using paraffin embedded A549 transfected 
with MARK4 siRNA it is possible that the staining within the tissue samples was unspecific. 
Poor specificity could explain the poor correlation between these data and our in vitro 
findings. Analysis of TMAs is also limited in power by the number of samples included. For 
this reason we pooled data between TMAs when possible to improve the sample size in 
each condition. However, MARK4 being one of many proteins that could influence 
dissemination and growth of lung tumours, the numbers at our disposal may not be 
sufficient to reveal the clinical relevance of this kinase in these processes. 
Indeed, when a larger number of samples was analysed using the online Kaplan 
Meier Plotter, data on patient survival suggested that our in vitro findings may be of 
clinical relevance (Figure 7.4). Here gene expression and survival data from 1712 patients 
indicated that low MARK4 expression improves survival significantly compared to the high 
MARK4 expression cohort. We were unable to examine survival statistics with reference 
to MARK4 expression within our TMAs, and further investigations would therefore be 
needed to independently confirm these findings. 
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8.1 General Discussion 
Lung cancer presents a unique challenge to clinicians and scientists. It still remains 
the most common cancer killer due to late diagnosis and the high occurrence of 
metastasis and chemoresistance. Research has largely focused on improving 
understanding of chemoresistance with advances made in the development of novel 
drugs and more personalised treatment programs. Within this thesis, however, we 
intended to focus upon the problem of metastasis. We optimised and performed a pilot 
screen with the aim of developing a high-throughput siRNA assay to identify novel NSCLC 
cell invasion regulators. In addition to this we have focused upon the role of MARK4 in 
cell motility and invasiveness. In addition, we have shown changes in microtubule 
dynamics when expression of this kinase is altered and the impact this has on motility and 
cell division. Insight into potential downstream targets and feedback mechanisms in 
response to MARK4 overexpression has also been provided. Although there is much still 
to be studied with regards to the role of MARK4 in NSCLC cell motility, we have begun to 
uncover the functions of this kinase. 
8.1.1 Robotisation of our 3D cell invasion siRNA screen provided 
limited reproducibility 
Despite thorough optimisation of the manual and robotised 3D invasion assay 
before performing the pilot screens of the Phosphatome, we experienced limited 
reproducibility between repeats and overlap of the hits identified from pilot screens 2 
and 3 with only 18-27% further validating (dependent on the growth factor stimulation 
applied). Multiple controls were included within the pilot screens, none of which 
highlighted the source of this poor overlap between the two repeat screens. The pilot 
screens were carried out with the assistance of minor robotics provided by Janssen 
Pharmaceutica within their laboratories in Beerse, Belgium. Time and access restraints 
prevented extensive testing and optimisation of the robotics used, though Pilot screen 1 
was carried out to identify issues with this adaptation of the optimised assay.  To date we 
are yet to identify the source of the observed inconsistency and further optimisation 
would be required before utilising this screening protocol for a high-throughput siRNA 
screen. 
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8.1.2 The involvement of MARK4 in NSCLC cell motility 
Though the screening project described in Chapter 3 of this thesis did not produce 
reliable hits that could be confidently followed up, a previous kinome siRNA screen 
project within our laboratory had identified novel modulators of A549 cell motility. 
Among these was Microtubule affinity regulating kinase 4 (MARK4). Silencing this kinase 
significantly reduced A549 migration (Lara et al. 2011). No evidence has previously been 
published describing changes in MARK4 expression affecting cell motility. There are four 
members of the MARK family, all of which have been previously implicated in the 
phosphorylation of microtubule associated proteins (MAPs). MAPs bind to microtubule 
filaments and stabilise these highly dynamic structures. When phosphorylated, MAPs 
detach leaving the microtubule filament more dynamic. As the microtubule network plays 
a crucial role in the control of cell polarisation and movement it is therefore not 
unexpected that cell motility is altered when a key regulator such as MARK4 is lost. 
Within Chapter 4 we validated the initial findings of the role of MARK4 in cell migration  
and expanded these to two NSCLC cell lines in which cell migration and invasion were 
significantly reduced upon silencing of this kinase. Additionally we overexpressed MARK4 
using a plasmid construct kindly donated by Dr Gerard Drewes (Trinczek et al. 2004a). 
Overexpression within the NSCLC cell line H1299, significantly increased motility within 
the assays tested.  
It was noted during these experiments that a change in cell morphology occurred 
after silencing of MARK4, this was quantified using tubulin area and a significant increase 
in cell area was seen. This observation, and the known link between MARK’s and 
microtubule stability, focused our investigations on microtubule dynamics. Use of a GFP-
tagged End Binding Protein-3 to track microtubule filament growth suggested elevated 
microtubule polymerisation in the absence of MARK4. However, experiments performed 
with the microtubule disrupting agent Nocodazole to observe microtubule regrowth gave 
a contrasting result, with slower regrowth observed in cells silenced for MARK4. A change 
in polymerisation of the MT is expected based on changes in MAP binding in the absence 
of MARK4. However it should be noted that MARKs 1-3 are also known to regulate MAP 
binding, therefore a change in stability upon removal of just one of this family suggests all 
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MARKs are required for adequate control of MT stability. We did not observe any change 
in microtubule polymerisation after transient overexpression of MARK4. 
8.1.3 Mechanistic studies provided insight into the downstream 
targets of MARK4 and feedback mechanisms to control activity 
Despite having confirmed changes in motility when MARK4 expression is altered 
and observing significant changes in cell morphology and microtubule stability we had not 
yet uncovered a mechanistic pathway to explain these changes. Within Chapter 5 we 
attempted to uncover both up and downstream signalling changes in response to MARK4 
depletion or overexpression. Having found no convincing changes in the expression of 
typical EMT markers and transcription factors, we concluded that EMT was not the driver 
behind the increase in invasion observed with increased MARK4 expression.  
We then moved forward to assess the role of a number of suggested interacting 
proteins in the changes in cell motility which we observed.  From existing literature we 
selected 13 targets which had been linked to cell polarity, MARK regulation or cell motility 
as well as proposed direct binding partners of MARK4 (Brajenovic et al. 2004; Naz et al. 
2013; S Illenberger et al. 1996). These 13 targets were silenced in the absence or 
overexpression of MARK4 and we analysed whether the absence of the interacting 
protein enhanced or rescued the known MARK4 phenotype on cell invasion. This small 
siRNA screen identified a number of potential downstream targets of MARK4, those that 
when absent, prevented the increase in invasion stimulated by overexpressing MARK4. 
These were 14-3-3η, PARD6A, MAP2, PPP2R1A, ARGHEF2, STRADA and STK11. Both 
STK11 and 14-3-3η have been implicated in the regulation of MARK activity (Göransson et 
al. 2006; Lizcano et al. 2004). We observed that silencing of PPP2CB, PKCλ and USP21 did 
not affect invasion in control, MARK4 overexpressing or MARK4 silenced H1299 cells. We 
would propose that these three proteins are therefore not involved in the regulation of 
motility through MARK4. The increase in invasion stimulated when MARK4 expression is 
elevated was further enhanced in the absence of CAB39, a supposed activator of MARK4 
through STK11, and MAP4, a microtubule-associated protein. The loss of MAP4, that 
stabilises MT upon binding, may be expected to increase invasion by allowing increased 
MT dynamics. However, loss of an activator of MARK4 was not predicted to increase 
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invasion. Additional screens and studies would be required to follow up these findings 
and the involvement of other MARK4 binding partners and their downstream targets. 
8.1.3.1 Regulation of MARK4 by PP2A 
Previous reports have identified Protein Phosphatase 2A (PP2A) as a regulator of 
MARK activity through dephosporylation of its activating site (G Drewes et al. 1997). 
Additionally, a direct interaction between MARK4 and two subunits of PP2A was 
suggested by a tandem affinity purification of MARK4 (Brajenovic et al. 2004). These two 
subunits were included within our small siRNA screen of interactors and silencing of the 
structural subunit PPP2R1A rescued the effect of MARK4 overexpression on invasion. An 
increase in the expression of MARK4 associated with a loss of the inhibitory 
phosphorylation Y307 of PP2A, suggesting an increased activity of this phosphatase. We 
also confirmed a direct interaction between these two proteins, with HA-MARK4 co-
immunoprecipitating with PP2A.  We propose that the observed increase in the activity of 
this known deactivator of MARK4 is part of a negative feedback mechanism that is 
activated by MARK4 overexpression. Interestingly two regulatory subunits of PP2A 
(PPP2R5C and PPP2R1B) were identified during the phosphatome screen described in 
Chapter 3 as increasing invasion upon knockdown.  Importantly it should be noted that 
there are many different isoforms of the three PP2A subunits (Xu et al. 2006) and that 
only a few of these have been investigated here. There may be merit in further studies to 
determine which subunits specifically bind to MARK4 and are responsible for control of its 
activity. However, the results obtained on a complex phenotype such as cell migration 
may be difficult to interpret as loss of certain subunits may affect several signalling 
pathways due promiscuous roles of phosphatases.  
8.1.3.2 Could GSK3 be involved downstream of MARK4 in addition to 
controlling its activity? 
Though not included within the siRNA screen described in Chapter 5, glycogen 
synthase kinase 3 (GSK3) had been linked to the regulation of MARK family members by 
two publications (Kosuga et al. 2005; Timm, Balusamy, et al. 2008). Phosphorylation of 
Ser 212 (MARK2) by GSK3β inhibits MARK activity preventing phosphorylation of MAPs. 
Upon overexpression of MARK4 we identified an increase in the inhibitory 
phosphorylation of GSK3α. Previous studies of this kinase have focused on the β form 
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preferentially. We also observed raised mRNA expression of MARK4 when GSK3α is 
silenced. We were unable to identify literature evidence to support an increase in GSK3α 
inhibition in response to increased cell motility or changes in MARK expression. However 
GSK3β is known to be inactivated at the leading edge of migrating cells. This was shown 
to be induced by the Cdc42-activated Par6-PKCζ complex and to lead to activation of FAK 
(Focal adhesion kinase) that in turn increases cell spreading and migration (Etienne-
manneville & Hall 2003; Bianchi et al. 2005). Further investigation would be required to 
understand whether in our system it is the inhibition of GSK3α in response to MARK4 
overexpression which is involved in this signalling pathway.  
PP2A could also be tied into this pathway, as this phosphatase is known to 
dephosphorylate, and thereby activate, GSK3α/β. We propose that although GSK3α/β is 
inactivated at the time-point of our experiment (48 h after MARK4 overexpression) the 
increased activity of PP2A at this time could lead, later on, to the activation of GSK3α/β. 
This would constitute a negative feed-back loop to reduce the impact of MARK4 
overexpression on motility. Further investigation into of the roles of both PP2A and 
GSK3α/β in MARK4 induced cell motility would be required to test this hypothesis. 
8.1.3.3 MARK4, similarly to MARK2, affects Rho GTPase activity 
Members of the Rho GTPase family, such as Rac, Rho and Cdc42, are involved in a 
wide range of cellular processes including playing a major role in the control of cell 
motility. Their activity is controlled by a number of regulatory proteins, including GEFH1 
(ARGHEF2). This protein was found to bind to MARK4 during the tandem affinity 
purification  performed by Brajenovic using this kinase as a bait (Brajenovic et al. 2004). 
GEFH1 is a member of the Rho GEF Family which activate Rho GTPases by stimulating the 
formation of Rho-GTP (Cook et al. 2013). MARK2 has also been linked to this regulatory 
protein and has been shown to inactivate GEFH1 through phosphorylation, resulting in 
reduced Rho activity (Yamahashi et al. 2011). We have observed a decrease in Rho 
activity upon MARK4 overexpression, matching what is seen upon MARK2 
overexpression. However, due to lack of suitable antibodies, we have been unable to 
show that this occurs through a change in the activity or phosphorylation status of 
GEFH1. Studies by Brajenovic et al. also identified Cdc42, another Rho GTPase as binding 
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to MARK4. Further investigation is required to validate this interaction and understand 
the involvement of this and other Rho GTPases in the functions of MARK4. 
8.1.3.4 MARK4 family members do not compensate for each other in 
expression or function 
Throughout this thesis we have focused only on the role of MARK4 in cell motility, 
although many experiments were based on prior knowledge of MARK2’s biology from 
published literature. However, we have tested the effect of depleting the other three 
members of the MARK family and found that this resulted in a 30% decrease of cell 
migration for each individual isoforms. In other protein families where members share 
overlapping functions and high sequence homology, the loss of expression of one 
member is often compensated by a raise in transcription or protein stability of another. 
However we did not observe significant changes in MARK4 expression when MARKs 1-3 
were silenced using RNAi. MARK4 depletion did however significantly decrease MARK2 
expression by ~30%. Though this is not compensation, and although comparison of the 
mRNA sequence and the RNAi sequences used did not suggest off-target effects, further 
experiments would be required to explain the nature of this effect. 
8.1.4 Loss of MARK4 impedes cell cycle progression increasing NSCLC 
cells resistance to chemotherapy 
The original aim of this thesis was to identify a novel therapeutic target that could 
be used to reduce metastasis in non-small cell lung cancer patients. The dramatic 
reduction to cell motility observed upon MARK4 depletion would suggest that this kinase 
is a potential therapeutic target. Within Chapter 6 we explored the effect of MARK4 on 
survival and proliferation. Initial studies provided further evidence in support of MARK4 
as a therapeutic target. Depletion of MARK4 significantly reduced NSCLC cells survival in 
suspension. This assay aims to mimic the second stage of the metastatic cascade, when 
tumour cells enter the blood or lymphatic circulation. This is a highly selective process 
and further reducing the probability of tumour cells survival at this stage by targeting 
MARK4 would be therapeutically desirable.  
The MARK family has previously been linked to cell cycle progression (Bachmann 
et al. 2004; Peng et al. 1998; Beghini et al. 2003; Kato et al. 2001; Tassan & Le Goff 2004; 
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S Illenberger et al. 1996). Consistent with this, we observed a decrease in cell division 
after silencing of MARK4. FACS analysis of EdU incorporation into DNA suggested minor 
G1 arrest or delayed entry into S phase. Past findings have associated the MARK family 
with G2/M transition rather than the G1/S checkpoint. However, we also noted increases 
in P53 and P21 protein levels after MARK4 silencing that may trigger P21 controlled G1 
arrest through inhibition of Cdk2 and Cdk4-cyclin complexes (Blajeski et al. 2002). We 
propose that this reduction and the accompanying slowing of cell cycle progression are 
responsible for the observed increase in NSCLC resistance to the chemotherapy agents, 
cisplatin and taxol upon MARK4 silencing. Nevertheless, overexpression of MARK4 did not 
conversely increase the sensitivity to these agents despite increasing cell proliferation. 
More experiments would be needed to address this discrepancy. 
8.1.5 Clinical implications of MARK4 expression 
We also wished to establish whether our findings had clinical relevance. We 
hypothesised that MARK4 expression could be indicative of cancer progression, 
occurrence of metastasis and overall survival. Although no suitable antibody was available 
for Western blotting, we were able to validate the N-terminal MARK4 antibody from 
Sigma-Aldrich for immunohistochemistry. This work was carried out with the kind 
assistance of Dr Francesco A. Mauri who stained and scored tissue microarrays (TMAs) 
and Dr Romain Lara who validated the antibody. We stained a total of six lung cancer 
TMAs (5 commercial available and 1 in-house) for MARK4 expression. The staining was 
scored and the data analysed with regards to the following factors; expression in different 
tumour types, presence of metastasis, expression in primary versus metastatic tissue, and 
the degree of staining in tumours of increasing stage, grade and size. We identified a 
higher occurrence of positive MARK4 staining in adenocarcinoma samples which may 
indicate a role for this kinase in the development of this lung cancer sub-type. We did not 
however observe the expected increase in MARK4 expression in metastatic lesions when 
compared to primary tumours. Although a greater number of cases showed higher 
expression in metastatic tissue than showed a reduction in expression, the difference in 
number of cases was not significant. The majority of cases displayed no change in 
expression between primary and metastatic tissue. No change in expression was 
observed with increasing tumour size though a decrease in expression was found in later 
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stage and higher grade lung cancer tumours. Data obtained from these TMAs did not 
therefore provide evidence to support MARK4 as a potential clinical biomarker or to 
suggest MARK4 expression may drive the development of metastasis.  
Use of online databases allows access to large publically available data sets. We 
used the Kaplan-Meier Plotter that has collated gene expression and matched clinical 
data from 1,715 lung cancer patients. This allowed us to compare two cohorts, those with 
high or low MARK4 expression. We found that low MARK4 expression significantly 
improved survival. We would conclude that further studies of MARK4 expression in 
clinical samples is required to ascertain the potential role of MARK4 in the clinic. In vivo 
studies may also provide further support of our in vitro findings.  
8.2 Future Directions 
The findings of this thesis raised several questions which are yet to be addressed. 
Future work on the projects included in this thesis would likely consider the following 
questions: 
8.2.1 Could further optimisation improve the reliability of the 
proposed high-throughput 3D invasion siRNA screen? 
Although within the time frame of this thesis we did not persist with optimisation 
of the 3D invasion assay to improve its suitability for screening, more work could be done. 
As mentioned, robotics was used to plate and transfect cells, as well as for the addition of 
collagen and growth factors. Access and time restraints prevented detailed optimisation 
of the robotics steps in the protocol; and this could be the focus of further work. Initially 
we had planned to use functional controls within each assay plate. These would allow us 
to confirm that we observed the expected changes in behaviour upon knockdown of 
these targets, and validate the inclusion of each plate in the analysis downstream. 
However due to problems experienced with the chosen functional controls in Pilot Screen 
1 these were excluded. We believe that the reintroduction of functional controls into the 
screen would be advantageous and therefore work to identify more reliable controls 
would be required. Finally, it must be established whether any future screen should be 
conducted in duplicate or triplicate rather than as an individual run as is most common. 
The data we obtained would suggest repeat screens would be required however due to 
8. Final Discussion & Future Directions 
212 
 
the significant additional cost and time this incurs, the necessity for this must be further 
demonstrated. An alternative approach would be to use high content pooled RNAi 
screening. Mass transfection with tagged or barcoded shRNA constructs allows for 
screening of whole pathways. Mass transfection, phenotypic studies, including in vivo 
followed by microarray analysis or deep sequencing to understand the affected pathways 
allows for more rapid and high content screening of pathways (Boettcher & Hoheisel 
2010). 
8.2.2 Can the observations of the role of MARK4 in NSCLC be extended 
to additional cancer types? 
Several reports indicate an important role for MARK4 in progression of other 
tumour types (Kato et al. 2001; Beghini et al. 2003). Testing of the role of MARK4 in cell 
motility within a panel of additional lung cancer cell types and other cancer forms will 
confirm whether our observations can be extended to other tumour types. Inclusion of 
non-cancerous cell lines will establish whether the effect of MARK4 on cell motility is 
limited to cancer cells or is more general. 
8.2.3 Is the kinase activity of MARK4 required for its functions in cell 
motility? 
One clear question that is yet to be addressed is the importance of the kinase 
activity of MARK4 for its role in cell motility. Use of kinase dead or phospho-mimic 
mutants of MARK4 would allow for this to be assessed. Overexpression of kinase active 
mutants would also be of use when establishing interactions and requirement for 
potential upstream factors. Importantly, siRNAs targeting the 3’UTR of MARK4 mRNA 
would be used in cells overexpressing these mutant kinases so that the phenotypes 
observed are not confounded by the presence of endogenous wild-type MARK4. The 
mutants would be generated using site-directed mutagenesis of the pCDNA3 HA/GFP-
MARK4 construct used within this thesis. If kinase activity was found to be dispensable to 
the effects of MARK4 on cell motility, truncation of the gene would allow for the involved 
structural sites or domains to be identified.  
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8.2.3.1 If kinase activity is required, could chemical inhibition of MARK4 
alter cell motility and division? 
Specific MARK4 inhibitors are not commercially available, though a MARK/Par-1 
Activity Inhibitor is now available from Merck Millipore. If the kinase activity was shown 
to be required for the role of MARK4 in cell motility through the genetic means described 
above further evidence could be provided by the testing of chemical inhibitors. As we 
have shown depletion of any MARK family member reduces tumour cell motility a pan-
MARK inhibitor may still be of interest. However, design and production of specific 
inhibitors for MARK4 and the other family members may be of use during studies on the 
individual functions of these family members. 
8.2.4 What is the molecular mechanism behind the effects of MARK4 
on cell motility and cell cycle? 
In order to further the mechanistic studies that we have initiated, a reliable 
antibody against MARK4 would need to be generated. All commercially available 
antibodies for this kinase tested in this thesis could not be validated as detecting MARK4 
as they failed to detect depletion or overexpression of this kinase. Production of an 
antibody for use for western blotting, immunofluorescence and co-immunoprecipitation 
would open the way for further characterisation of the biological functions of this kinase. 
Phospho-antibodies for the key activating and inactivation sites on MARK4 (Thr 214 and 
Ser 218) would also be of great use to assess upstream activation pathways and signalling 
feedback loops. 
However, our work already highlighted many possible avenues for further 
investigation of the modulation of MARK4 function. Future work may want to confirm 
direct interactions between MARK4 and Tau, GSK3, GEFH1 and the RhoGTPases. While 
published literature has provided evidence for these interactions we were so far unable 
to reproduce these findings.  
With regards to the changes in microtubule polymerisation which we propose as 
an explanation for the altered cell motility upon changes in MARK4 expression, further 
studies focussing on depolymerisation of the microtubule filaments may be important to 
confirm altered dynamics. This may also shed light on the conflicting data we obtained 
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between the E3-GFP and the nocodazole experiments. Depolymerisation could be 
observed using cells transfected with fluorescently tagged tubulin. Treatment with 
microtubule disrupting drugs such as nocodazole would trigger depolymerisation of the 
MT network, which may occur at an altered speed in MARK4 depleted or overexpressing 
cells. MARK4 is known to phosphorylate Tau and other MAPs triggering their detachment 
from the MT, increasing microtubule dynamics (Trinczek et al. 2004a). We have been 
unable to show a change in phospho-Tau within our cell system after modulation of 
MARK4 protein levels. Further work would need to confirm these findings. 
Immunofluorescence may also be used to observe a change in the cellular localisation of 
MAPs upon modulation of MARK4 expression and activity. 
Finally, fluorescently tagged tubulin could also be used to observe spindle 
formation and separation during cell division when MARK4 expression is modulated to 
identify whether the altered MT dynamics are responsible for the observed delay in cell 
division. 
8.2.4.1 Is protein phosphatase 2A activated as part of a feedback 
mechanism in response to increased MARK4 expression? 
We have shown changes in PP2A activity after MARK4 overexpression. Changes 
should also be investigated after MARK4 silencing, and the activity of other downstream 
targets of PP2A should also be assessed to confirm PP2A is activated. PP2A is known to 
deactivate MARKs, and to dephosphorylate MAPs (Liu et al. 2002; Qian et al. 2010; Sontag 
1999; G Drewes et al. 1997). These observations should be reproduced within NSCLC cell 
lines in the absence and overexpression of MARK4 to confirm this regulation occurs 
within our cells and what changes are induced by altered MARK4 levels. MARK4 has been 
shown to bind to two subunits of PP2A, and we have confirmed a direct interaction 
between the two proteins, however there are many subunits of PP2A which combine to 
form a variety of combinations. Studies could be carried out to confirm which 
combination of PP2A regulates MARK4. These would include co-immunoprecipitation of 
MARK4 with the individual subunits to identify binding partners, and observation of 
MARK4 activity using recombinant proteins of both the kinase and phosphatase.  
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8.2.4.2 Does MARK4 trigger the inactivation of its known regulator 
GSK3α/β? 
GSK3α/β has been associated with the regulation of the MARK family via 
phosphorylation resulting in the inactivation of the kinase (Timm, Balusamy, et al. 2008). 
GSK3α/β has also been associated with the regulation of MT stability and shown to be 
activated by PP2A (Qian et al. 2010). We have seen inactivation of GSK3α with MARK4 
overexpression, but were unable to assess changes in GSK3β activity. Previous literature 
suggested inactivation of GSK3β leads to activation of FAK triggering increased cell 
spreading and motility. We proposed MARK4 may be involved in this pathway, and 
perhaps within our cell system GSK3α is the GSK3 isoform involved. This could be 
confirmed using a series of genetic experiments (modulation of GSK3 and  expression 
levels) as well as Western blotting for phosphorylation of FAK and GSK3β. 
8.2.4.3 How are the Rho GTPase family involved in the biological 
functions of MARK4?  
MARK4 has been linked to the Rho GTPase family via an association with Cdc42 
and a known regulator of Rho GTPase activity ARGHEF2 (Brajenovic et al. 2004). MARK2 
has also been shown to interact with the same regulator and negatively affect Rho 
activity through inactivation of ARGHEF2 (Yamahashi et al. 2011). We observed changes 
in Rho activity upon overexpression of MARK4 but further study is required to conclude 
this is due to an effect on ARGHEF2 by MARK4. The effect of MARK4 silencing and the 
activity of Rho GTPases must also be investigated using Rho, Rac and Cdcd42 activity pull 
down assays. Direct interaction between MARK4 and these Rho GTPases may also be 
confirmed by co-immunoprecipitation. The activity of Rho GTPases often determines their 
localisation to sites where they act upon downstream targets. FRET constructs may be 
used to determine the localisation of RhoGTPases upon MARK4 silencing and 
overexpression along with their activity (Zawistowski et al. 2013; Machacek et al. 2009). 
8.2.5 Do MARK family members interact with one another to carry out 
their functions?  
Within this thesis, little investigation has been undertaken as to the role of the 
three other MARK family members in the motility of lung cancer cells. Further 
investigations should confirm the degree to which depletion or overexpression of MARK1, 
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MARK2 and MARK3 affect motility. Data obtained so far suggests no compensation in 
expression or role between the members of this family. It should be investigated whether 
these proteins interact directly with each other, hence requiring the presence of all four 
members to carry out their joint roles. Co-immunoprecipitation will confirm a direct 
binding and immunofluorescence studies would highlight sites of co-localisation of these 
kinases. No previous literature suggests that these kinases directly interact with each 
other. It should also be noted that different patterns of expression for these proteins are 
observed within different tissues.  
8.3 On-going work for publication 
A recent collaboration has uncovered microRNA mir-515-5p as a novel regulator of 
MARK4. Using chromatin immunoprecipitation sequencing (ChIP-Seq), Miss Filipa Pinho, a 
member of the Breast, Gastro-intestinal and Basic Cancer Research group within Imperial 
College London, has identified this microRNA, as a regulator of MARK4 expression. Mir-
515-5p has been  shown to act as a tumour suppressor in breast cancer (Pinho et al. 
2013). Recent findings by this group have confirmed a decrease in Breast cancer cell 
motility when this mircoRNA is expressed, ChIP-Seq also identified many potential targets 
of mir-515-5p through which cell motility could be modulated, MARK4 being one such hit. 
Collaborative efforts reproduced both the observations of this thesis and that of Pinho et 
al in both lung and breast cancer cell lines and validated this direct interaction. Further 
work included the analysis of MARK4 expression in breast cancer and metastatic tissue 
confirming an inverse correlation with miR-515-5p expression. Additionally we 
demonstrated that exogenous MARK4 overexpression could rescue the observed 
decrease in cell motility following miR-515-5p overexpression. This work was carried out 
by Miss Pinho and Miss Munro with the guidance of Dr Olivier Pardo & Dr Leandro 
Castellano. 
8.4 Final conclusions 
This work aimed to identify novel therapeutic targets involved in the regulation of 
cell motility. Initial work to optimise a 3 dimensional Invasion assay for use within a high-
throughput siRNA screen did not prove successful with a lower than expected 
reproducibility rate. A previous siRNA screen did however identify a novel regulator of cell 
motility; MARK4. We have further characterised the roles of this kinase within NSCLC cells 
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and have begun to uncover the underlying mechanism of its effect on cell motility. 
Further work is however required to fully understand the downstream effects of MARK4 
signalling. Though tissue microarrays have provided no positive correlation between 
MARK4 expression and the occurrence of metastasis, online data bases have suggested 
reduced MARK4 expression may improve lung cancer patient survival.  
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Appendix Figure 10.1. Second Harmonic imaging of the collagen structure.  
Using the Zeiss 7 80 Confocal microscope a collagen matirx, through which A549 cells had 
invaded, was placed on a coverslip and imaged at 440nm and 880nm. The natural fluorescent 
properties of collagen allowed for confirmation of the presence of fibres without the need for 
staining. 
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Appendix Figure 10.2. Technical details for 3D invasion screen of the Phosphatome.  
The Silencer Select Human Phosphatome library (AMBION) contains 894 unique siRNA’s targeting 
298 phosphatases. Each phosphatase gene product is targeted by three separate siRNA 
sequences, each located on separate plates (A). The siRNA within the Mother library plates were 
diluted to 5 μM. A set of daughter plates with a final siRNA concentration of 1 μM were then 
created using the CyBi-well  robot (CyBio) to transfer siRNA from Mother to Daughter plates. At 
this point siRNA controls were added to the right hand side wells (A12-G12, Red). siRNAs were 
added to assay plates using the CyBi-well robot, to obtain a final siRNA concentration of 30 nM 
(B). 
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Appendix Figure 10.3. KD alert confirms optimal knockdown conditions.  
GAPDH silencing was quantified using the KDalert GAPDH Assay Kit (Life Technologies). The 
degree of GAPDH enzyme knockdown efficiency is assessed by measuring the enzyme’s activity 
following the addition of substrate and the resulting fluorescence emission due to cleavage. 
GAPDH silencing was assessed using 30 nM or 50 nM siRNA (30_, 50_) and a range of 
concentrations of the transfection reagent HiPerFect (I= 0.25 %, II=0.5 %, III=0.75 %, IV=1.0 %). 
Results are the average of two biological replicate experiments with three technical repeats. Error 
bars indicate SEM.  
 
 
 
 
 
 
 
 
 
Appendix Figure 10.4. Screen data was normalised against the median of the two non-targeting 
control (NS) siRNAs used.  
Two non-targeting siRNA controls were used within the pilot phosphatome screens; NS#1 and 
NS#2. The level of invasion observed was different between these two controls with transfection 
of NS#2 giving a slightly higher level of invasion that NS#1. We therefore determined the median 
level of invasion between NS#1 and NS#2 and used it to normalise the data on a plate by plate 
basis. 
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Appendix Figure 10.5. MARK4 expression is significantly altered is response to transfection with 
MARK4 siRNA or expression plasmid.  
RNA was harvested from cells 24 h after transfection with siRNA (A) or plasmid (B) using the 
RNeasy Mini Kit (QIAGEN). MARK4 expression was quantified by qPCR. Expression was measured 
against that of two housekeeping genes GAPDH and HPRT using the software qBase, then 
normalised against the control (A - NS, B - Empty Vector, EV). (A) Transfection with MARK4 siRNA 
significantly reduces MARK4 mRNA expression. (B) MARK4 expression is significantly increased 
by transfection with pCDNA3 HA/GFP-MARK4. 
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Appendix Figure 10.6. EB3-GFP comets can be identified and tracked.  
A549 cells transfected with EB3-GFP construct were imaged using a Zeiss LSM-780 inverted 
confocal microscope and the Zen Black software (Zeiss). One image was taken ever second for 
two minute. EB3-GFP comets can be seen to move across frames. Arrows on the images above (A 
& B) highlight comets moving over frames. Frames shown are 6 seconds apart to allow for 
movement to be seen by eye.  
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Appendix Figure 10.7. MARK4 mRNA expression levels are altered by GSK3α/β knockdown.  
H1299 (A) and A549 (B) cells were transfected with non-targeting (NS), GSK3α or GSK3β siRNA. 48 
h after siRNA transfection RNA was extracted and expression of MARK4 analysed by qPCR. (A) 
MARK4 expression is further increased by GSK3α knockdown in the presence of MARK4 
overexpression. H1299 cells were transfected with plasmid, control (EV) or pCDNA3 HA-MARK4 
(MARK4) 24 h before being transfected with the indicated siRNA’s. (B) MARK4 expression in A549 
cells upon GSK3α silencing. Results are the average of three biological repeats. Error bars indicate 
SEM. Asterisks represent statistically significant values from a minimum of three biological repeat 
experiments (*, P<0.05; **, P<0.01; ***, P<0.001, ****, P<0.0001; ANOVA, Bonferroni’s multiple 
comparisons test). 
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